10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the quarterly period ended September 30, 2014

¨    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No.

000-25809

Apollo Medical Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware	46-3837784
State of Incorporation	IRS Employer Identification No.

700 North Brand Blvd., Suite 220

Glendale, California 91203

(Address of principal executive offices)

(818) 396-8050

(Issuer’s telephone number) 

(Former name, former address and former fiscal year, if changed since last report)

Securities Registered Pursuant to Section 12(b) of the Act:

Title of each Class	Name of each Exchange on which Registered
	None

Securities Registered Pursuant to Section 12(g) of the Act:

Common Stock, $.001 Par Value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:   x  Yes     ¨   No.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     x  Yes     ¨   No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

Large accelerated filer       ¨	Accelerated filer       ¨
Non-accelerated filer         ¨	Smaller reporting company      x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):   ¨  Yes    x No

As of November 14, 2014, there were 48,634,549 shares of common stock, $.001 par value per share, issued and outstanding.

APOLLO MEDICAL HOLDINGS, INC.

INDEX TO FORM 10-Q FILING

TABLE OF CONTENTS

		PAGE
	PART I
	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements – Unaudited	3
	Balance Sheets as of September 30, 2014 and March 31, 2014	3
	Statements of Operations and Comprehensive Income (Loss) for the Three and Six Months Ended September 30, 2014 and 2013	4
	Statement of Changes in Stockholders’ Equity for the Six Months Ended September 30, 2014	5
	Statements of Cash Flows for the Six Months Ended September 30, 2014 and 2013	6
	Notes to Condensed Consolidated Financial Statements - Unaudited	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	36
Item 4.	Control and Procedures.	36
	PART II
	OTHER INFORMATION
Item 1.	Legal Proceedings	37
Item 1A	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and the Use of Proceeds	37
Item 3.	Defaults upon Senior Securities	37
Item 4.	Mine Safety Disclosures	37
Item 5.	Other Information	37
Item 6.	Exhibits	38

2

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS  

APOLLO MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30,			March 31,
	2014			2014
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	3,950,125		$	6,831,478
Marketable securities		422,181			-
Restricted cash		40,000			20,000
Accounts receivable, net		3,369,780			1,508,461
Other receivable		5,382,617			-
Due from affiliates		49,377			24,041
Prepaid expenses		145,110			42,200
Total current assets		13,359,190			8,426,180
Deferred financing costs, net		324,003			366,286
Property and equipment, net		620,036			94,948
Intangible assets, net		1,206,319			59,627
Goodwill		439,694			494,700
Other assets		108,747			41,636
TOTAL ASSETS	$	16,057,989		$	9,483,377
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued liabilities	$	3,792,645		$	1,447,040
Medical liabilities		1,642,497			552,561
Note and line of credit payable, net of discount, current portion		304,764			444,764
Holdback consideration		136,822			-
Total current liabilities		5,876,728			2,444,365
Notes payable, net of discount – non-current portion		5,343,644			5,344,565
Convertible notes payable, net of discount		1,953,587			962,978
Warrant liability		2,750,480			2,354,624
Conversion feature liability		547,784			-
Deferred tax liability		89,791			-
Total liabilities		16,562,014			11,106,532
COMMITMENTS, CONTINGENCIES AND SUBSEQUENT EVENTS  (NOTES 10 AND 11)
STOCKHOLDERS' DEFICIT
Preferred stock, par value $0.001;
5,000,000  shares authorized; none issued		-			-
Common Stock, par value $0.001; 100,000,000 shares authorized, 49,134,549  shares issued and outstanding as of September 30, 2014 and March 31, 2014, respectively		49,135			49,135
Additional paid-in-capital		16,191,023			15,083,365
Accumulated other comprehensive income		33,088			-
Accumulated deficit		(16,649,019	)		(16,347,588	)
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.		(375,773	)		(1,215,088	)
Non-controlling interest		(128,252	)		(408,067	)
Total		(504,025	)		(1,623,155	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	16,057,989		$	9,483,377

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.  

3

APOLLO MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

	Three Months Ended September 30,						Six Months Ended September 30,
	2014			2013			2014			2013
Net revenues	$	11,665,294		$	2,521,421		$	15,759,780		$	5,136,115
Costs and expenses
Cost of services		6,161,645			2,257,945			9,421,484			4,715,875
General and administrative		3,451,907			1,043,565			5,461,239			2,965,395
Depreciation and amortization		193,281			6,528			205,180			12,883
Total costs and expenses		9,806,833			3,308,038			15,087,903			7,694,153
Income (loss) from operations		1,858,461			(786,617	)		671,877			(2,558,038	)
Other (expense) income
Interest expense		(329,258	)		(200,562	)		(606,125	)		(362,252	)
Gain on change in fair value of warrant and conversion feature liabilities		152,140			-			122,135			-
Other		(58,436	)		6,441			(60,912	)		7,490
Total other expense		(235,554	)		(194,121	)		(544,902	)		(354,762	)
Income (loss) before provision for income taxes		1,622,907			(980,738	)		126,975			(2,912,800	)
Provision for income taxes		86,989			-			98,591			800
Net income (loss)		1,535,918			(980,738	)		28,384			(2,913,600	)
Net income attributable to noncontrolling interest		(159,608	)		-			(329,815	)		-
Net income (loss) attributable to Apollo Medical Holdings, Inc.	$	1,376,310		$	(980,738	)	$	(301,431	)	$	(2,913,600	)
Other comprehensive income (loss):
Unrealized change in value of marketable securities		14,499			-			33,088
Comprehensive income (loss)	$	1,390,809		$	(980,738	)	$	(268,343	)	$	(2,913,600	)
NET INCOME (LOSS) PER SHARE:
BASIC	$	0.03		$	(0.03	)	$	(0.01	)	$	(0.08	)
DILUTED	$	0.03		$	(0.03	)	$	(0.01	)	$	(0.08	)
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING:
BASIC		49,134,549			36,353,413			49,134,549			37,261,375
DILUTED		54,393,442			36,353,413			49,134,549			37,261,375

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2014

(UNAUDITED)

	Preferred  Shares		Amount		Common Shares		Amount		Additional Paid-In Capital		Accumulated other comprehensive income		Accumulated Deficit			Stockholders' Equity Attributable to Apollo Medical Holdings,  Inc.			Non-controlling Interest			Total
Balance - beginning of period		-		-		49,134,549	$	49,135	$	15,083,365	$	-	$	(16,347,588	)	$	(1,215,088	)	$	(408,067	)	$	(1,623,155	)
Net income		-		-		-		-		-		-		(301,431	)		(301,431	)		329,815			28,384
Issuance of warrants										132,000							132,000			-			132,000
Contribution by non-controlling interest										-		-		-			-			550,000			550,000
Distribution to non-controlling interest										-		-		-			-			(600,000	)		(600,000	)
Unrealized change in value of marketable securities		-		-		-		-		-		33,088		-			33,088			-			33,088
Stock-based compensation expense		-		-		-		-		975,658		-		-			975,658			-			975,658
Balance - end of period		-		-		49,134,549	$	49,135	$	16,191,023	$	33,088	$	(16,649,019	)	$	(375,773	)	$	(128,252	)	$	(504,025	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

APOLLO MEDICAL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED) 

	Six Months Ended September 30,
	2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	28,384		$	(2,913,600	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization expense		205,180			12,883
Deferred income taxes		59,314			-
Stock-based compensation expense		975,658			2,121,012
Amortization of financing costs		62,283			4,298
Amortization of debt discount		177,963			116,248
Change in fair value of warrant and conversion feature liability		(122,135	)		-
Changes in assets and liabilities:
Accounts receivable		(993,669	)		323,859
Other receivable		(5,382,617	)		-
Due from affiliates		42,378			17,706
Prepaid expenses and advances		(14,167	)		15,290
Other assets		(347	)		(4,100	)
Accounts payable and accrued liabilities		2,170,739			(6,276	)
Medical liabilities		668,779			-
Net cash used in operating activities		(2,122,257	)		(312,680	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions, net of $620,960 in cash and cash equivalents acquired		(1,947,431	)		(248,800	)
Property and equipment acquired		(15,583	)		(2,219	)
Net cash used in investing activities		(1,963,014	)		(251,019	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of convertible note payable		2,000,000			-
Principal payments on notes payable		(726,082	)		55,235
Contribution by non-controlling interest		550,000			-
Distributions to non-controlling interest shareholder		(600,000	)		(240,000	)
Proceeds from issuance of common stock		-			728,753
Debt issuance costs		(20,000	)		-
Net cash provided by financing activities		1,203,918			543,988
NET DECREASE IN CASH & CASH EQUIVALENTS		(2,881,353	)		(19,711	)
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD		6,831,478			1,094,973
CASH & CASH EQUIVALENTS, END OF PERIOD	$	3,950,125		$	1,075,262
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	$	356,196		$	169,802
Income taxes paid	$	18,588		$	38,356
Non-Cash Financing Activities:
Acquisition related holdback liability consideration	$	136,822		$	-
Convertible note warrant	$	487,620		$	13,316
Convertible note conversion feature	$	578,155		$	125,000
Acquisition related warrant consideration	$	132,000		$	101,817

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

APOLLO MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.            Description of Business

Apollo Medical Holdings, Inc. (the “Company” or “ApolloMed”) and its affiliated physician groups are a physician-centric, integrated healthcare delivery system serving Medicare, Commercial and Medi-Cal beneficiaries in California.  ApolloMed’s physician network consists of hospitalists, primary care physicians and specialist physicians primarily through the Company’s owned and affiliated physician groups. ApolloMed operates as a medical management holding company through the following subsidiary management companies: Apollo Medical Management, Inc. (“AMM”), Pulmonary Critical Care Management, Inc. (“PCCM”), Verdugo Medical Management, Inc. (“VMM”), and ApolloMed ACO, Inc. (“ApolloMed ACO). Through AMM, PCCM, and VMM, the Company manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH"), ApolloMed Care Clinic (“ACC”), Maverick Medical Group, Inc. (“MMG”), Los Angeles Lung Center (“LALC”), Eli Hendel, M.D., Inc. (“Hendel”), AKM Medical Group, Inc. (“AKM”) (see Note 3), and Southern California Heart Centers (“SCHC”) (see Note 3); and a controlling interest in ApolloMed Palliative Services, LLC (“APS”). AMM, PCCM and VMM each operate as a physician practice management company (“PPM”) and are in the business of providing management services to physician practice corporations (“PPC”) under long-term management service agreements. ApolloMed ACO participates in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. 

Change in Fiscal Year

On May 16, 2014, the board of directors of the Company approved a change to the Company's fiscal year end from January 31 to March 31. The March 31, 2014 amounts included in the accompanying condensed consolidated financial statements and related notes thereto are unaudited.

2.        Summary of Significant Accounting Policies

Accounting Principles

These condensed consolidated statements reflect all adjustments, consisting of normal recurring adjustments, which, in management’s opinion, are necessary, and should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2014 as filed with the Securities and Exchange Commission (“SEC”) on May 8, 2014.

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of (1) Apollo Medical Holdings, Inc. and its wholly owned subsidiaries AMM, PCCM, and VMM, (2) the Company’s controlling interest in ApolloMed ACO, and APS, which is a newly formed entity with no operations to date to provide home health and hospice medical services and in which a non-controlling interest in APS contributed $550,000 in cash; and (3) PPCs managed under long-term management service agreements including AMH, MMG, ACC, LALC, Hendel, AKM and SCHC. Some states have laws that prohibit business entities, such as ApolloMed, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In California, the Company operates by maintaining long-term management service agreements with the PPCs, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, the Company provides and performs all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. Each management agreement typically has a term from 10 to 20 years unless terminated by either party for cause. The management agreements are not terminable by the PPCs, except in the case of material breach or bankruptcy of the respective PPM.

Through the management agreements and the Company’s relationship with the stockholders of the PPCs, the Company has exclusive authority over all non-medical decision making related to the ongoing business operations of the PPCs. Consequently, the Company consolidates the revenue and expenses of each PPC from the date of execution of the applicable management agreement.

All intercompany balances and transactions have been eliminated in consolidation.

7

Revenue Recognition

Revenue consists of contracted, fee-for-service, and capitation revenue. Revenue is recorded in the period in which services are rendered. Revenue is principally derived from the provision of healthcare staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services may vary by customer. The following is a summary of the principal forms of the Company’s billing arrangements and how net revenue is recognized for each.

Contracted revenue

Contracted revenue represents revenue generated under contracts for which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates. Revenue in such cases is recognized as the hours are worked by the Company’s staff and contractors. Additionally, contract revenue also includes supplemental revenue from hospitals where the Company may have a fee-for-service contract arrangement or provide physician advisory services to the medical staff at a specific facility. Contract revenue for the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms generally either provides for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or collections per visit compared to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. Additionally, the Company derives a portion of the Company’s revenue as a contractual bonus from collections received by the Company’s partners and such revenue is contingent upon the collection of third-party billings. These revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in accordance with the contractual arrangements for such services.

Fee-for-service revenue 

Fee-for-service revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted and employed physicians. Under the fee-for-service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. Fee-for-service revenue is recognized in the period in which the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the case of those patients having third-party payor coverage. The recognition of net revenue (gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services.

Capitation revenue

Capitation revenue (net of capitation withheld to fund risk share deficits) is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted health maintenance organizations (each, an “HMO”) finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a provider service agreement (PSA) or capitated arrangements directly made with various managed care providers including HMO’s. Capitation revenue under the PSA and HMO contracts is prepaid monthly to the Company based on the number of enrollees electing the Company as their healthcare provider. Additionally, Medicare pays capitation using a “Risk Adjustment model,” which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on an interim basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.

8

HMO contracts also include provisions to share in the risk for enrollee hospitalization, whereby the Company can earn additional incentive revenue or incur penalties based upon the utilization of hospital services. Typically, any shared risk deficits are not payable until and unless the Company generates future risk sharing surpluses, or if the HMO withholds a portion of the capitation revenue to fund any risk share deficits. At the termination of the HMO contract, any accumulated risk share deficit is typically extinguished. Due to the lack of access to information necessary to estimate the related costs, shared-risk amounts receivable from the HMOs are only recorded when such amounts are known. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following fiscal year.

In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. These incentives, which are included in other revenues, are generally recorded in the third and fourth quarters of the fiscal year and are recorded when such amounts are known.

Under full risk capitation contracts, an affiliated hospital entered into agreements with several HMOs, pursuant to which, the affiliated hospital will provide hospital, medical, and other healthcare services to enrollees under a fixed capitation arrangement ("Capitation Arrangement"). Under the risk pool sharing agreement, the affiliated hospital and medical group agreed to establish a Hospital Control Program to serve the enrollees, pursuant to which, the medical group is allocated a 90% residual interest in the profit or loss, after deductions for costs to affiliated hospitals. The Company participates in the full risk programs under the terms of the PSA, whereby the Company is wholly liable for the deficits allocated to the medical group under the arrangement. The related liability is included in medical liabilities in the accompanying unaudited condensed consolidated balance sheets at September 30 and March 31, 2014 (see "Medical Liabilities" in this Note 2, below).

Medicare Shared Savings Program Revenue

The Company through its subsidiary, ApolloMed ACO, participates in the MSSP sponsored by the Centers for Medicare & Medicaid Services (“CMS”). The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants trailing 24 month medical service history. The MSSP is a newly formed program with minimal history of payments to ACO participants. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined by CMS, and are not considered earned and therefore are not recognized as revenue until notice from CMS that cash payments are to be imminently received.

During the second quarter of 2014, CMS announced that ApolloMed ACO generated $10.98 million in program savings from cost savings created in connection with rendering medical services to Medicare patients in 2012. In connection with these cost savings, the Company earned $5.38 million which has been reported in the line items “Net Revenue and “other receivable” in the September 30, 2014 condensed consolidated financial statements. Revenue from the MSSP is determined and awarded annually, and the Company does not anticipate additional revenue in fiscal 2015. Future ACO program savings for services performed in calendar year 2013 and 2014 are not estimable.

Concentrations  

Excluding the MSSP related revenue, the Company had no major payors during the three months ended September 30, 2014 which contributed more than 10% of net revenues, and had three major payors during the three months ended September 30, 2013 which contributed 16.1%, 16.1% and 16.8% of net revenues, respectively. During the six months ended September 30, 2014, excluding the MSSP related revenue, the Company had no major payors which contributed more than 10% of net revenues and had three major payors during the six months ended September 30, 2013 which contributed 15.8%, 16.1% and 17.6% of net revenues, respectively.

The Company had one major payor that accounted for 12.5 % of accounts receivable as of September 30, 2014, and two major payors that accounted for 21.7% and 9.6% of accounts receivable, respectively, as of March 31, 2014.

9

Cash Equivalents and Marketable Securities

The Company’s cash equivalents consist of bank demand deposits and highly liquid investments with original maturities of three months or less from the original purchase date.

The Company’s marketable securities consist of our holdings in equity securities and mutual funds. These are classified as available-for-sale, which are measured each reporting period at fair value, with any unrealized change in value reflected in other comprehensive income or loss, and realized gains or losses in the statement of operations in the accompany condensed consolidated statements of operations and comprehensive income (loss). Other than temporary impairments are evaluated for securities that have been in a continuous unrealized loss position longer than one year.

The following is a summary of cash equivalents and marketable securities:

As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
			Unrealized		Unrealized		Fair		Cash		Securities
	Cost		Gain		Loss		Value		Equivalents		(all current)
Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
Money market funds		93,840		-		-		93,840		93,840		-
Mutual funds		148,028		966		-		148,994		-		148,994
Equity securities		241,065		32,122		-		273,187		-		273,187
	$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181

As of March 31, 2014			Gross		Gross		Estimated		Cash and
			Unrealized		Unrealized		Fair		Cash
	Cost		Gain		Loss		Value		Equivalents
Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
	$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478

Medical Liabilities

The Company is responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees under risk-pool arrangements. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in cost of services.

An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying condensed consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates of incurred but not reported claims (“IBNR”). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. The Company has a $20,000 per member professional stop-loss, none on institutional risk pools. Any adjustments to reserves are reflected in current operations.

The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	274,000
Incurred health care costs:
Current year		1,566,856
Prior years		-
Total incurred health care costs		1,566,856
Acquired medical liabilities (see Note 3 )		292,309
Claims paid:
Current year		(997,390	)
Prior years		(64,482	)
Total claims paid		(1,061,872	)
Adjustments		(197,938	)
Balance, end of period	$	873,355

10

The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	278,561
Acquired medical liabilities (see Note 3)		128,848
Claims paid:		-
Accrual for net deficit from full risk capitation contracts		361,733
Balance, end of period	$	769,142

The Company’s total medical liability at September 30, 2014 and March 31, 2014 was $1,642,497 and $552,561, respectively.

 Fair Value of Financial Instruments

The Company’s accounting for Fair Value Measurement and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level one — Quoted market prices in active markets for identical assets or liabilities;

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.

The fair values of the Company’s financial instruments are measured on a recurring basis. The carrying amount reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value because of the short-term maturity of those instruments. The carrying amount for borrowings under the NNA Term Loan and the Convertible Notes approximates fair value which is determined by using interest rates that are available for similar debt obligations with similar terms at the balance sheet date.

Warrant liability

The fair value of the warrant liability issued in connection with 2014 NNA Financing at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.5 years, risk free rate of 2.1%, no dividends, volatility of 72.2%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. The fair value of the warrant liability at March 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 50% probability of down-round financing. 

The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.

Holdback liability 

The holdback liability (see Note 3) fair value was determined based on the probability adjusted cash consideration, discounted at the Company's cost of debt.

11

Conversion feature liability

The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.5 years, risk free rate of 1.6%, no dividends, volatility of 55.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability that the Company will participate in a “down-round” financing at price per share lower than the initial NNA Financing 8% Convertible Note conversion price of $1.00 per share.

The carrying amounts and fair values of the Company's financial instruments are presented below as of:

September 30, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market currency funds	$	-	$	93,840	$	-	$	93,840
Mutual funds		-		148,994		-		148,994
Equity securities		273,187		-		-		273,187
	$	273,187	$	242,834	$	-	$	516,021
Liabilities:
Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
Holdback consideration		-		-		136,822		136,822
Conversion feature liability		-		-		547,784		547,784
	$	-	$	-	$	3,435,086	$	3,435,086

March 31, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
	$	-	$	-	$	2,354,624	$	2,354,624

The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:

	Three months			Six months
Balance, beginning of period	$	2,521,451		$	2,354,624
Warrant liability incurred (Note 7)		487,620			487,620
Change in warrant liability		(121,769	)		(91,764	)
Holdback consideration		-			136,822
Conversion feature liability incurred (Note 7)		578,155			578,155
Change in conversion feature liability		(30,371	)		(30,371	)
Balance, end of period	$	3,435,086		$	3,435,086

The unrealized gain on changes in fair value of warrant and conversion feature liability is included in the accompanying condensed consolidated statement of operations and comprehensive loss. 

Non-controlling Interest

The non-controlling interest recorded in the Company’s condensed consolidated financial statements represents the pre-acquisition equity of those PPC’s in which the Company has determined that it has a controlling financial interest and for which consolidation is required as a result of management contracts entered into with these entities. The nature of these contracts provide the Company with a monthly management fee to provide the services described above, and as such, the adjustments to non-controlling interests in any period subsequent to initial consolidation would relate to either capital contributions or distributions by the non-controlling parties as well as income or losses attributable to certain non-controlling interests.

12

Basic and Diluted Earnings per Share

Basic net income (loss) per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income (loss) per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for secured convertible notes, and the treasury stock method for options and warrants.

The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:

	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
Options	-		4,373,687		3,657,216		4,547,125
Warrants		-		1,428,067		1,495,803		1,535,402
9% Convertible Notes		799,523		674,528		748,824		785,714
		799,523		6,476,282		5,901,843		6,868,241

New Accounting Standards

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40). The guidance in this ASU requires disclosure of uncertainties about an entity’s ability to continue as a going concern even if an entity’s liquidation is not imminent. There may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting and this guidance should be followed to determine whether to disclose information about the relevant conditions and events. This guidance is effective for the Company on December 31, 2016 and the adoption of this standard is not expected to have a significant impact on its condensed consolidated financial statements or notes thereto.

13

Use of Estimates

The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may materially differ from these estimates under different assumptions or conditions.

Reclassifications

Certain reclassifications have been made to the accompanying March 31, 2014 condensed consolidated financial statements to conform them to the September 30, 2014 presentation.

3.  Acquisitions

SCHC

On July 22, 2014, pursuant to a Stock Purchase Agreement dated as of July 21, 2014 (the “Purchase Agreement”) among the Southern California Heart Centers, a Medical Corporation, a medical group that provides professional medical services in Los Angeles County, California (“SCHC”), the shareholders of SCHC (the “Sellers”) and a Company affiliate, SCHC Acquisition, A Medical Corporation (the “Affiliate”), solely owned by Dr. Warren Hosseinion as physician shareholder and the Chief Executive Officer of the Company, the Affiliate acquired all of the outstanding shares of capital stock of SCHC from the Sellers. The purchase price for the shares was (i) $2,000,000 in cash, (ii) $428,391 to pay off and discharge certain indebtedness of SCHC (iii) warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and (iv) a contingent amount of up to $1,000,000 payable, if at all, in cash. The acquisition was funded by an intercompany loan from AMM, which also provided an indemnity in favor of one of the Sellers relating to certain indebtedness of SCHC that remained outstanding following the closing of the acquisition. Following the acquisition of SCHC, the Affiliate was merged with and into SCHC, with SCHC being the surviving corporation. The indebtedness of SCHC was paid off following the acquisition and did not remain outstanding as of September 30, 2014.

In connection with the acquisition of SCHC, AMM entered into a management services agreement with the Affiliate on July 21, 2014. As a result of the Affiliate’s merger with and into SCHC, SCHC is now the counterparty to this management services agreement and bound by its terms. Pursuant to the management services agreement, AMM will manage all non-medical services for SCHC, will have exclusive authority over all non-medical decision making related to the ongoing business operations of SCHC, and is the primary beneficiary of SCHC, and the financial statements of SCHC will be consolidated as a variable interest entity with those of the Company from July 21, 2014.

The Company accounted for the acquisition as a business combination using the acquisition method of accounting which requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The acquisition-date fair value of the consideration transferred was as follows:

Cash consideration	$	2,428,391
Fair value of warrant consideration		132,000
	$	2,560,391

The warrants were classified as equity. The fair value of the warrants was determined using the Black-Scholes option pricing model using the following inputs: share price of $0.54 (adjusted for a lack of control discount), exercise price of $1.00, expected term of 4 years, volatility of 54% and a risk free interest rate of 1.35%.

A contingent payment obligation of $1,000,000 was considered a post-combination transaction and therefore it will be recorded as post-combination compensation expense over the term of the arrangement and not as purchase consideration. The compensation expense will be accrued in each reporting period using the total probability weighted payment of $827,000, allocated to each quarter, and between each Seller, pro rata over the term of the arrangement according to the relative weight of the payment milestones. The remaining liability will be re-measured at every reporting period date, with any adjustment reflected prospectively in compensation expense.

14

Transaction costs are not included as a component of consideration transferred and were expensed as incurred. The related transaction costs expensed for the three and six months ended September 30, 2014 were approximately $124,000 in each period and are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss).

Under the acquisition method of accounting, the total purchase price was allocated to the underlying tangible and intangible assets acquired and liabilities assumed based on their respective fair values, with the remainder allocated to goodwill. The preliminary allocation of the total purchase price to the net assets acquired and liabilities assumed and included in the Company’s condensed consolidated balance sheet at September 30, 2014 is as follows:

Cash and cash equivalents	$	264,601
Accounts receivable		840,433
Receivable from affiliate		67,714
Prepaid expenses and other current assets		82,430
Property and equipment		584,377
Identifiable intangible assets		1,121,000
Goodwill		161,559
Other assets		66,762
Total assets acquired		3,188,876
Accounts payable and accrued liabilities		134,427
Note payable to financial institution		463,582
Deferred tax liability		30,477
Total liabilities assumed		628,485
Net assets acquired	$	2,560,391

The intangible assets acquired consisted of the following:

	Life (yrs)		Additions
Network relationships		5	$	910,000
Trade name		5		110,000
Non-compete agreements		3		101,000
			$	1,121,000

The network relationships were valued using the multi-period excess earnings method based on projected revenue and earnings over a 5 year period. The trade name was computed using the relief from royalty method, assuming a 1% royalty rate, and the non-compete agreements were valued using a with-and-without method.

See below for the combined SCHC and AKM pro forma results of operations.

AKM

In May 2014, AMM entered into a management services agreement with AKM Acquisition Corp, Inc. (“AKMA”), a newly-formed provider of physician services and an affiliate of the Company owned by Dr. Warren Hosseinion as a physician shareholder, to manage all non-medical services for AKMA. AMM has exclusive authority over all non-medical decision making related to the ongoing business operations of AKMA and is the primary beneficiary; consequently, AMM consolidated the revenue and expenses of AKMA from the date of execution of the management services agreements. On May 30, 2014 (the “Closing Date”) AKMA entered into a stock purchase agreement (the “AKM Purchase Agreement”) with the shareholders of AKM Medical Group, Inc.(“AKM”), a Los Angeles, CA-based independent practice association (“IPA”) .. Immediately following the closing, AKMA merged with and into AKM, with AKM being the surviving entity and assuming the rights and obligations under the management services agreement. Under the AKM Purchase Agreement all of the issued and outstanding shares of capital stock of AKM was acquired for approximately $280,000, of which $140,000 was paid at closing and $136,822 (the “Holdback Liability”) is payable subject to the outcome of incurred but not reported risk-pool claims and other contingent claims that existed at the acquisition date. The acquisition allows the Company to execute on its strategy to provide high-quality, cost-efficient healthcare delivery through integrated services and network offerings.

15

The Company accounted for the acquisition as a business combination using the acquisition method of accounting which requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates.  The acquisition-date fair value of the consideration transferred was as follows:

Cash consideration	$	140,000
Fair value of holdback consideration due to seller		136,822
Total purchase consideration	$	276,822

Under the acquisition method of accounting, the total purchase price was allocated to AKM’s net tangible assets based on their estimated fair values as of the closing date. The preliminary allocation of the total purchase price to the net assets acquired and included in the Company’s condensed consolidated balance sheet is as follows:

Cash and cash equivalents	$	356,359
Marketable securities		389,094
Accounts receivable		27,217
Prepaid expenses and other assets		26,311
Intangibles		156,000
Goodwill		(216,563	)
Accounts payable and accrued liabilities		(40,439	)
Medical payables		(421,157	)
Net assets acquired	$	276,822

Before recognizing a gain from a bargain purchase, the Company is required to reassess its identification of assets acquired and liabilities assumed to validate that all assets and liabilities that the acquirer is able to identify at the acquisition date are properly recognized. The guidance in ASC 805 requires that this additional reassessment be performed to verify that the identification and measurement of all components of the business combination were consistent with the requirements of ASC 805. Accordingly, as the purchase price allocation is preliminary and subject to reassessment, the Company will classify the goodwill bargain purchase as a contra to goodwill until it has completed its review of the procedures used to measure the included amounts, which is expected to be during the quarter ending December 31, 2014.      

Under the AKM Purchase Agreement, former shareholders of AKM are entitled to be paid the Holdback Amount of up to approximately $140,000 within 6 months of the Closing Date. No later than 30 days after the six month period, AKM will prepare a closing statement which will state the actual cash position (as defined) (“Actual Cash Position”) of AKM. If the actual cash position of AKM is less than $461,104 (the “Target Amount”), the former shareholders of AKM will pay the difference between the Target Amount and the Actual Cash Position, which will be deducted from the Holdback Amount, but in no case will exceed the amount previously paid to the former shareholders of AKM in connection with the transaction. If the Actual Cash Position exceeds the Target Amount, then that difference will be added to the Holdback Amount. Any indemnification payment made by the former shareholders of AKM will also be paid from the Holdback Amount; if the Holdback Amount is insufficient, the former shareholders of AKM are liable for paying the balance, which cannot exceed amounts previously paid to the former shareholders of AKM under the AKM Purchase Agreement. The Company determined the preliminary fair value was determined based on the cash consideration discounted at the Company's cost of debt.

Transaction costs are not included as a component of consideration transferred and were expensed as incurred. The related transaction costs expensed for the three and six months ended September 30, 2014 were approximately $0 and $37,000, respectively.

16

Pro Forma Financial Information

The results of operations for AKM and SCHC are included in the condensed consolidated statements of operations from the acquisition date of each. The pro forma results of operations are prepared for comparative purposes only and do not necessarily reflect the results that would have occurred had the acquisitions occurred at the beginning of the years presented or the results which may occur in the future. The following unaudited pro forma results of operations for the three and six months ended September 30, 2014 assume both the AKM and SCHC acquisitions had occurred on April 1, 2014, and for the six months ended September 30, 2013 assume the acquisitions had occurred on April 1, 2013:

	Three months ended September 30,					Six months ended September 30,
	2014		2013			2014			2013
	(unaudited)		(unaudited)			(unaudited)			(unaudited)
Net revenue	$	11,899,142	$	4,477,640		$	17,956,326		$	9,135,956
Net income (loss)	$	1,410,936	$	(1,067,658	)	$	(209,441	)	$	(3,054,008	)
Basic income (loss) per share	$	0.03	$	(0.02	)	$	(0.00	)	$	(0.08	)
Diluted income (loss) per share	$	0.03	$	(0.02	)	$	(0.00	)	$	(0.08	)

From the applicable closing date to September 30, 2014, revenues and net loss related to AKM and SCHC included the accompanying condensed and consolidated statement of operations were $1,872,529 and $(260,624), respectively.

4. Goodwill and Other Intangible Assets

Goodwill

The following is a summary of goodwill activity for the six months ended September 30, 2014:

Balance, beginning of period	$	494,700
Acquisition of AKM		(216,565	)
Acquisition of SCHC		161,559
Balance, end of period	$	439,694

Other Intangible Assets

Other intangible assets consisted of the following:

	Weighted-average life	Balance at						Balance at
	(Yrs)	March 31, 2014			Additions			September 30, 2014
Intangible assets:
Exclusivity	4.0	$	40,000		$	-		$	40,000
Non-compete	4.0		28,400			120,000			148,400
Payor relationships	5.0		-			94,000			94,000
Network relationships	5.0		-			910,000			910,000
Trade name	5.0		-			153,000			153,000
Totals			68,400			1,277,000			1,345,400
Accumulated amortization			(8,773	)		(130,308	)		(139,081	)
Total other intangibles, net		$	59,627		$	1,146,692		$	1,206,319

The amortization expense for the three and six months ended September 30, 2014 was approximately $125,000 and $130,000, respectively. The amortization expense for the three and six months ended September 30, 2013 was approximately $1,000 in each period.

Future amortization expense is estimated to be as follows for the period from October 1, 2014 to March 31, 2015 and for each for the five years ending March 31 thereafter:

October 1, 2014 to March 31, 2015	$       255,000
2016	$       326,000
2017	$       259,000
2018	$       192,000
2019	$       125,000
Thereafter	$         46,000

17

5. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

	September 30,		March 31,
	2014		2014
Accounts payable	$	1,456,796	$	824,334
Physician share of MSSP ACO savings		1,400,000		-
Accrued compensation		809,772		546,078
Income taxes payable		85,477		4,149
Accrued interest		28,049		19,780
Accrued professional fees		12,550		52,699
	$	3,792,645	$	1,447,040

6. Notes and Line of Credit Payable

Notes and line of credit payable consist of the following:

	September 30,		March 31,
	2014		2014
Term loan payable to NNA due March 28, 2019, net of debt discount of $1,183,856 (September 30, 2014) and $1,305,435 (March 31, 2014)	$	5,553,644	$	5,694,565
Unsecured revolving line of credit due to financial institution due June 5, 2015		94,764		94,764
	$	5,648,408	$	5,789,329

Senior Secured Note

The Company entered into a Senior Secured Note (“Note”) agreement on February 1, 2012 with SpaGus Capital Partners, LLC (“SpaGus”) an entity in which Gary Augusta, a director and shareholder of the Company, holds an ownership interest.

On September 15, 2012, SpaGus agreed to allow the Company to defer payment of the scheduled principal payments due on September 15 and October 15, 2012, and amended the Note effective October 15, 2012 in which SpaGus agreed to provide additional principal to the Company in the amount of $230,000. The terms of the amended Note in the amount of $500,000 provided for borrowings to bear interest at 8.0 % per annum with accrued interest payable in arrears on each of December 28, 2012, March 31, 2013, June 30, 2013, and October 15, 2013. The amended Note matured and was repaid, including accrued unpaid interest, on October 16, 2013.

Medical Clinic Acquisition Promissory Notes

In connection with the September 1, 2013 acquisition of a Los Angeles, CA medical clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in ten installments of $15,000 per month commencing December 1, 2013.  The Company determined the fair value of the note using an interest rate of 5.45% per annum to discount future cash flows, which was based on Moody’s Baa-rated corporate bonds at the valuation date.  The note was secured by substantially all assets of the clinic.

18

In connection with the January 6, 2014 acquisition of Fletcher Medical Clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in installments of $15,000 per month for five months commencing April 1, 2014 under a non-interest bearing promissory note. The Company determined the fair value of the note using an interest rate of 5.30% per annum to discount future cash flows, which was based on Moody’s Baa-rated corporate bonds at the valuation date. The note was secured by substantially all assets of the acquired clinic.

In connection with the December 7, 2013 acquisition of Eagle Rock Medical Clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in installments of $10,000 per month for eight months commencing March 1, 2014 under a non-interest bearing promissory. The Company determined the fair value of the note using an interest rate of 5.46 % per annum to discount future cash flows, which was based on based on index of Moody's Baa-rated corporate bonds at of the valuation date. The note was secured by substantially all assets of the acquired clinic.

The medical clinic acquisition promissory notes described above were repaid in connection with the equity and debt financing with NNA of Nevada, Inc. that closed on March 28, 2014 (see 2014 NNA Financing below).

NNA Credit Agreements

On October 15, 2013, the Company entered into a $2.0 million secured revolving credit facility (the “Revolving Credit Agreement”) with NNA of Nevada, Inc., (“the Lender” or “NNA”).  On December 20, 2013 the Company entered into the First Amendment to the Credit Agreement (the “Amended Credit Agreement”), which increased the revolving credit facility from $2 million to $4 million.   The proceeds of the Amended Credit Agreement were used by the Company to repay the $500,000 Note to SpaGus Apollo, LLC, and were used to pay or repay certain of the Company’s 10% Notes (see Note 7), to refinance certain other indebtedness of the Company, and for working capital and for general corporate purposes. The Amended Credit Agreement was refinanced on March 28, 2014 in connection with 2014 NNA Financing.

2014 NNA Financing

On March 28, 2014, the Company entered into certain credit and investment agreements with NNA (the “2014 NNA Financing”) which provided for a $7.0 million secured term loan (“Term Loan”), a $1.0 million secured line of credit (“Revolving Loan”), and a $2.0 million convertible note commitment (“Convertible Note”). In addition, NNA acquired 2,000,000 shares of the Company’s common stock, warrants to acquire the Company’s common stock, and certain registration rights (see Note 9). The Term Loan and Revolving Loan are secured by substantially all assets of the Company, and are guaranteed by the Company’s subsidiaries and certain of its consolidated medical corporations.

The Company determined the fair value of the proceeds of $9.0 million in part based on the following inputs for the warrant liability: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share and a 50% probability of down-round financing. The common stock issuance was recorded at $899,739 (a discount of $1,100,261 to the face amount), the Term Loan was recorded at $5,745,637 (a discount of $1,254,363 to the face amount), and a corresponding warrant liability of $2,354,624 was recorded.

The Term Loan accrues interest at a rate of 8.0% per annum. A portion of the principal amount of the Term Loan is repaid on the last business day of each calendar quarter, which provides for quarterly payments of $87,500 in the first year, $122,500 in the second year, $122,500 in the third year, $175,000 in the fourth year, and $210,000 in the fifth year. The Term Loan reflected an original issue discount of $1,305,435 associated with the issuance of 3 million warrants to acquire the Company’s common stock (see Note 9) and payment of a fee to NNA of $80,000 of which $51,072 was considered a debt discount, $7,998 was recorded to equity, and $20,930 allocated to warrant liability was immediately recorded as interest expense. The discount will be amortized to interest expense over the expected term of the loan using the effective interest method.

The Revolving Loan will bear interest at the rate of three month LIBOR plus 6.0% per annum. No amounts were borrowed under the Revolving Loan at September 30, 2014. The Term Loan and Revolving Loan mature on March 28, 2019.

19

The NNA 8% Convertible Note commitment provided for a convertible note commitment of $2,000,000, which, on July 31, 2014, the Company fully exercised (see Note 7).

The Company incurred $235,119 in third party costs related to the 2014 NNA Financing, which were allocated to the related debt and equity instruments based on their relative fair values, of which $150,101 was classified as deferred financing costs which will be deferred and amortized over the life of the loan using the effective interest method.

The 2014 NNA Financing credit agreement and the Convertible Note provide for certain financial covenants which financial covenants the Company was in compliance with as of and for the six-month period ended September 30, 2014.

In addition, the 2014 NNA Financing credit agreement and the Convertible Note include: (1) certain negative covenants that, subject to exceptions, limit the Company’s ability to, among other things incur additional indebtedness, engage in future mergers, consolidations, liquidations and dissolutions, sell assets, pay dividends and distributions on or repurchase capital stock, and enter into or amend other material agreements; and (2) certain customary representations and warranties, affirmative covenants and events of default, which are set forth in more detail in the 2014 NNA Financing credit agreement and Convertible Note.

Unsecured revolving line of credit

Included in “Note and line of credit payable” in the accompanying condensed consolidated balance sheet is a $100,000 revolving line of credit with a financial institution of which $94,764 was outstanding at September 30, 2014 and March 31, 2014. Borrowings under the line of credit bear interest at the prime rate (as defined) plus 4.50% (7.75% per annum at March 31, 2014 and September30, 2014), interest only is payable monthly, and the line of credit matures June 5, 2015. The line of credit is unsecured.

Interest expense associated with the notes and lines of credit payable consisted of the following:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
Interest expense	$	143,845	$	25,089	$	287,998	$	56,087
Amortization of loan fees and discount		71,673		35,061		142,924		39,780
	$	215,518	$	60,151	$	430,922	$	95,868

7.  Convertible Notes Payable

Convertible notes payable consist of the following:

	September 30,		March 31,
	2014		2014
9% Senior Subordinated Convertible Notes due February 15, 2016, net of debt discount of $99,973 (September 30, 2014) and $137,393 (March 31, 2014)	$	1,000,398	$	962,978
8% Senior Subordinated Convertible Note Payable to NNA due March 28, 2019, net of debt discount of $1,046,811		953,189		-
	$	1,953,587	$	962,978

10% Senior Subordinated Callable Convertible Notes

On October 16, 2009, the Company issued $1,250,000 of 10% Senior Subordinated Callable Convertible Notes (the “10% Notes”). The 10% Notes were sold through a placement agent in the form of Units. Each Unit comprised one 10% Senior Subordinated Callable Convertible Note with a par value $25,000, and warrants to purchase shares of the Company’s common stock.

On December 20, 2013, the Company redeemed the 10% Notes for cash and/or conversion into shares of the Company’s Common Stock.

20

8% Senior Subordinated Convertible Promissory Notes due February 1, 2015

On or about February 21, 2013, the Company entered into a Settlement Agreement and Release (collectively, the “Settlement Agreements”) with each of the holders of 8% Notes (each, an “8% Holder” and, collectively, the “8% Holders”). Under the Settlement Agreements, the Company agreed to redeem for cash and/or convert into shares of the Company’s common stock the 8% Notes of the 8% Holders. In February 2014 the Company redeemed and converted $150,000 in original principal amount plus accrued interest thereon, for total cash payments of approximately $106,000 and issuance of approximately182,000 shares of the Company’s common stock.

9% Senior Subordinated Callable Convertible Promissory Notes due February 15, 2016

The 9% Notes bear interest at a rate of 9% per annum, payable semi-annually on August 15 and February 15, and mature February 15, 2016, and are subordinated. The principal of the 9% Notes plus any accrued yet unpaid interest is convertible at any time by the holder at a conversion price of $0.40 per share of Common Stock, subject to adjustment for stock splits, stock dividends and reverse stock splits. After 60 days prior notice, the Note is callable in full or in part by the Company at any time after January 31, 2015. If the Average Daily Value of Trades (“ADVT”) during the prior 90 days as reported by Bloomberg is greater than $100,000, the Note is callable at a price of 105% of the Note’s par value, and if the ADVT is less than $100,000, the 9% Notes are callable at a price of 110% of the Note’s par value.

In connection with the issuance of the 9% Notes, the holders of the 9% Notes received warrants to purchase 660,000 shares of the Company’s common stock at an exercise price of $0.45 per share, subject to adjustment for stock splits, reverse stock splits and stock dividends, and which are exercisable at any date prior to January 31, 2018, and were classified in equity. The fair value of the 9% Notes warrants was based on the Company’s closing stock price at the transaction date and inputs to the Black-Scholes option pricing model.

NNA 8% Convertible Note

The NNA 8% Convertible Note commitment provided for the Company to borrow up to $2,000,000. On July 31, 2014, the Company exercised its option to borrow $2,000,000, received $2,000,000 of proceeds and recorded a debt discount of $1,065,775 related to the fair value of a conversion feature liability and warrant liability discussed below. Borrowings bear interest at the rate of 8.0 % per annum payable semi-annually, and are convertible into shares of the Company’s common stock initially at $1.00 per share. The conversion price will be subject to adjustment in the event of subsequent down-round equity financings, if any, by the Company. The conversion feature included a non-standard anti-dilution feature that has been bifurcated and recorded as a conversion feature liability at the issuance date of $578,155. The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.7 years, risk free rate of 1.6%, no dividends, volatility of 54.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. In addition the Company was required to issue 1,000,000 warrants to NNA with an exercise price of $1.00 per share. The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.

Interest expense associated with the convertible notes payable consisted of the following:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
Interest expense	$	52,856	$	111,387	$	77,881	$	185,619
Amortization of loan fees and discount		60,884		29,025		97,322		80,766
	$	113,740	$	140,411	$	175,203	$	266,384

21

8. Income Taxes

Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Significant management judgment is required in determining the Company’s provision for income taxes and the recoverability of the Company’s deferred tax assets. Such determination is based primarily on the Company’s historical taxable income, with some consideration given to the Company’s estimates of future taxable income by jurisdictions in which the Company operates and the period over which the Company’s deferred tax assets will be recoverable. Due to overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets as of September 30, 2014 and March 31, 2014. The Company is subject to U.S. federal income tax, as well as income tax of multiple state tax jurisdictions.

ASC No. 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC No. 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure requirements. The Company and its subsidiaries are currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2010 and later. The Company’s state income tax returns are open to audit under the statute of limitations for the years ended December 31, 2009 and later. The Company does not anticipate any material unrecognized tax benefits within the next twelve months.

9. Stockholders’ Equity

Common Stock Placement

On March 28, 2014, the Company entered into an equity and debt investment for up to $12.0 million with NNA. As part of the investment, the Company entered into an Investment Agreement with NNA, dated March 28, 2014 (the “Investment Agreement”), pursuant to which the Company sold NNA 2,000,000 shares of the Company’s common stock (the “Purchased Shares”) at a purchase price of $1.00 per share. In addition with the issuance of common shares, the Company issued to NNA 1,000,000 warrants to purchase the Company’s common stock for $1.00 per share. The Company used the Monte Carlo Method to value the warrants, which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share and a 50% probability of down-round financing. The Company determined that the fair value of the shares issued was approximately $900,000, or approximately $0.45 per share. The Company also entered into a registration rights agreement (“RRA”) with NNA which requires the Company to file a registration statement to register its shares with the Securities and Exchange Commission no later than March 28, 2015. The RRA requires the Company to use commercially reasonable efforts to cause the RRA to be declared effective by the SEC. If the Initial Registration Statement is not filed with the SEC on or prior to the filing deadline the Company must pay to NNA an amount in Common Stock based upon its then fair market value, as liquidated damages equal to 1.50% of the aggregate purchase price paid by NNA.

Equity Incentive Plans  

The Company’s amended 2010 Equity Incentive Plan (the “2010 Plan”) allowed the Board to grant up to 12,000,000 shares of the Company’s common stock, and provided for awards including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. As of September 30, 2014, there were no shares available for grant.

On April 29, 2013 the Company’s Board of Directors approved the Company’s 2013 Equity Incentive Plan (the “2013 Plan”), pursuant to which 5,000,000 shares of the Company’s common stock were reserved for issuance thereunder. The Company received approval of the 2013 Plan from the Company’s stockholders on May 19, 2013. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of September 30, 2014 there were approximately 1,900,000 shares available for future grants under the 2013 Plan.

Stock options and restricted common stock issued to non-employees as compensation for services to be provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair value of the option or share, whichever can be more clearly determined. The Company recognizes this expense over the period in which the services are provided.   

Share Issuances   

A summary of the Company’s restricted stock sold to employees, directors and consultants with a right of repurchase of unlapsed or unvested shares is as follows for the six months ended September 30, 2014:

				Weighted Average Remaining Vesting		Weighted Average Per Share		Weighted- average Per Share
				Life		Intrinsic		Grant Date
	Shares			(In years)		Value		Fair Value
Unvested or unlapsed shares, beginning of period		907,407			1.3	$	-	$	0.41
Granted		-			-		-		-
Vested / lapsed		(611,111	)		-		-		-
Forfeited		-			-		-		-
Unvested or unlapsed shares, end of period		296,296			1.1	$	0.06	$	0.41

22

Options

In July 2014, the Company issued 565,000 options to acquire the Company’s common stock to certain employees and consultants. The Company determined that the weighted average fair value of the options of $0.24 per share using the Black-Scholes method with the following weighted-average inputs: term of 6 years, risk free rate of 1.63%, no dividends, volatility of 63.7%, share price of $0.54 per share.

Stock option activity for the six months ended September 30, 2014 is summarized below:

	Shares			Weighted Average Per Share Exercise Price		Weighted Average Remaining Life (Years)		Weighted Average Per Share Intrinsic Value
Balance, beginning of period		6,287,000		$	0.20		8.7	$	0.11
Granted		565,000			1.00		-		-
Cancelled		(100,000	)		-		-		-
Exercised		-			-		-		-
Expired		-			-		-		-
Forfeited		-			-		-		-
Balance, end of period		6,752,000		$	0.22		8.2	$	0.24
Vested and exercisable, end of period		6,145,889		$	0.21		7.5	$	0.26

ApolloMed ACO 2012 Equity Incentive Plan

On October 18, 2012 ApolloMed ACO’s Board of Directors adopted the ApolloMed Accountable Care Organization, Inc. 2012 Equity Incentive Plan (the “ACO Plan”) and reserved 9,000,000 shares of ApolloMed ACO’s common stock for issuance thereunder. The purpose of the ACO Plan is to encourage selected employees, directors, consultants and advisers to improve operations and increase the profitability of ApolloMed ACO and encourage selected employees, directors, consultants and advisers to accept or continue employment or association with ApolloMed ACO.

The following table summarizes the restricted stock award in the ACO Plan during the six months ended September 30, 2014:

	Shares			Weighted Average Remaining Vesting Life (Years)		Weighted Average Per Share Intrinsic Value		Weighted Average Per Share Fair Value
Balance, beginning of period		3,752,000			0.8	$	0.02	$	0.03
Granted		112,000			-		-		0.78
Released		(183,996	)		-		-		-
Balance, end of period		3,680,004			0.6	$	0.73	$	0.05
Vested and exercisable, end of period		2,461,694

Awards of restricted stock under the Plan vest (i) one-third on the date of grant; (ii) one-third on the first anniversary of the date of grant, if the grantee has remained in service continuously until that date; and (iii) one-third on the second anniversary of the date of grant if the grantee has remained in service continuously until that date. 

23

As of September 30, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Company’s 2010 and 2013 Equity Plans, and the ACO Plan’s and the weighted-average period of years expected to recognize those costs are as follows:

Common stock options	$	198,195
Restricted stock	$	139,400
ACO Plan restricted stock	$	57,179

Stock-based compensation expense related to common stock and common stock option awards is recognized over their respective vesting periods and was included in the accompanying condensed consolidated statement of operations as follows:

	Three Months Ended September 30,					Six Months Ended September 30,
	2014			2013		2014		2013
Stock-based compensation expense:
Cost of services	$	(17,822	)	$	86,630	$	10,921	$	575,509
General and administrative		874,341			482,078		964,737		1,545,503
	$	856,519		$	568,708	$	975,658	$	2,121,012

Warrants

Warrants consisted of the following for the six months ended September 30, 2014:

	Weighted Average Per Share
	Intrinsic		Number of
	Value		warrants
Outstanding, beginning of period	$	0.02		7,145,000
Granted		-		2,000,000
Exercised		-		-
Cancelled		-		-
Outstanding, end of period	$	-		9,145,000

				Weighted
				average				Weighted
Exercise Price Per		Warrants		remaining		Warrants		average
Share		outstanding		contractual life		exercisable		exercise price per share
$	0.11485		1,250,000		1.8		1,250,000	$	0.1149
$	0.11485		250,000		1.8		250,000	$	0.1149
$	0.45000		500,000		1.8		500,000	$	0.4500
$	0.50000		100,000		3.1		100,000	$	0.5000
$	0.45000		825,000		3.3		825,000	$	0.4500
$	0.40000		220,000		3.3		220,000	$	0.4000
$	1.00000		2,000,000		6.5		2,000,000	$	1.0000
$	2.00000		2,000,000		6.5		2,000,000	$	1.0000
$	1.00000		1,000,000		6.5		1,000,000	$	1.0000
$	1.00000		1,000,000		3.8		1,000,000	$	1.0000
			9,145,000		4.8		9,145,000		0.9700

24

In connection with the 2014 NNA Financing, NNA received warrants to purchase up to 2,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and up to 2,000,000 shares at an exercise price of $2.00 per share, subject to adjustment for stock splits, reverse stock splits and stock dividends, and which are exercisable at any date prior to March 28, 2021. The warrants also contained down-round protection under which the exercise price of the warrants is subject to adjustment in the event the Company issues future common shares at a price below $0.90 per share. The Company determined that the warrants should be classified as liabilities under ASC 815-40, which requires the Company to determine the fair value of the warrants at the transaction date and at each subsequent reporting date (see Notes 2 and 6). Following the funding of the Convertible Note on July 30, 2014, additional warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share that had been issued in connection with the 2014 NNA Financing became exercisable (see Note 6).

Authorized stock

At September 30, 2014 the Company was authorized to issue up to 100,000,000 shares of common stock. The Company is required to reserve and keep available out of the authorized but unissued shares of common stock such number of shares sufficient to effect the conversion of all outstanding shares of the 9% Senior Subordinated Callable Notes, the exercise of all outstanding warrants exercisable into shares of common stock, and shares granted and available for grant under the Company’s 2013 Plan. The amount of shares of common stock reserved for these purposes is as follows at September 30, 2014: 

Common stock issued and outstanding	49,134,549
Conversion of 9% Notes	2,750,000
Conversion of 8% Notes	2,000,000
Warrants outstanding	9,145,000
Stock options outstanding	6,752,000
Remaining shares issuable under 2013 Equity  Incentive Plan	1,900,000
	71,681,549

10. Commitments and Contingencies

Regulatory Matters

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. The Company believes that it is in compliance with all applicable laws and regulations.

Legal

On May 16, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., two independent physician associations who compete with the Company in the greater Los Angeles area, filed an action against the Company and two affiliates of the Company, Maverick Medical Group, Inc. and ApolloMed Hospitalists, a Medical Corporation, in Los Angeles County Superior Court. The complaint alleged that the Company and its two affiliates made misrepresentations and engaged in other acts in order to improperly solicit physicians and patient-enrollees from Plaintiffs. The Complaint sought compensatory and punitive damages. On June 30, 2014, the Company and its affiliates filed a motion requesting the Court to stay the court proceeding and order the parties to arbitrate this dispute subject to existing arbitration agreements. On August 11, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. On August 12, 2014, the Plaintiffs served the Company and its affiliates with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration. The Company and its affiliates are preparing a defense to the allegations and the Company intends to vigorously defend the action.

On August 28, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., filed a similar lawsuit against Warren Hosseinion, the Chief Executive Officer of the Company. Dr. Hosseinion is defending the action and is currently being indemnified by the Company subject to the terms of an indemnification agreement and the Company’s charter. On September 9, 2014, Dr. Hosseinion filed a motion requesting the Court to stay the court proceeding and, pursuant to existing arbitration agreements, order the parties to arbitrate the dispute as part of the pending arbitration proceedings before JAMS (as discussed above). On October 29, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. Plaintiffs have informed the Company that Plaintiffs will be serving Dr. Hosseinion with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. Dr. Hosseinion and the Company will seek to consolidate the proceedings against Dr. Hosseinion with the existing proceedings against the Company and its affiliates. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration.

25

In the ordinary course of the Company’s business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated hospitalists. The Company may also become subject to other lawsuits which could involve significant claims and/or significant defense costs. The Company believes, based upon the Company’s review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows in a future period

Liability Insurance

The Company believes that the Company’s insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that the Company’s insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company’s affiliated professional organizations or the Company’s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business.

Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to the Company in future years at acceptable costs, and on favorable terms.

11. Subsequent Events

Lease Agreement

The Company had a lease with EOP-700 North Brand, L.L.C., a Delaware limited liability company (“Landlord”),

for 3,111 rentable square feet at 700 North Brand Boulevard, Suite No. 220, Glendale, California that commenced

on December 16, 2011, and was set to expire on January 14, 2014. The lease was amended by a Commencement

Letter dated February 6, 2012 and First Amendment dated November 8, 2012.

On October 14, 2014, the lease was amended by a Second Amendment. The Second Amendment relocates the leased premises from Suite No. 220 to Suite Nos. 1400, 1425 and 1450, which collectively include 16,484 rentable square feet (the “New Premises”). The New Premises will be improved with an allowance of up to $659,360, provided by the Landlord, for construction and installation of equipment for the New Premises. Before the improved New Premises are available, the Company shall also use Suite No. 240 on a temporary basis. The Second Amendment also extends the term of the lease to be for approximately six years after the Company begins operations in the New Premises and increases the Company’s initial security deposit. The Second Amendment sets the New Premises base rent at $37,913.20 per month for the first year and schedules annual increases in base rent each year until the final rental year, which is capped at $43,957.33 per month. However, the base rent will be abated by up to $228,049.27 subject to other terms of the lease.

Termination of a Material Definitive Agreement

On October 23, 2014, the Company entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Raouf Khalil (“Khalil”). Effective October 23, 2014, the Settlement Agreement terminates the Company’s obligations with respect to Khalil under that certain Stock Purchase Agreement, dated as of February 15, 2011 (the “Purchase Agreement”), among the Company, Aligned Healthcare Group, LLC (“Aligned LLC”), Aligned Healthcare Group – California, Inc. (“Aligned Corp.”), Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC (collectively, the “Aligned Affiliates”), as amended by that certain First Amendment to Stock Purchase Agreement, dated as of July 8, 2011, among the Company, Aligned LLC, Aligned Corp., Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC.

Under the Settlement Agreement, the Company has reconveyed to Khalil all of the shares of Aligned Healthcare, Inc. (“AHI”) common stock that the Company acquired from Khalil under the Purchase Agreement. In addition, in consideration of a $10,000 cash payment, Khalil has reconveyed to the Company 500,000 shares of the Company’s common stock, constituting all of the shares that were issued to him under the Purchase Agreement. Following these reconveyances, the Company no longer owns any of the outstanding shares of AHI’s capital stock, and neither Khalil nor any of the other Aligned Affiliates own any shares of the Company’s capital stock.

26

The Settlement Agreement was entered into by the parties to settle and resolve any claims, differences or disagreements that may exist between the Company and Khalil, and the Settlement Agreement provides for a mutual general release of all claims between the Company and Khalil.

Purchase Agreement

On October 27, 2014, Apollo Medical Management, Inc., a Delaware corporation (“AMM”), an affiliate of the Company made an initial capital contribution of $613,889 (the “Initial Contribution”) to Apollo Palliative Services LLC, a California limited liability company (the “APS”) in exchange for 51% of the membership interests of APS. APS used the Initial Contribution, in conjunction with funds provided by other investors in APS, to finance the closing payments described immediately below. In connection with this arrangement, the Company entered into a consulting agreement with one of the members. The term of this agreement is 6 years, and provides for the member to received $15,000 in cash per month, and be eligible to receive stock-based awards under the Company’s 2013 Equity Incentive Plan as determined by the Company’s Board of Directors

Immediately prior to closing the transactions described below, and as condition precedent to APS closing the transactions, the selling equity owners in each transaction described below contributed specific equity interests to APS in return for interests in APS pursuant to contributions agreements.

Subject to the terms and conditions of that certain Membership Interest Purchase Agreement (the “BCHC Agreement”), dated October 27, 2014, by and among APS, the Company, the sole members of Best Choice Hospice Care, LLC, a California limited liability company (“BCHC”), and BCHC, APS agreed to purchase all of the remaining membership interests in BCHC for $900,000 in cash, subject to reduction if BCHC’s working capital was less than $145,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $400,000 (the “BCHC Contingent Payment”) to one seller and one employee of BCHC. The BCHC Contingent Payment will be paid in two installments of $100,000 to each of the seller and the employee within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s and the employee’s employment, as applicable, continuing or having been terminated without cause and, for the employee, meeting certain productivity targets. The Company absolutely, unconditionally and irrevocably guaranteed payment of the BCHC Contingent Payment if APS fails to make any payment.

Subject to the terms and conditions of that certain Stock Purchase Agreement (the “HCHHA Agreement”), dated October 27, 2014, by and among APS, the sole shareholder of Holistic Care Home Health Agency, Inc., a California corporation (“HCHHA”), and HCHHA, APS agreed to purchase all of the remaining shares of HCHHA for $300,000 in cash, subject to reduction if HCHHA’s working capital was less than $50,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $150,000 (the “HCHHA Contingent Payment”). The HCHHA Contingent Payment will be paid in two installments of $75,000 to the seller within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s employment continuing or having been terminated without cause and meeting certain productivity targets.

27

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K for the former year ended January 31, 2014, filed with the Securities and Exchange Commission (SEC) on May 8, 2014.

In this Quarterly Report, unless otherwise expressly stated or the context otherwise requires, “Apollo,” “we,” “us” and “our” refer to Apollo Medical Holdings, Inc., a Delaware corporation, and its subsidiaries and affiliated medical groups.  Our affiliated professional organizations are separate legal entities that provide physician services in California and with which we have management agreements. For financial reporting purposes we consolidate the revenues and expenses of all our practice groups that we own or manage because we have a controlling financial interest in these practices based on applicable accounting rules and as described in our accompanying financial statements. Also, unless otherwise expressly stated or the context otherwise requires, “our affiliated hospitalists” refer to physicians employed or contracted by either our subsidiaries or our affiliated professional organizations. References to “practices” or “practice groups” refer to our subsidiary-management company and the affiliated professional organizations of Apollo that provide medical services, unless otherwise expressly stated or the context otherwise requires.

The following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of Apollo  that are based on management’s current expectations, estimates, projections, and assumptions about our business. Words such as “may,” “will,” “could,” “should,” “target,” “potential,” “project,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “sees,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including, but not limited to, those discussed in our most recent Annual Report on Form 10-K, including the section entitled “Risk Factors”, as well as those discussed from time to time in the Company’s other SEC filings and reports. In addition, such statements could be affected by general industry and market conditions. Such forward-looking statements speak only as of the date of this Report or, in the case of any document incorporated by reference, the date of that document, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Report, or for changes made to this document by wire services or Internet service providers. If we update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections with respect to other forward-looking statements.

Overview

ApolloMed is a patient-centered, physician-centric, integrated healthcare delivery system nearly 15 years of experience providing coordinated, outcomes-based medical care in a cost-effective manner. ApolloMed’s businesses operate primarily under risk and value-based contracts with health plans, independent practice associations (“IPAs”), hospitals and the Centers for Medicare and Medicaid Services’ (“CMS”) Medicare Shared Savings Program and serve Medicare, Medicaid, HMO and uninsured patients in California, Mississippi and Ohio. ApolloMed provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. All of these constituents can benefit from better coordinated care and population health management. As an efficient operator of integrated healthcare delivery networks, ApolloMed is favorably positioned to benefit from current industry trends.

The predecessor business to ApolloMed was a hospitalist company incorporated in California in June 2001,

and which began operations at Glendale Memorial Hospital. Through a reverse merger, ApolloMed became a publicly held company in June 2008. The Company was initially organized around the admission and care of patients at inpatient facilities such as hospitals. ApolloMed has successfully grown its inpatient strategy in a competitive market by providing high-quality care and innovative solutions for our hospital and managed care clients by focusing. ApolloMed focuses on improving the inefficiencies associated with inpatient care, reducing readmissions and improving outcomes through better care coordination. As of November 1, 2014, ApolloMed provided inpatient services at over 28 hospitals and long-term acute care facilities in Los Angeles and Central California where it has contracted with over 50 hospitals, IPAs and health plans to provide a range of inpatient services including hospitalist, intensivist, physician advisor and consulting services.

28

In 2011, the Company formed an Accountable Care Organization (“ACO”), ApolloMed Accountable Care Organization, Inc. (“ApolloMed ACO”), to participate in the Centers for Medicare and Medicaid Services’ (“CMS”) Medicare Shared Savings Program (“MSSP”). The program allows certain providers and suppliers (including hospitals, physicians and other designated professionals) to voluntarily form ACOs and work together with other ACO participants to invest in infrastructure and redesign delivery processes to achieve high quality and efficient delivery of medical services for Medicare Fee-For-Service (“FFS”) patients. ApolloMed ACO was approved by CMS to participate in the MSSP in July, 2012 and started with 130 physicians and 9000 beneficiaries. As of November 1, 2014, our ACO had over 700 physicians and nearly 30,000 Medicare FFS beneficiaries. ApolloMed ACO leverages the inpatient and outpatient medical management capabilities of ApolloMed’s core company.

In 2013, ApolloMed formed Maverick Medical Group, Inc. (“MMG”), a risk-bearing entity that participates in the Medicare Advantage, HMO-Medicaid, Commercial and Dual-Eligible segments. Many health plans subcontract a significant portion of the responsibility for managing patient care to integrated healthcare systems such as ApolloMed. These integrated healthcare systems, whether medical groups or IPAs, offer a comprehensive medical delivery system and sophisticated care management know-how and infrastructure to more efficiently provide for the healthcare needs of the population enrolled with that health plan. Maverick Medical Group is responsible for paying the provider component of fees (which includes Primary Care Physicians and Specialists). For certain health plans, Maverick also has risk-sharing agreements with hospitals that entitle us to receive a percentage of the institutional savings. Under these agreements, Maverick also agrees to be responsible should the institutional expenses exceed the institutional capitation revenue. As of November 1, 2014, Maverick had nearly 1000 Medicare Advantage and dual-eligible enrollees and nearly 7000 Commercial and Medicaid HMO patients. In 2014, ApolloMed acquired AKM Medical Group, a Los Angeles-based IPA founded in 1990 that is a similar business to MMG, and serves over 2000 patients

In 2014, ApolloMed launched ApolloMed Care Clinics, which currently consist of acquired primary care and specialty clinics. ApolloMed’s clinics focus on the coordinated, efficient delivery of ambulatory treatment and ancillary services, with an increasing emphasis on preventive care and management of chronic conditions. 

ApolloMed’s clinics have served their communities for a combined total of over 30 years and handle over 20,000 patient visits per year.

On March 28, 2014, the Company entered into certain credit and investment agreements with NNA of Nevada, Inc. (the “NNA”) which provided for a $7.0 million secured term loan, a $1.0 million secured line of credit, and a $2.0 million convertible note commitment. In addition, NNA acquired 2,000,000 shares of the Company’s common stock, warrants to acquire the Company’s common stock, and certain registration rights. The term loan and revolving loan are secured by substantially all assets of the Company, and are guaranteed by the Company’s subsidiaries and certain of its consolidated medical corporations.

On October 27, 2014, ApolloMed completed the acquisitions of Best Choice Hospice Care LLC and Holistic Health Home Health Care Inc., and launched Apollo Palliative Care Services, which will be a provider of hospice, palliative and home health services for each company’s own patients as well as other customers.

As of November 1, 2014, the ApolloMed physician network consists of over 900 hospitalists, primary care physicians and specialist physicians through our owned and affiliated physician groups.

29

Recent Developments

On July 22, 2014, pursuant to a Stock Purchase Agreement dated as of July 21, 2014 (the “Purchase Agreement”) among the Southern California Heart Centers, a Medical Corporation, a medical group that provides professional medical services in Los Angeles County, California (“SCHC”), the shareholders of SCHC (the “Sellers”) and a Company affiliate, SCHC Acquisition, A Medical Corporation (the “Affiliate”), solely owned by Dr. Warren Hosseinion, a physician and the Chief Executive Officer of the Company, the Affiliate acquired all of the outstanding shares of capital stock of a SCHC from the Sellers. The purchase price for the shares was (i) $2,000,000 in cash, (ii) $362,646 to pay off and discharge certain indebtedness of SCHC (iii) warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and (iv) a contingent amount of up to $1,000,000 payable, if at all, in cash. The acquisition was funded by an intercompany loan from AMM, which also provided an indemnity in favor of one of the Sellers relating to certain indebtedness of SCHC that remained outstanding following the closing of the acquisition. Following the acquisition of SCHC, the Affiliate was merged with and into SCHC, with SCHC being the surviving corporation.

In connection with the acquisition of SCHC, AMM entered into a management services agreement with the Affiliate on July 21, 2014. As a result of the Affiliate’s merger with and into SCHC, SCHC is now the counterparty to this management services agreement and bound by its terms. Pursuant to the management services agreement, AMM will manage all non-medical services for SCHC and will have exclusive authority over all non-medical decision making related to the ongoing business operations of SCHC, and is the primary beneficiary of SCHC, and the financial statements of SCHC will be consolidated as a variable interest entity with those of the Company from the date of the management services agreement.

On July 31, 2014, the Company received proceeds of $2,000,000 from the NNA 8.0% convertible note. In connection with this drawdown, the Company was required to issue 1,000,000 warrants to NNA with an exercise price of $1.00 per share.

On October 14, 2014, the Company’s lease with EOP-700 North Brand, L.L.C., a Delaware limited liability company (“Landlord”) was amended by a Second Amendment. The Second Amendment relocates the leased premises from Suite No. 220 to Suite Nos. 1400, 1425 and 1450, which collectively include 16,484 rentable square feet (the “New Premises”). The New Premises will be improved with an allowance of up to $659,360, provided by the Landlord, for construction and installation of equipment for the New Premises. Before the improved New Premises are available, the Company shall also use Suite No. 240 on a temporary basis. The Second Amendment also extends the term of the lease to be for approximately six years after the Company begins operations in the New Premises and increases the Company’s initial security deposit. The Second Amendment sets the New Premises base rent at $37,913.20 per month for the first year and schedules annual increases in base rent each year until the final rental year, which is capped at $43,957.33 per month. However, the base rent will be abated by up to $228,049.27 subject to other terms of the lease.

On October 23, 2014, the Company entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Raouf Khalil (“Khalil”). Effective October 23, 2014, the Settlement Agreement terminates the Company’s obligations with respect to Khalil under that certain Stock Purchase Agreement, dated as of February 15, 2011 (the “Purchase Agreement”), among the Company, Aligned Healthcare Group, LLC (“Aligned LLC”), Aligned Healthcare Group – California, Inc. (“Aligned Corp.”), Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC (collectively, the “Aligned Affiliates”), as amended by that certain First Amendment to Stock Purchase Agreement, dated as of July 8, 2011, among the Company, Aligned LLC, Aligned Corp., Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC.

Under the Settlement Agreement, the Company has reconveyed to Khalil all of the shares of Aligned Healthcare, Inc. (“AHI”) common stock that the Company acquired from Khalil under the Purchase Agreement. In addition, in consideration of a $10,000 cash payment, Khalil has reconveyed to the Company 500,000 shares of the Company’s common stock, constituting all of the shares that were issued to him under the Purchase Agreement. Following these reconveyances, the Company no longer owns any of the outstanding shares of AHI’s capital stock, and neither Khalil nor any of the other Aligned Affiliates own any shares of the Company’s capital stock.

The Settlement Agreement was entered into by the parties to settle and resolve any claims, differences or disagreements that may exist between the Company and Khalil, and the Settlement Agreement provides for a mutual general release of all claims between the Company and Khalil.

30

On October 27, 2014, Apollo Medical Management, Inc., a Delaware corporation (“AMM”), an affiliate of the Company made an initial capital contribution of $613,889 (the “Initial Contribution”) to Apollo Palliative Services LLC, a California limited liability company (the “APS”) in exchange for 51% of the membership interests of APS. APS used the Initial Contribution, in conjunction with funds provided by other investors in APS, to finance the closing payments described immediately below. In connection with this arrangement, the Company entered into a consulting agreement with one of the members. The term of this agreement is 6 years, and provides for the member to received $15,000 in cash per month, and be eligible to receive stock-based awards under the Company’s 2013 Equity Incentive Plan as determined by the Company’s Board of Directors.

Immediately prior to closing the transactions described below, and as condition precedent to APS closing the transactions, the selling equity owners in each transaction contributed specific equity interests to APS in return for interests in APS pursuant to contributions agreements.

Subject to the terms and conditions of that certain Membership Interest Purchase Agreement (the “BCHC Agreement”), dated October 27, 2014, by and among APS, the Company, the sole members of Best Choice Hospice Care, LLC, a California limited liability company (“BCHC”), and BCHC, APS agreed to purchase all of the remaining membership interests in BCHC for $900,000 in cash, subject to reduction if BCHC’s working capital was less than $145,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $400,000 (the “BCHC Contingent Payment”) to one seller and one employee of BCHC. The BCHC Contingent Payment will be paid in two installments of $100,000 to each of the seller and the employee within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s and the employee’s employment, as applicable, continuing or having been terminated without cause and, for the employee, meeting certain productivity targets. The Company absolutely, unconditionally and irrevocably guaranteed payment of the BCHC Contingent Payment if APS fails to make any payment.

Subject to the terms and conditions of that certain Stock Purchase Agreement (the “HCHHA Agreement”), dated October 27, 2014, by and among APS, the sole shareholder of Holistic Care Home Health Agency, Inc., a California corporation (“HCHHA”), and HCHHA, APS agreed to purchase all of the remaining shares of HCHHA for $300,000 in cash, subject to reduction if HCHHA’s working capital was less than $50,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $150,000 (the “HCHHA Contingent Payment”). The HCHHA Contingent Payment will be paid in two installments of $75,000 to the seller within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s employment continuing or having been terminated without cause and meeting certain productivity targets.

31

Results of Operations

Three months ended September 30, 2014 compared to three months ended September 30, 2013

The Company’s results of operations were as follows for the three months ended September 30:

	2014		2013			Change		Percentage change
Net revenues	$	11,665,294	$	2,521,421		$	9,143,873		362.6	%
Costs and expenses:
Cost of services		6,161,645		2,257,945			3,903,700		172.9	%
General and administrative		3,451,907		1,043,565			2,408,342		230.8	%
Depreciation		193,281		6,528			186,753		2860.8	%
Total costs and expenses		9,806,833		3,308,038			6,498,795		196.5	%
Income (loss) from operations		1,858,461		(786,617	)	$	2,645,078		-336.3	%

The following table sets forth consolidated statements of operations for the three months ended September 30, 2014 and 2013, respectively, stated as a percentage of net revenues:

	% of Net Revenues
	2014			2013
Net revenues		100.0	%		100.0	%
Costs and expenses:
Cost of services		52.8	%		89.6	%
General and administrative		29.6	%		41.4	%
Depreciation		1.7	%		0.3	%
Total costs and expenses		84.1	%		131.2	%
Income (loss) from operations		15.9	%		-31.2	%

Net revenues are comprised of net billings under the various fee structures from health plans, medical groups/IPA’s and hospitals, and income from service fee agreements. The increase was attributable to: 

$	214,153	Increase in hospitalist revenue, primarily due to expansion of  Medicare reimbursement guidelines under the Affordable Care Act
$	1,693,127	Acquisition of AKM and SCHC
$	1,615,210	Increase in MMG revenues due to higher patient lives
$	5,382,617	ACO shared savings revenue
$	238,766	Increase in clinic revenues due to ACC acquisitions

Cost of services are comprised primarily of physician compensation and related expenses. The increase (decrease) was attributable to:

$	1,156,404	Acquisition of AKM and SCHC
$	1,479,854	Increase in MMG claim costs due to higher patient lives
$	299,327	Increase in ACC clinic costs due to acquisitions in October 2013
$	1,400,000	Participating physician share of ACO savings revenue
$	(84,801)	Decrease in physician related costs attributable to fewer hospitalist contracts.
$	(347,085)	Decrease in physician stock-based compensation

Cost of services as percentage of net revenues decreased principally due to the lower cost of ACO shared savings revenue (of approximately 26.0%).

General and administrative expenses include all non-physician salaries, benefits, supplies and operating expenses, including billing and collections functions, and our corporate management and overhead not specifically related to the day-to-day operations of our physician group practices. The increase (decrease) in general and administrative expenses was attributable to:

$	836,149	Increase in stock-based compensation, primarily related to higher valuation of ACO shares awarded to ACO physicians
$	705,213	Increase in legal and professional fees related to Lakeside litigation and to support corporate initiatives.
$	347,253	Increase in personnel, services and related expenses related to the ACO initiative.
$	214,269	Increase in administrative personnel and facilities costs to support growth in the business
$	515,229	Acquisition of AKM and SCHC
$	(209,772)	Decrease in other administrative costs

	2014		2013		Change
Depreciation and amortization expense	$	193,281	$	6,528	$	186,753

Depreciation and amortization increased due to the acquisition of AKM and SCHC which added additional depreciation expense of approximately $61,000 and additional amortization expense of $121,000 related to the intangible assets acquired during the current fiscal year (See Note 3 – Acquisitions in the Condensed Consolidated Financial Statements).

Income from operations increased $2,645,000 due to increased net revenues as discussed above, partially offset by higher costs including higher cost of medical services in ACC and MMG, and an increase in stock-based compensation and legal and professional fees. 

32

	2014		2013		Change
Interest expense	$	329,258	$	200,562	$	128,696

Interest expense increased in 2014 primarily due to higher interest expense due to an increase in borrowings primarily related to the 2014 NNA financing.

	2014		2013		Change
Gain on change in fair value of warrant and conversion liabilities	$	152,140	$	-	$	152,140

Gain on change in fair value of warrant and conversion liabilities resulted from the change in the fair value measurement of the Company’s warrant and conversion feature liabilities, which considers among other things, expected term, the volatility of the Company’s share price, interest rates, and the probability of additional financing of the underlying NNA Term Loan and NNA 8% Convertible Note.

	2014		2013			Change
Net income (loss)	$	1,376,310	$	(980,738	)	$	2,357,048

Net income attributable to Apollo Medical Holdings, Inc. increased primarily due to ACO shared savings revenue partially offset by higher cost of medical services in ACC and MMG and an increase in legal and professional fees and stock-based compensation.

Six months ended September 30, 2014 compared to six months ended September 30, 2013

The Company’s results of operations were as follows for the six months ended September 30:

	2014		2013			Change		Percentage change
Net revenues	$	15,759,780	$	5,136,115		$	10,623,665		206.8	%
Costs and expenses:
Cost of services		9,421,484		4,715,875			4,705,609		99.8	%
General and administrative		5,461,239		2,965,395			2,495,844		84.2	%
Depreciation		205,180		12,883			192,297		1492.6	%
Total costs and expenses		15,087,903		7,694,153			7,393,750		96.1	%
Income (loss) from operations		671,877		(2,558,038	)	$	3,229,915		-126.3	%

The following table sets forth consolidated statements of operations for the six months ended September 30 stated as a percentage of net revenues:

	% of Net Revenues
	2014			2013
Net revenues		100.0	%		100.0	%
Costs and expenses:
Cost of services		59.8	%		91.8	%
General and administrative		34.7	%		57.7	%
Depreciation		1.3	%		0.3	%
Total costs and expenses		95.7	%		149.8	%
Income (loss) from operations		4.3	%		-49.8	%

Net revenues are comprised of net billings under the various fee structures from health plans, medical groups/IPA’s and hospitals, and income from service fee agreements. The increase was attributable to: 

$	1,872,529	Acquisition of AKM and SCHC
$	2,852,293	Increase in MMG services due to increase in patient lives.
$	5,382,617	ACO shared savings revenue
$	500,378	Increase in clinic revenues due to ACC acquisitions
$	15,848	Other increase - net

Cost of services are comprised primarily of physician compensation and related expenses. The increase (decrease) was attributable to:

$	1,302,624	Acquisition of AKM and SCHC
$	2,463,383	Increase in MMG claim costs due to higher patient lives
$	617,117	Increase in ACC clinic costs due to acquisitions in October 2013
$	1,400,000	Participating physician share of ACO savings revenue
$	(282,015)	Decrease in physician related costs attributable to fewer hospitalist contracts.
$	(795,500)	Decrease in physician stock-based compensation

33

Cost of services as percentage of net revenues decreased principally due to the lower cost of ACO shared savings revenue (of approximately 26.0%).

General and administrative expenses include all non-physician salaries, benefits, supplies and operating expenses, including billing and collections functions, and our corporate management and overhead not specifically related to the day-to-day operations of our physician group practices. The increase (decrease) in general and administrative expenses was attributable to:

$	(107,905)	Decrease in stock-based compensation to employees, partially offset by higher valuation of ACO shares to ACO physicians
$	1,373,624	Increase in legal and professional fees related to Lakeside litigation and to support corporate initiatives.
$	193,947	Increase in personnel, services and related expenses related to the ACO initiative.
$	522,674	Increase in administrative personnel and facilities costs to support  growth in the business
$	548,946	Acquisition of AKM and SCHC
$	(35,443)	Decrease in other administrative costs

	2014		2013		Change
Depreciation and amortization expense	$	205,180	$	12,883	$	192,297

Depreciation and amortization increased due to the acquisition of AKM and SCHC which added additional depreciation expense of approximately $61,000 and additional amortization expense of $121,000 related to the intangible assets acquired during the current fiscal year (See Note 3 – Acquisitions in the Condensed Consolidated Financial Statements).

Income from operations increased $3,230,000 due to increased ACO shared savings revenue as discussed above partially offset by higher costs such the higher cost of medical services in ACC and MMG, and an increase in legal and professional fees. 

	2014		2013		Change
Interest expense	$	606,125	$	362,252	$	243,873

Interest expense increased in 2014 primarily due to higher interest expense due to an increase in borrowings primarily related to the 2014 NNA financing.

	2014		2013		Change
Gain on change in fair value of warrant and conversion liabilities	$	122,135	$	-	$	122,135

 Gain on change in fair value of warrant and conversion liabilities resulted from the change in the fair value measurement of the Company’s warrant and conversion feature liabilities, which considers among other things, expected term, the volatility of the Company’s share price, interest rates, and the probability of additional financing of the underlying NNA Term Loan and NNA 8% Convertible Note.

	2014			2013			Change
Net income (loss)	$	(301,431	)	$	(2,913,600	)	$	2,612,169

Net income attributable to Apollo Medical Holdings, Inc. decreased primarily due to ACO shared savings revenue partially offset by higher cost of medical services in ACC and MMG and an increase in legal and professional fees and stock-based compensation.

Liquidity and Capital Resources

At September 30, 2014, the Company had cash equivalents and marketable securities of $4.0 million compared to cash and cash equivalents of $6.8 million at March 31, 2014. At September 30, 2014 the Company had borrowings totaling $7.6 million compared to borrowings at March 31, 2014 of $6.7 million.

34

The Company incurred the following net operating income and cash used in operating activities for the six months ended September 30, 2014: 

Income from operations	$	671,877
Cash used in operating activities	$	2,122,257

The Company’s accumulated deficit and stockholders’ equity at September 30, 2014 was as follows: 

Accumulated deficit	$	16,649,019
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	$	375,773

To date the Company has funded its operations from internally generated cash flow and external sources, including the proceeds from the issuance of debt and equity securities which have provided funds for near-term operations and growth. On March 28, 2014, the Company entered into an equity and debt arrangement with NNA to provide $12,000,000 in funding, which included $2,000,000 investment in Company common stock, $8,000,000 in term and revolving loans, and a $2,000,000 convertible note commitment which was drawn by the Company on July 31, 2014. The Company used approximately $2,000,000 in cash to finance the acquisitions of AKM and SCHC during the six months ended September 30, 2014. The Company believes its current cash balances, coupled with cash flow from operating activities will be sufficient to meet its working capital requirements for the foreseeable future. If the need for financing arises, the Company cannot assure that it will be available on acceptable terms, or at all.

Six months ended September 30, 2014

For the six months ended September 30, 2014, cash used in operating activities was $2,122,257. This was the result of income from operations of $671,877 and by cash provided by non-cash expenses of $1,358,263 offset by the change in working capital of $3,508,904. Non-cash expenses primarily include depreciation expense, issuance stock-based compensation expense, amortization of financing costs, and accretion of debt discount.

Cash provided by working capital was due to:

Increase in Accounts payable and accrued liabilities	$	2,170,739
Increase in due from affiliates	$	42,378
Increase in medical liabilities	$	668,779

Cash used by working capital was due to: 

Increase in Accounts receivable, net	$	(993,669	)
Increase in other receivable	$	(5,382,617	)
Increase in prepaid expenses and advances	$	(14,167	)
Increase in Other assets	$	(347	)

For the six months ended September 30, 2014, cash used in investing activities was $1,963,014 related to the acquisition of AKM and SCHC aggregating $1,947,431( net of cash and cash equivalents acquired of $620,960); and investment in office and technology equipment.

For the six months ended September 30, 2014, net cash provided by financing activities was $1,203,918 primarily as the result of the issuance of convertible notes payable of $2,000,000 and the contributions by a non-controlling interest of $550,000 offset by principal payments on the term loan of $726,000, debt issuance costs of $20,000 and distributions of $600,000 to a non-controlling interest shareholder.

Critical Accounting Policies

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.  We believe that our critical accounting policies are limited to those described in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2014. 

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-9 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

35

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40). The guidance in this ASU requires disclosure of uncertainties about an entity’s ability to continue as a going concern even if an entity’s liquidation is not imminent. There may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting and this guidance should be followed to determine whether to disclose information about the relevant conditions and events. This guidance is effective for the Company on December 31, 2016 and the adoption of this standard will not have a significant impact on its condensed consolidated financial statements or notes thereto.

Off Balance Sheet Arrangements

As of September 30, 2014, the Company had no off-balance sheet arrangements. 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.  CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures.

In connection with the preparation of this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, of the effectiveness of our disclosure controls and procedures, as of September 30, 2014, in accordance with Rules 13a-15(b) and 15d-15(b) of the Exchange Act.

Based on that evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were not effective as of September 30, 2014.

We have identified the following three material weaknesses in our disclosure controls and procedures:

1. We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act. Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures, and concluded that the control deficiency that resulted represented a material weakness.

2. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible.  Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures, and concluded that the control deficiency that resulted represented a material weakness.

3. We do not have review and supervision procedures for financial reporting functions. The review and supervision function of internal control relates to the accuracy of financial information reported. The failure to review and supervise could allow the reporting of inaccurate or incomplete financial information. Due to our size and nature, review and supervision may not always be possible or economically feasible.

Based on the foregoing material weaknesses, we have determined that, as of September 30, 2014, our internal controls over our financial reporting are not effective. The Company is taking remediating steps to address each material weakness. We continue to add employees and consultants to address these issues and we will continue to broaden the scope of our accounting and billing capabilities and realign responsibilities in our financial and accounting review functions.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable and not absolute assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of certain events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

36

Changes in Internal Controls over Financial Reporting

There has been no change in our internal control over financial reporting during the three month period ended September 30, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

On May 16, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., two independent physician associations who compete with the Company in the greater Los Angeles area, filed an action against the Company and two affiliates of the Company, Maverick Medical Group, Inc. and ApolloMed Hospitalists, a Medical Corporation, in Los Angeles County Superior Court. The complaint alleged that the Company and its two affiliates made misrepresentations and engaged in other acts in order to improperly solicit physicians and patient-enrollees from Plaintiffs. The Complaint sought compensatory and punitive damages. On June 30, 2014, the Company and its affiliates filed a motion requesting the Court to stay the court proceeding and order the parties to arbitrate this dispute subject to existing arbitration agreements. On August 11, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. On August 12, 2014, the Plaintiffs served the Company and its affiliates with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration. The Company and its affiliates are preparing a defense to the allegations and the Company intends to vigorously defend the action.

On August 28, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., filed a similar lawsuit against Warren Hosseinion, the Chief Executive Officer of the Company. Dr. Hosseinion is defending the action and is currently being indemnified by the Company subject to the terms of an indemnification agreement and the Company’s charter. On September 9, 2014, Dr. Hosseinion filed a motion requesting the Court to stay the court proceeding and, pursuant to existing arbitration agreements, order the parties to arbitrate the dispute as part of the pending arbitration proceedings before JAMS (as discussed above). On October 29, 2014, the Plaintiffs files a request for dismissal without prejudice of the action. Plaintiffs have informed the Company that Plaintiffs will be serving Dr. Hosseinion with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angles. Dr. Hosseinion and the Company will seek to consolidate the proceedings against Dr. Hosseinion with the existing proceedings against the Company and its affiliates. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration.

In the ordinary course of the Company’s business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated hospitalists. The Company may also become subject to other lawsuits which could involve significant claims and/or significant defense costs. The Company believes, based upon the Company’s review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows in a future period.

ITEM 1A. RISK FACTORS

Omitted. 

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On July 22, 2014, the Company issued warrants to the shareholders of SCHC to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share in connection with the Company’s affiliate’s acquisition of SCHC in July 2014. The Company issued the warrants as part of the consideration paid to selling shareholders of SCHC as disclosed above and used the proceeds from the unregistered sale in connection with consummation of the transaction. The warrants issuance was effected pursuant to Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving a public offering.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.  OTHER INFORMATION

The Company had a lease with EOP-700 North Brand, L.L.C., a Delaware limited liability company (“Landlord”), for 3,111 rentable square feet at 700 North Brand Boulevard, Suite No. 220, Glendale, California that commenced on December 16, 2011, and was set to expire on January 14, 2014. The lease was amended by a Commencement Letter dated February 6, 2012 and First Amendment dated November 8, 2012.

On October 14, 2014, the lease was amended by a Second Amendment. The Second Amendment relocates the leased premises from Suite No. 220 to Suite Nos. 1400, 1425 and 1450, which collectively include 16,484 rentable square feet (the “New Premises”). The New Premises will be improved with an allowance of up to $659,360, provided by the Landlord, for construction and installation of equipment for the New Premises. Before the improved New Premises are available, the Company shall also use Suite No. 240 on a temporary basis. The Second Amendment also extends the term of the lease to be for approximately six years after the Company begins operations in the New Premises and increases the Company’s initial security deposit. The Second Amendment sets the New Premises base rent at $37,913.20 per month for the first year and schedules annual increases in base rent each year until the final rental year, which is capped at $43,957.33 per month. However, the base rent will be abated by up to $228,049.27 subject to other terms of the lease.

The description of the lease and the Second Amendment is qualified in its entirety by the Second Amendment, which is attached hereto as Exhibit 10.5. 

37

ITEM 6.  EXHIBITS

Exhibit Number	Description
2.1	Stock Purchase Agreement dated July 21, 2014 by and between SCHC Acquisition, A Medical Corporation, the Shareholders of Southern California Heart Centers, A Medical Corporation and Southern California Heart Centers, A Medical Corporation (filed as an exhibit to Quarterly Report on Form 10-Q on August 14, 2014, and incorporated herein by reference)
3.1	Certificate of Incorporation (filed as an exhibit to Registration Statement on Form 10-SB filed on April 19, 1999, and incorporated herein by reference).
3.2	Certificate of Ownership (filed as an exhibit to Current Report on Form 8-K filed on July 15, 2008, and incorporated herein by reference).
3.3	Second Amended and Restated Bylaws (filed as an exhibit to Form 10-Q filed on September 14, 2011, and incorporated herein by reference).
4.1	Form of Investor Warrant, dated October 16, 2009, for the purchase of 25,000 shares of common stock (filed as an exhibit on Annual Report on Form 10-K/A on March 28, 2012, and incorporated herein by reference).
4.2	Form of Investor Warrant, dated October 29, 2012, for the purchase of common stock (filed as an exhibit on Form 10-Q on December 17, 2012 and incorporated herein by reference)
4.3	Form of Amendment to October 16, 2009 Warrant to Purchase Shares of Common Stock, dated October 29, 2012 (filed as an exhibit on Form 10-Q on December 17, 2012 and incorporated herein by reference)
4.4	Form of 9% Senior Subordinated Callable Convertible Note, dated January 31, 2013 (filed as an exhibit on Annual Report on Form 10-K on May 1, 2013 and incorporated herein by reference)
4.5	Form of Investor Warrant for purchase of 37,500 shares of common stock, dated January 31, 2013 (filed as an exhibit on Annual Report on Form 10-K on May 1, 2013, and incorporated herein by reference)
4.6	Convertible Note, issued by Apollo Medical Holdings, Inc. to NNA of Nevada, Inc., dated March 28, 2014 (filed as an exhibit on Form 8-K on March 31, 2014, and incorporated herein by reference).
4.7	Common Stock Purchase Warrant to purchase 1,000,000 shares, issued by Apollo Medical Holdings, Inc. to NNA of Nevada, Inc., dated March 28, 2014 (filed as an exhibit on Form 8-K on March 31, 2014, and incorporated herein by reference).
4.8	Common Stock Purchase Warrant to purchase 2,000,000 shares, issued by Apollo Medical Holdings, Inc. to NNA of Nevada, Inc., dated March 28, 2014 (filed as an exhibit on Form 8-K on March 31, 2014, and incorporated herein by reference).
4.9	Common Stock Purchase Warrant to purchase 1,000,000 shares, issued by Apollo Medical Holdings, Inc. to NNA of Nevada, Inc., dated March 28, 2014 (filed as an exhibit on Form 8-K on March 31, 2014, and incorporated herein by reference).
4.1	Common Stock Purchase Warrant to purchase 1,000,000 shares, issued by Apollo Medical Holdings, Inc. to NNA of Nevada, Inc., dated March 28, 2014 (filed as an exhibit on Form 8-K on March 31, 2014, and incorporated herein by reference).
10.1	Contribution Agreement, dated as of October 27, 2014, by and between Dr. Sandeep Kapoor, M.D, Marine Metspakyan and Apollo Palliative Services LLC (filed as an exhibit on Form 8-K on October 27, 2014, and incorporated herein by reference).
10.2	Contribution Agreement, dated as of October 27, 2014, by and between Rob Mikitarian and Apollo Palliative Services LLC (filed as an exhibit on Form 8-K on October 27, 2014, and incorporated herein by reference).
10.3	Membership Interest Purchase Agreement, entered into as of October 27, 2014, by and among Apollo Palliative Services LLC, Apollo Medical Holdings, Inc., Dr. Sandeep Kapoor, M.D., Marine Metspakyan and Best Choice Hospice Care, LLC (filed as an exhibit on Form 8-K on October 27, 2014, and incorporated herein by reference).
10.4	Stock Purchase Agreement entered into as of October 27, 2014, by and among Apollo Palliative Services LLC, Rob Mikitarian and Holistic Care Home Health Agency, Inc. (filed as an exhibit on Form 8-K on October 27, 2014, and incorporated herein by reference).
10.5+	Lease Agreement dated October 14, 2014 by and among Apollo Medical Holdings, Inc. and EOP-700 North Brand, LLC.

38

	Exhibit 31 - Rule 13a-14(d)/15d-14(d) Certifications
31.1+	Certification by Chief Executive Officer
31.2+	Certification by Chief Financial Officer
	Exhibit 32 - Section 1350 Certifications
32.1+	Certification by Chief Executive Officer pursuant to 18 U.S.C. section 1350.
32.2+	Certification by Chief Financial Officer pursuant to 18 U.S.C. section 1350
	Exhibit 101 – Interactive Data Files
101.INS+	XBRL Instance Document
101.SCH+	XBRL Taxonomy Extension Schema Document
101.CAL+	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+	XBRL Taxonomy Extension Label Linkbase Document
101.PRE+	XBRL Taxonomy Extension Presentation Linkbase Document

+ Filed herewith.

39

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	APOLLO MEDICAL HOLDINGS, INC.
Dated:  November 14, 2014	By:	/s/ Warren Hosseinion
		Warren Hosseinion
		Chief Executive Officer and Director
Dated:  November 14, 2014	By:	/s/ Mitchell R. Creem
		Mitchell R. Creem
		Chief Financial Officer and Director
		(Principal Financial and Accounting Officer)

40

EX-10.5

Exhibit 10.5

SECOND AMENDMENT

THIS SECOND AMENDMENT (this "Amendment") is made and entered into as of October 14, 2014, by and between EOP-700 NORTH BRAND, L.L.C., a Delaware limited liability company ("Landlord"), and APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation ("Tenant").

RECITALS

A. Landlord and Tenant are parties to that certain lease dated December 16, 2011 (the "Original Lease"), as previously amended by Commencement Letter dated February 6, 2012 and First Amendment dated November 8, 2012 (the "First Amendment")(as amended, the "Lease"). Pursuant to the Lease, Landlord has leased to Tenant space currently containing approximately 3,111 rentable square feet (the "Existing Premises") described as Suite No. 220 on the second (2nd) floor of the building commonly known as 700 North Brand located at 700 North Brand Boulevard, Glendale, California (the "Building").

B. The Lease will expire by its terms on January 14, 2017 (the "Extended Expiration Date"), and the parties wish to extend the term of the Lease on the following terms and conditions.

C. The parties wish to relocate the Premises (defined in the Lease) from the Existing Premises to the space containing approximately 16,484 rentable square feet described as Suite Nos. 1400, 1425 and 1450 on the 14th floor of the Building and shown on Exhibit A attached hereto (the "Substitution Space"), on the following terms and conditions.

NOW, THEREFORE, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant agree as follows:

1. Extension. The term of the Lease is hereby extended through the last day of the 72nd full calendar month following the Substitution Rent Commencement Date (defined in Section 2.l.A. below) (the "Second Extended Expiration Date"). The portion of the term of the Lease begi1ming January 15, 2017 (the "Second Extension Date") and ending on the Second Extended Expiration Date shall be referred to herein as the "Second Extended Term".

2. Substitution.

2.1. Substitution Term. From and after the Substitution Effective Date (defined in Section 2.l.A below), the Premises shall be the Substitution Space, subject to the terms hereof (the "Substitution"). The term of the Lease for the Substitution Space (the "Substitution Term") shall commence on the Substitution Effective Date and, unless sooner terminated in accordance with the Lease, end on the Extended Expiration Date. From and after the Substitution Effective Date, the Substitution Space shall be subject to all the terms and conditions of the Lease except as provided herein. Except as may be expressly provided herein, (a) Tenant shall not be entitled to receive, with respect to the Substitution Space, any allowance, free rent or other financial concession granted with respect to the Existing Premises, and (b) no representation or warranty made by Landlord with respect to the Existing Premises shall apply to the Substitution Space. Notwithstanding anything herein to the contrary, Landlord and Tenant acknowledge that Landlord shall have primary possession of the Substitution Space for the purpose of performing the Tenant Improvement Work during the period beginning on the Substitution Effective Date and ending on the Substitution Rent Commencement Date (the "Construction Period"). Tenant shall have no obligation to pay Base Rent or Additional Rent for the Substitution Space during the Construction Period. In addition, Landlord shall indemnify, defend, protect, and hold Tenant harmless from any obligation, loss, claim, action, liability, penalty, damage, cost or expense (including reasonable attorneys' and consultants' fees and expenses) that is imposed or asserted by any third party and arises from (a) any negligence or willful misconduct of Landlord or any Landlord Parties (defined in Section 10.1 of the Original Lease) in the Substitution Space during the Construction Period, or (b) the performance of Tenant Improvement Work by Landlord in the Substitution Space.

A. Substitution Effective Date; Substitution Rent Commencement Date. As used herein, "Substitution Effective Date" means December 15, 2014. As used herein, the "Substitution Rent Commencement Date" the earlier to occur of (i) the date on which Tenant first conducts business in the Substitution Space, or (ii) the date on which the Tenant Improvement Work (defined in Exhibit B attached hereto) is Substantially Complete (defined in Exhibit B attached hereto), which is anticipated to be February 1, 2015 (the "Target Substitution Rent Commencement Date"). The adjustment of the Substitution Rent Commencement Date and, accordingly, the postponement of Tenant's obligation to pay rent for the Substitution Space shall be Tenant's sole remedy if the Tenant Improvement Work is not Substantially Complete on the Substitution Rent Commencement Date. Without limiting the foregoing, during the period prior to the Substitution Rent Commencement Date, Tenant shall continue to pay rent for the Existing Premises in accordance with the terms of the Lease.

B. Confirmation Letter. At any time after the Substitution Rent Commencement Date, Landlord may deliver to Tenant a notice substantially in the form of Exhibit C attached hereto, as a confirmation of the information set forth therein. Tenant shall execute and return (or, by written notice to Landlord, reasonably object to) such notice within five (5) days after receiving it.

2.2. Existing Premises. Subject to the terms hereof, effective as of the Existing Premises Expiration Date (defined below), the term of the Lease shall expire with respect to the Existing Premises with the same force and effect as if such term were, by the provisions of the Lease, fixed to expire with respect to the Existing Premises on the Existing Premises Expiration Date. As used herein, "Existing Premises Expiration Date" means the day prior to the Substitution Rent Commencement Date. Without limiting the foregoing:

A. Tenant shall surrender the Existing Premises to Landlord in accordance with the ten11s of the Lease on or before the Existing Premises Expiration Date.

B. Tenant shall remain liable for all Rent and other amounts payable under the Lease with respect to the Existing Premises for the period up to and including the Existing Premises Expiration Date, even though billings for such amounts may occur after the Existing Premises Expiration Date.

C. Tenant's restoration obligations with respect to the Existing Premises shall be as set forth in the Lease.

D. If Tenant fails to surrender any portion of the Existing Premises on or before the Existing Premises Expiration Date, Tenant's tenancy with respect to the Existing Premises shall be subject to Section 16 of the Original Lease.

E. Any other rights or obligations of Landlord or Tenant under the Lease relating to the Existing Premises that, in the absence of the Substitution, would have survived the expiration date of the Lease shall survive the Existing Premises Expiration Date.

3. Base Rent. With respect to the Substitution Space during the Substitution Term, the schedule of

Base Rent shall be as follows:

Period During Substitution  Term	Annual Rate Per Square Foot (rounded to the nearest 100the  of a dollar)		Monthly Base Rent
Substitution  Effective Date through the day prior to the Substitution Rent Commencement Date	$	0	$	0
Substitution  Rent Commencement Date through last day of the 12th full calendar month following the Substitution Rent Commencement Date	$	27.60	$	37,913.20
13th through 24th full calendar months following the Substitution Rent Commencement Date	$	28.43	$	39,053.34
25th through 36th full calendar months following the Substitution Rent Commencement Date	$	29.28	$	40,220.96
37th through 48th full calendar months following the Substitution Rent Commencement Date	$	30.16	$	41,429.79
49th through 60th full calendar months following the Substitution Rent Commencement Date	$	31.06	$	42,666.09
61 sty full calendar month of Substitution  Term following the Substitution Rent Commencement Date through the last day of Substitution  Term	$	32.00	$	43,957.33

All such Base Rent shall be payable by Tenant in accordance with the terms of the Lease.

BASE RENT ABATEMENT. Notwithstanding anything in this Section of the Amendment to the contrary, so long as Tenant is not in Default (as defined in Section 19 of the Original Lease) under the Lease, Tenant shall be entitled to an abatement of Base Rent in the amount of: (a) $18,956.60 per month applicable to 11 consecutive full calendar months of the Substitution Term beginning with the second (2"d) full calendar month of the Substitution Term following the Substitution Rent Commencement Date, and (b) $19,526.67 applicable to the 13th full calendar month of the Substitution Term following the Substitution Rent Commencement Date. The total amount of Base Rent abated in accordance with the foregoing shall equal $228,049.27 (the "Abated Base Rent"). If Tenant Defaults at any time during the Substitution Term and fails to cure such Default within any applicable cure period under the Lease, all Abated Base Rent shall immediately become due and payable. The payment by Tenant of the Abated Base Rent in the event of a Default shall not limit or affect any of Landlord's other rights, pursuant to this Amendment, the Lease or at law or in equity. Only Base Rent shall be abated pursuant to this Section, and all Additional Rent (as defined in Section 3 of the Original Lease) and other costs and charges specified in this Amendment and/or the Lease shall remain as due and payable pursuant to the provisions of this Amendment and/or the Lease.

Notwithstanding the foregoing, upon written notice to Tenant from time to time (a "Purchase Notice"), Landlord shall have the right to purchase, by check or wire transfer of available funds, all or any part (in whole-month increments only) of the Abated Base Rent that had not previously been applied as a credit against Base Rent. Landlord's Purchase Notice shall set forth the month(s) of abatement that Landlord elects to purchase and the total Abated Base Rent that Landlord elects to purchase (the "Purchase Amount"). The Purchase Amount to be paid by Landlord shall be paid simultaneously with the giving of such notice. Upon payment of the Purchase Amount by Landlord to Tenant, the Abated Base Rent shall be reduced by an amount equal to the Purchase Amount. Upon request by Landlord, Landlord and Tenant shall enter into an amendment to the Lease to reflect the Purchase Amount paid by Landlord and the corresponding reduction of the Abated Base Rent.

4. Additional Security Deposit. Upon Tenant's execution hereof, Tenant shall pay Landlord the sum of $102,340.50, which shall be added to and become part of the Security Deposit, if any, held by Landlord pursuant to Section 21 of the Original Lease. Accordingly, simultaneously with the execution hereof, the Security Deposit is hereby increased from $29,531.49 to $131,871.99.

5. Tenant's Share. With respect to the Substitution Space during the Substitution Term following the Substitution Rent Commencement Date, Tenant's Share shall be 7.7571%.

6. Expenses and Taxes. With respect to the Substitution Space during the Substitution Term following the Substitution Rent Commencement Date, Tenant shall pay for Tenant's Share of Expenses and Taxes in accordance with the terms of the Lease; provided, however, that, with respect to the Substitution Space during the Substitution Term following the Substitution Rent Commencement Date, the Base Year for Expenses and Taxes shall be calendar year 2015.

7. Improvements to Substitution Space.

7.I. Condition and Configuration of Substitution Space. Tenant acknowledges that it has inspected the Substitution Space and agrees to accept it in its existing condition and configuration, without any representation by Landlord regarding its condition or configuration and without any obligation on the part of Landlord to perform or pay for any alteration or improvement, except as may be otherwise expressly provided in this Amendment.

7.2. Responsibility for Improvements to Substitution Space. Landlord shall perform improvements to the Substitution Space in accordance with Exhibit B attached hereto.

8. Representations. Tenant represents and warrants that, as of the date hereof and the Existing Premises Expiration Date: (a) Tenant is the rightful owner of all of the Tenant's interest in the Lease; (b) Tenant has not made any disposition, assignment, sublease, or conveyance of the Lease or Tenant's interest therein; (c) Tenant has no knowledge of any fact or circumstance which would give rise to any claim, demand, obligation, liability, action or cause of action arising out of or in com1ection with Tenant's occupa11cy of the Existing Premises; (d) no other person or entity has an interest in the Lease, collateral or otherwise; and (e) there are no outstanding contracts for the supply of labor or material and no work has been done or is being done in, to or about the Existing Premises which has not been fully paid for and for which appropriate waivers of mechanic's liens have not been obtained.

9. Other Pertinent Provisions. Landlord and Tenant agree that, effective as of the date of this Amendment (unless different effective date(s) is/are specifically referenced in this Section), the Lease shall be amended in the following additional respects:

9.1. California Public Resources Code § 25402.10. If Tenant (or any party claiming by, through or under Tenant) pays directly to the provider for any energy consumed at the Property, Tenant, promptly upon request, shall deliver to Landlord (or, at Landlord's option, execute and deliver to Landlord an instrument enabling Landlord to obtain from such provider) any data about such consumption that Landlord, in its reasonable judgment, is required to disclose to a prospective buyer, tenant or mortgage lender under California Public Resources Code § 25402.10 or any similar law.

9.2. California Civil Code Section 1938. Pursuant to California Civil Code § 1938, Landlord hereby states that the Existing Premises and the Substitution Space have not undergone inspection by a Certified Access Specialist (CASp) (defined in California Civil Code § 55.52).

.3. Temporary Space.

A. During the period beginning on the later of the full and final execution of this Amendment by Landlord and Tenant, delivery of the additional Security Deposit and delivery of all initial certificates of insurance required by this Lease (which certificates of insurance shall specifically cover both the Temporary Space during the Temporary Space Term, as hereinafter defined, and the Premises), and ending on the Substitution Rent Commencement Date (such period being referred to herein as the "Temporary Space Term"), Landlord shall allow Tenant to use approximately 2,397 rentable square feet of space known as Suite No. 240 located on the second (2nd) floor of the Building as shown on Exhibit A-1 of this Amendment (the "Temporary Space") for the Permitted Use. During the Temporary Space Term, the Temporary Space shall be deemed the "Premises" for purposes of Section 10 (Indemnification; Insurance) of the Original Lease. Such Temporary Space shall be accepted by Tenant in its "as-is" condition and configuration, it being agreed that Landlord shall be under no obligation to perform any work in the Temporary Space or to incur any costs in connection with Tenant's move in, move out or occupancy of the Temporary Space. Tenant acknowledges that it shall be entitled to use and occupy the Temporary Space at its sole cost, expense and risk. Tenant shall not construct any improvements or make any alterations of any type to the Temporary Space without the prior written consent of Landlord. All costs in connection with making the Temporary Space ready for occupancy by Tenant shall be the sole responsibility of Tenant.

B. The Temporary Space shall be subject to all the terms and conditions of the Lease except as expressly modified herein and except that (i) Tenant shall not be entitled to receive any allowances, abatement or other financial concession in connection with the Temporary Space which was granted with respect to the Premises unless such concessions are expressly provided for herein with respect to the Temporary Space, (ii) the Temporary Space shall not be subject to any renewal or expansion rights of Tenant under the Lease, (iii) Tenant shall not be required to pay Base Rent for the Temporary Space during the Temporary Space Term, and (iv) Tenant shall not be required to pay Tenant's Share of Expenses and Taxes for the Temporary Space during the Temporary Space Term.

C. Upon termination of the Temporary Space Term, Tenant shall vacate the Temporary Space and deliver the same to Landlord in the same condition that the Temporary Space was delivered to Tenant, ordinary wear and tear excepted. At the expiration or earlier termination of the Temporary Space Term, Tenant shall remove all debris, all items of Tenant's personalty, and any trade fixtures of Tenant from the Temporary Space. Tenant shall be fully liable for all damage Tenant or Tenant's agents, employees, contractors, or subcontractors cause to the Temporary Space.

D. Tenant shall have no right to hold over or otherwise occupy the Temporary Space at any time following the expiration or earlier termination of the Temporary Space Term, and in the event of such holdover, Landlord shall immediately be entitled to institute dispossessory proceedings to recover possession of the Temporary Space, without first providing notice thereof to Tenant. In the event of holding over by Tenant after expiration or termination of the Temporary Space Term without the written authorization of Landlord, Tenant shall pay, for such holding over, $9,588.00 for each month or partial month of holdover, plus all consequential damages that Landlord incurs as a result of the Tenant's hold over. During any such holdover, Tenant's occupancy of the Temporary Space shall be deemed that of a tenant at sufferance, and in no event, either during the Temporary Space Term or during any holdover by Tenant, shall Tenant be determined to be a tenant-at-will under applicable law. While Tenant is occupying the Temporary Space, Landlord or Landlord's authorized agents shall be entitled to enter the Temporary Space, upon reasonable notice, to display the Temporary Space to prospective tenants

9.4. Parking. During the Substitution Term, Tenant shall have the right, but not the obligation, to rent from Landlord up to 58 unreserved parking passes, at the rate of $60.00 per unreserved parking pass, per month, plus applicable taxes during the Substitution Tenn. Such rate shall not be subject to increase during the Substitution Term. Prior to the Substitution Rent Commencement Date, Tenant shall notify Landlord in writing of the number of unreserved parking passes which Tenant initially elects to use during the Substitution Term, but in no event more than the maximum number of unreserved parking passes set forth herein. Thereafter, Tenant may increase or decrease the number of unreserved parking passes to be used by Tenant pursuant to this Section 9.4 upon a minimum of 30 days prior written notice to Landlord, provided that in no event may Tenant elect to use more than the maximum number of unreserved parking passes set forth herein.

Subject to availability, Tenant shall also have the right to lease additional unreserved parking passes on a month-to-month basis (the "Month-to-Month Passes"). The term for only the Month-to-Month Passes shall automatically renew for consecutive periods of one (1) month each until terminated by either party by written notice of termination delivered to the other party. Any such termination shall be effective as of the last day of the first full month following the date written notice of termination is delivered to the other party by the terminating party. Tenant shall pay Landlord, as Additional Rent in accordance with Section 3 of the Original Lease, the then current rate for unreserved parking in the Parking Facility (as defined in Section 24 of the Original Lease) for such Month-to-Month Passes, as such rate may be adjusted from time to time.

9.5. No Options. The parties hereto acknowledge and agree that during the Substitution Term Tenant shall have no rights to extend the term of the Lease, or expand, terminate or contract the Premises. The parties agree that any rights existing in the Lease to extend the term of the Lease, or expand, terminate or contract the Premises shall be deleted in their entirety and are of no further force ru1d effect.

10. Miscellaneous.

10.1. This Amendment and the attached exhibits, which are hereby incorporated into and made a part of this Amendment, set forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements. Tenant shall not be entitled, in connection with entering into this Amendment, to any free rent, allowance, alteration, improvement or similar economic incentive to which Tenant may have been entitled in connection with entering into the Lease, except as may be otherwise expressly provided in this Amendment.

10.2. Except as herein modified or amended, the provisions, conditions and terms of the Lease shall remain unchanged and in full force and effect.

10.3. In the case of any inconsistency between the provisions of the Lease and this Amendment, the provisions of this Amendment shall govern and control.

10.4. Submission of this Amendment by Landlord is not an offer to enter into this Amendment but rather is a solicitation for such an offer by Tenant. Landlord shall not be bound by this Amendment until Landlord has executed and delivered it to Tenant.

10.5. Capitalized terms used but not defined in this Amendment shall have the meanings given in the Lease.

10.6. Tenant shall indemnify and hold Landlord, its trustees, members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents harmless from all claims of any brokers claiming to have represented Tenant in connection with this Amendment. Landlord shall indemnify and hold Tenant, its trustees, members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents harmless from all claims of any brokers claiming to have represented Landlord in connection with this Amendment. Tenant acknowledges that any assistance rendered by any agent or employee of any affiliate of Landlord in connection with this Amendment has been made as an accommodation to Tenant solely in furtherance of consummating the transaction on behalf of Landlord, and not as agent for Tenant.

IN WITNESS WHEREOF, Landlord and Tenant have duly executed this Amendment as of the day and year first above written.

LANDLORD:
EOP-700 NORTH BRAND, L.L.C., a Delaware limited liability company
By:	Frank Campbell
	Name:	Frank Campbell
	Title:	Market Managing Dir.
TENANT:
APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation
By:	/s/ Warren Hossenian
Name:	Warren Hossenian
Title:	CEO

EXHIBIT A

OUTLINE AND LOCATION OF SUBSTITUTION
SPACE

EXHIBIT A-1

OUTLINE AND LOCATION OF TEMPORARY SPACE

2ND FLOOR • SUITE 240 • 2,397 RSF

EXHIBIT B

WORK LETTER

As used in this Exhibit B (this "Work Letter"), the following terms shall have the following meanings: "Agreement" means the Amendment of which this Work Letter is a pa1i. "Premises" means the Substitution Space. "Tenant Improvements" means all improvements to be constructed in the Premises pursuant to this Work Letter. "Tenant Improvement Work" means the construction of the Tenant Improvements, together with any related work (including demolition) that is necessary to construct the Tenant Improvements.

1 ALLOWANCE.

1.1       Allowance. Tenant shall be entitled to a one-time tenant improvement allowance (the "Allowance") in the amount of $659,360.00 (i.e., $40.00 per rentable square foot of the Premises) to be applied toward the (i) Allowance Items (defined in Section 1.2 below) and to the extent that the Allowance exceeds the Construction Pricing Proposal, (ii) a credit against Base Rent coming due under the Lease from and after the last day of the 13th full calendar month of the Substitution Term following the Substitution Rent Commencement Date, and/or (iii) the cost of purchasing and installing cabling, furniture, fixtures, and equipment to be used in the Premises by Tenant; provided that the total portion of the Allowance that is applied toward the items described in (ii) and (iii) shall not exceed, in the aggregate,$329,680.00 (i.e., $20.00 per rentable square foot of the Premises). Tenant, by written notice to Landlord (the "Allowance Notice") shall advise Landlord of the manner in which Tenant desires to apply any unused Allowance. Any portion of the Allowance that is applied as a credit against Base Rent shall be applied against 50% of the installment of Base Rent for the 14th full calendar month of the Substitution Term following the Substitution Rent Commencement Date, and, if necessary, 50% of the installment of Base Rent for consecutive calendar months thereafter. Any portion of the Allowance that is applied toward the cost of purchasing and installing cabling, furniture, fixtures, and/or equipment to be used in the Premises shall be disbursed to Tenant within 30 days after the later to occur of: (x) receipt of paid invoices from Tenant with respect to Tenant's actual costs of purchasing and installing the cabling, furniture, fixtures, and/or equipment to be used in the Premises as described above, and (y) the Substitution Rent Commencement Date; provided that Tenant shall also be required to provide Landlord the unconditional waivers of mechanics lien with respect to any items that relate to work of a type for which a mechanics lien could be potentially be filed. Tenant shall be responsible for all costs associated with the Tenant Improvement Work, including the costs of the Allowance Items, to the extent such costs exceed the lesser of (a) the Allowance, or (b) the aggregate amount that Landlord is required to disburse for such purpose pursuant to this Work Letter. Notwithstanding any contrary provision of this Agreement, if Tenant fails to use the entire Allowance by the last day of the 24 full calendar month of the Substitution Term, the unused amount shalt reve1i to Landlord and Tenant shall have no further rights with respect thereto; provided, however, that any portion of the Allowance that Tenant previously elected to apply as a credit against Base Rent shall not be forfeited and such Base Rent credits shall continue for as long as necessary to assure that Tenant has received the full benefit of such credit against Base Rent.

1.2 Disbursement of Allowance.

1.2.1       Allowance Items. Except as otherwise provided in this Work Letter, the Allowance shall be disbursed by Landlord only for the following items (the "Allowance Items"): (a) the fees of the Architect (defined in Section 2.1 below) and the Engineers (defined in Section 2.1 below), and any fees reasonably incurred by Landlord for review of the Plans (defined in Section 2.1 below) (which fees, notwithstanding any contrary provision of this Agreement, shall not exceed $0.12 per rentable square foot of the Premises) by Landlord's third party consultants; (b) plan-check, permit and license fees relating to performance of the Tenant Improvement Work; (c) the cost of performing the Tenant Improvement Work, including after hours charges, testing and inspection costs, freight elevator usage, hoisting and trash removal costs, and contractors' fees and general conditions; (d) the cost of any change to the base, shell or core of the Premises or Building required by the Plans (including if such change is due to the fact that such work is prepared on an unoccupied basis), including all direct architectural and/or engineering fees and expenses incurred in connection therewith; (e) the cost of any change to the Plans or Tenant Improvement Work required by Law; (f) the Coordination Fee (defined in Section 3.2.2 below); (g) sales and use taxes; and (h) all other costs expended by Landlord in connection with the performance of the Tenant Improvement Work.

2 PLANS AND PRICING.

2.1       Selection of Architect. Landlord shall retain the architect/space planner (the "Architect") and the engineering consultants (the "Engineers") of Landlord's choice to prepare all architectural plans for the Premises and all engineering working drawings relating to the structural, mechanical, electrical, plumbing, HVAC, life-safety, and sprinkler work in the Premises. The plans and drawings to be prepared by the Architect and the Engineers shall be referred to in this Work Letter as the "Plans." Tenant shall be responsible for ensuring that all elements of the design of the Plans are suitable for Tenant's use of the Premises, and neither the preparation of the Plans by the Architect or the Engineers nor Landlord's approval of the Plans shall relieve Tenant from such responsibility.

2.2       Initial Programming Information. Tenant shall deliver to Landlord, in writing, all information necessary in the judgment of Landlord, the Architect and the Engineers for the preparation of a conceptual space plan for the Premises (a "Space Plan"), including layout and designation of all offices, rooms and other partitioning, their intended use, and equipment to be contained therein, the number and sizes of workstations, number and size of kitchen, copy, reception and storage areas (collectively, the "Initial Programming Information"). The Initial Programming Information shall be consistent with Landlord's requirements for avoiding aesthetic, engineering or other conflicts with the design and function of the balance of the Building (collectively, the "Landlord Requirements") and shall otherwise be subject to Landlord's reasonable approval. Landlord shall provide Tenant with notice approving or reasonably disapproving the Initial Programming Information within 5 business days after the later of Landlord's receipt thereof or the mutual execution and delivery of this Agreement. If Landlord disapproves the Initial Programming Information, Landlord's notice of disapproval shall describe with reasonable specificity the basis for such disapproval and the changes that would be necessary to resolve Landlord's objections. If Landlord disapproves the Initial Programming Information, Tenant shall modify the Initial Programming Information and resubmit it for Landlord's review and approval. Such procedure shall be repeated as necessary until Landlord has approved the Initial Programming Information.

2.3      Space Plan. After approving the Initial Programming Information, Landlord shall cause the Architect to prepare and deliver to Tenant a Space Plan that conforms to the Initial Programming Information. Such preparation and delivery shall occur within I 0 business days after the later of Landlord's approval of the Initial Programming Information or the mutual execution and delivery of this Agreement. Tenant shall approve or disapprove the Space Plan by notice to Landlord. If Tenant disapproves the Space Plan, Tenant's notice of disapproval shall specify any revisions Tenant desires in the Space Plan. After receiving such notice of disapproval, Landlord shall cause the Architect to revise the Space Plan, taking into account the reasons for Tenant's disapproval (provided, however, that Landlord shall not be required to cause the Architect to make any revision to the Space Plan that is inconsistent with the Landlord Requirements or that Landlord otherwise reasonably disapproves), and resubmit the Space Plan to Tenant for its approval. Such revision and resubmission shall occur within 5 business days after the later of Landlord's receipt of Tenant's notice of disapproval or the mutual execution and delivery of this Agreement if such revision is not material, and within such longer period of time as may be reasonably necessary if such revision is material. Such procedure shall be repeated as necessary until Tenant has approved the Space Plan.

2.4         Additional Programming Information. After approving the Space Plan, Tenant shall deliver to Landlord, in writing, all information that, together with the Space Plan, is necessary in the judgment of Landlord, the Architect and the Engineers to complete the architectural, engineering and final architectural working drawings for the Premises in a form that is sufficient to enable subcontractors to bid on the work and to obtain all applicable permits for the Tenant Improvement Work (the "Construction Drawings"), including electrical requirements, telephone requirements, special HVAC requirements, plumbing requirements, and all interior and special finishes (collectively, the "Additional Programming Information"). The Additional Programming Information shall be consistent with the Landlord Requirements and shall otherwise be subject to Landlord's reasonable approval. Landlord shall provide Tenant with notice approving or reasonably disapproving the Additional Programming Information within5 business days after the later of Landlord's receipt thereof or the mutual execution and delivery of this Agreement. If Landlord disapproves the Additional Programming Information, Landlord's notice of disapproval shall describe with reasonable specificity the basis for such disapproval and the changes that would be necessary to resolve Landlord's objections. If Landlord disapproves the Additional Programming Information, Tenant shall modify the Additional Programming Information and resubmit it for Landlord’s review and approval. Such procedure shall be repeated as necessary until Landlord has approved the Additional Programming Information. If requested by Tenant, Landlord, in its sole and absolute discretion, may assist Tenant, or cause the Architect and/or the Engineers to assist Tenant, in preparing all or a portion of the Additional Programming Information; provided, however, that, whether or not the Additional Programming Information is prepared with such assistance, Tenant shall be solely responsible for the timely preparation and delivery of the Additional Programming Information and for all elements thereof and, subject to Section 1 above, all costs relating thereto.

2.5         Construction Drawings. After approving the Additional Programming Information, Landlord shall cause the Architect and the Engineers to prepare and deliver to Tenant Construction Drawings that conform to the approved Space Plan and the approved Additional Programming Information. Such preparation and delivery shall occur within 10 business days after the later of Landlord's approval of the Additional Programming Information or the mutual execution and delivery of this Agreement. Tenant shall approve or disapprove the Construction Drawings by notice to Landlord. If Tenant disapproves the Construction Drawings, Tenant's notice of disapproval shall specify any revisions Tenant desires in the Construction Drawings. After receiving such notice of disapproval, Landlord shall cause the Architect and/or the Engineers to revise the Construction Drawings, taking into account the reasons for Tenant's disapproval (provided, however, that Landlord shall not be required to cause the Architect or the Engineers to make any revision to the Construction Drawings that is inconsistent with the Landlord Requirements or that Landlord otherwise reasonably disapproves), and resubmit the Construction Drawings to Tenant for its approval. Such revision and resubmission shall occur within 5 business days after the later of Landlord's receipt of Tenant's notice of disapproval or the mutual execution and delivery of this Agreement if such revision is not material, and within such longer period of time as may be reasonably necessary if such revision is material. Such procedure shall be repeated as necessary until Tenant has approved the Construction Drawings; provided that if Tenant requests more than two (2) sets of revisions to the Construction Drawings, any delays in connection with the third (3rd) and subsequent revisions shall be deemed to be a Tenant Delay. The Construction Drawings approved by Landlord and Tenant are referred to in this Work Letter as the "Approved Construction Drawings".

2.6      Construction Pricing. Within a reasonable time after the Approved Construction Drawings are approved by Landlord and Tenant, Landlord shall provide Tenant with Landlord's reasonable estimate (the "Construction Pricing Proposal") of the cost of all Allowance Items to be incurred by Tenant in connection with the performance of the Tenant Improvement Work pursuant to the Approved Construction Drawings. Tenant shall provide Landlord with notice approving or disapproving the Construction Pricing Proposal. If Tenant disapproves the Construction Pricing Proposal, Tenant's notice of disapproval shall be accompanied by proposed revisions to the Approved Construction Drawings that Tenant requests in order to resolve its objections to the Construction Pricing Proposal, and Landlord shall respond as required under Section 2.7 below. Such procedure shall be repeated as necessary until the Construction Pricing Proposal is approved by Tenant. Upon Tenant's approval of the Construction Pricing Proposal, Landlord may purchase the items set forth in the Construction Pricing Proposal and commence construction relating to such items.

2.7       Revisions to Approved Construction Drawings. If Tenant requests any revision to the Approved Construction Drawings, Landlord shall provide Tenant with notice approving or reasonably disapproving such revision, and, if Landlord approves such revision, Landlord shall have such revision made and delivered to Tenant, together with notice of any resulting change in the most recent Construction Pricing Proposal, if any, within 5 business days after Landlord's receipt of such request if such revision is not material, and within such longer period of time as may be reasonably necessary if such revision is material, whereupon Tenant, within one (1) business day, shall notify Landlord whether it desires to proceed with such revision. If Landlord has commenced performance of the Tenant Improvement Work, then, in the absence of such authorization, Landlord shall have the option to continue such performance disregarding such revision. Landlord shall not revise the Approved Construction Drawings without Tenant's consent, which shall not be unreasonably withheld, conditioned or delayed.

2.8      Time Deadlines. Tenant shall use its best effo1is to cooperate with Landlord and its architect, engineers and other consultants to complete all phases of the Plans, approve the Construction Pricing Proposal and obtain the permits for the Tenant Improvement Work as soon as possible after the execution of this Agreement, and Tenant shall meet with Landlord, in accordance with a schedule determined by Landlord, to discuss the parties' progress. Without limiting the foregoing, Tenant shall approve the Construction Pricing Proposal pursuant to Section 2.6 above on or before Tenant's Approval Deadline (defined below). As used in this Work Letter, "Tenant's Approval Deadline" means October 24, 2014 provided, however, that Tenant's Approval Deadline shall be extended by one day for each day, if any, by which Tenant's approval of the Construction Pricing Proposal pursuant to Section 2.6 above is delayed by any failure of Landlord to perform its obligations under this Section 2.

3 CONSTRUCTION.

3.1      Contractor. A contractor designated by Landlord (the "Contractor") shall perform the Tenant Improvement Work. In addition, Landlord may select and/or approve of any subcontractors, mechanics and material men used in connection with the performance of the Tenant Improvement Work.

3.2      Construction.

3.2.1      Over-Allowance Amount. If the Construction Pricing Proposal exceeds the Allowance, then, concurrently with its delivery to Landlord of approval of the Construction Pricing Proposal, Tenant shall deliver to Landlord cash in the amount of such excess (the "Over-Allowance Amount"). Any Over-Allowance Amount shall be disbursed by Landlord before the Allowance and pursuant to the same procedure as the Allowance. After the Construction Pricing Proposal is approved by Tenant, if any revision is made to the Approved Construction Drawings or the Tenant Improvement Work that increases the Construction Pricing Proposal, or if the Construction Pricing Proposal is otherwise increased to reflect the actual cost of all Allowance Items to be incurred by Tenant in connection with the performance of the Tenant Improvement Work pursuant to the Approved Construction Drawings, then Tenant shall deliver any resulting Over-Allowance Amount (or any resulting increase in the Over- Allowance Amount) to Landlord immediately upon Landlord's request.

3.2.2      Landlord's Retention of Contractor. Landlord shall independently retain the Contractor to perform the Tenant Improvement Work in accordance with the Approved Construction Drawings. Tenant shall pay a construction supervision and management fee (the "Landlord Supervision Fee") to Landlord in an amount equal to 3% of the aggregate amount of all Allowance Items other than the Landlord Supervision Fee.

3.2.3      Contractor's Warranties. Tenant waives all claims against Landlord relating to any defects in the Tenant Improvements; provided, however, that Landlord shall obtain a commercially reasonable one-year warranty from Contractor with respect to the performance of the Tenant Improvement Work (the "Warranty"). If, within the period covered by the Warranty, Tenant provides notice to Landlord of any defect in the Tenant Improvements, then Landlord shall, at Landlord's expense, use reasonable efforts to enforce such Warranty directly against the Contractor for Tenant's benefit.

4 COMPLETION.

4.1      Substantial Completion. For purposes of determining the Substitution Rent Commencement Date, and subject to Section 4.2 below, the Tenant Improvement Work shall be deemed to be "Substantially Complete" upon the completion of the Tenant Improvement Work pursuant to the Approved Construction Drawings (as reasonably determined by Landlord), with the exception of any details of construction, mechanical adjustment or any other similar matter the non-completion of which does not materially interfere with Tenant's use of the Premises.

4.2      Tenant Delay. If the Substantial Completion of the Tenant Improvement Work is delayed (a "Tenant Delay") as a result of (a) any failure of Tenant to approve the Construction Pricing Proposal pursuant to Section 2.6 above on or before Tenant's Approval Deadline; (b) Tenant's failure to timely approve any matter requiring Tenant's approval; (c) any breach by Tenant of this Work Letter or the Lease; (d) any request by Tenant for a revision to the Approved Construction Drawings (except to the extent such delay results from any failure of Landlord to perform its obligations under Section 2.7 above); (e) Tenant's requirement for materials, components, finishes or improvements that are not available in a commercially reasonable time given the anticipated date of Substantial Completion of the Tenant Improvement Work as set forth in this Agreement; or (f) any other act or omission of Tenant or any of its agents, employees or representatives, then, notwithstanding any contrary provision of this Agreement, and regardless of when the Tenant Improvement Work is actually Substantially Completed, the Tenant Improvement Work shall be deemed to be Substantially Completed on the date on which the Tenant Improvement Work would have been Substantially Completed if no such Tenant Delay had occurred. Notwithstanding the foregoing, Landlord shall not be required to tender possession of the Premises to Tenant before the Tenant Improvement Work has been Substantially Completed, as determined without giving effect to the preceding sentence.

5     MISCELLANEOUS. Notwithstanding any contrary provision of this Agreement, if Tenant defaults under this Agreement before the Tenant Improvement Work is completed, then (a) Landlord's obligations under this Work Letter shall be excused, and Landlord may cause the Contractor to cease performance of the Tenant Improvement Work, until such default is cured, and (b) Tenant shall be responsible for any resulting delay in the completion of the Tenant Improvement Work. This Work Letter shall not apply to any space other than the Premises.

6      LANDLORD’S INITIAL CONSTRUCTION. Landlord, at its sole cost and expense, shall remove the existing internal staircase connecting the Substitution Space to the 12th floor of the Building and restore the concrete slab floor, to a slab finish (collectively, the "Initial Landlord Work"). Without limitation, Tenant, at its cost, shall be responsible for any improvements or finishes to be installed over such concrete slab floor. Notwithstanding any contrary provision of this Agreement, the Initial Landlord Work shall be performed at Landlord's expense and shall not be deemed Tenant Improvements, Tenant Improvement Work or an Allowance Item. Landlord shall use commercially reasonable efforts to cause the Initial Landlord Work to be performed in a manner that efficiently coordinated with the performance of the Tenant Improvement Work; provided, however, that Landlord shall not be required to delay performance of, or pay overtime rates for, the Initial Landlord Work.

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Warren Hosseinion, Chief Executive Officer, certify that:

1.    I have reviewed this report on Form 10-Q of Apollo Medical Holdings, Inc.

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this quarterly  report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    Apollo Medical Holdings, Inc. other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.    Apollo Medical Holdings, Inc. other certifying officer and I are have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated : November 14, 2014	By:	Warren Hosseinion M.D.
		/S/ Warren Hosseinion M.D.
		Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Mitchell R. Creem, Chief Financial Officer, certify that:

1.    I have reviewed this report on Form 10-Q of Apollo Medical Holdings, Inc.

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this quarterly  report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    Apollo Medical Holdings, Inc. other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.    Apollo Medical Holdings, Inc. other certifying officer and I are have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Dated:    November 14, 2014	By:	Mitchell R. Creem
		/S/ Mitchell R. Creem
		Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Report of Apollo Medical Holdings, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Warren Hosseinion, Chief Executive Officer of the Company, certify that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. section  1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Dated:  November 14, 2014	By:	Warren Hosseinion M.D.
		/ S/ Warren Hosseinion M.D.
		Chief Executive Officer

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Report of Apollo Medical Holdings, Inc. (the “Company”) on Form 10-Q for the three months ended September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mitchell R. Creem, Chief Financial Officer and Principal Accounting Officer of the Company, certify, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Dated :  November 14, 2014	By:	Mitchell R. Creem
		/S/ Mitchell R. Creem
		Chief Financial Officer

XML

Summary of Goodwill Activity (Detail) (USD $)			6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014 AKM Medical Group, Inc [Member]	Sep. 30, 2014 Southern California Heart Centers [Member]
Goodwill [Line Items]
Balance, beginning of period	$ 439,694	$ 494,700
Acquisition			(216,565)	161,559
Balance, end of period	$ 439,694	$ 494,700

XML

Summary of Restricted Stock Award (Detail) (USD $)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Schedule Of Share Based Compensation Restricted Stock Units Award Activity [Line Items]
Shares,Balance, Beginning	3,752,000
Shares,Granted	112,000
Shares,Released	(183,996)
Shares,Balance, Ending	3,680,004	3,752,000
Vested and exercisable	2,461,694
Balance, Weighted Average Remaining Vesting Life (Years)	7 months 6 days	9 months 18 days
Balance, Weighted Average Remaining Vesting Life, Granted	0 years
Balance, Weighted Average Remaining Vesting Life, Released	0 years
Weighted Average Per Share Intrinsic Value, Balance, Beginning	$ 0.02
Weighted Average Per Share Intrinsic Value, Granted	0
Weighted Average Per Share Intrinsic Value, Released	0
Weighted Average Per Share Intrinsic Value, Balance, Ending	$ 0.73	$ 0.02
Weighted Average Per Share Fair Value, Balance, Beginning	$ 0.03
Weighted Average Per Share Fair Value, Granted	$ 0.78
Weighted Average Per Share Fair Value, Released	$ 0
Weighted Average Per Share Fair Value, Balance, Ending	$ 0.05	$ 0.03

XML

Long-Term Debt (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Feb. 21, 2013
Debt Instrument [Line Items]
Convertible Notes Payable	$ 1,953,587	$ 962,978
9% Senior Subordinated Convertible Notes due February 15, 2016
Debt Instrument [Line Items]
Convertible Notes Payable	1,000,398	962,978
8% Senior Subordinated Convertible Notes due
Debt Instrument [Line Items]
Convertible Notes Payable	$ 953,189	$ 0	$ 150,000

XML

Total Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements (Detail) (USD $)	Sep. 30, 2014
Common stock options
Employee Service Share -Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Line Items]
Unrecognized compensation cost	$ 198,195
Restricted stock
Employee Service Share -Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Line Items]
Unrecognized compensation cost	139,400
ACO Plan restricted stock
Employee Service Share -Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized [Line Items]
Unrecognized compensation cost	$ 57,179

XML

Interest Expense Associated with Notes Payable (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Associated of Interest Expense [Line Items]
Interest expense	$ 329,258	$ 200,562	$ 606,125	$ 362,252
Notes Payable
Associated of Interest Expense [Line Items]
Interest expense	143,845	25,089	287,998	56,087
Amortization of loan fees and discount	71,673	35,061	142,924	39,780
Interest expense, debt	$ 215,518	$ 60,151	$ 430,922	$ 95,868

XML

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jul. 22, 2014 SCHC	Sep. 30, 2014 SCHC	Sep. 30, 2014 SCHC	May 31, 2014 AKM Medical Group, Inc	Sep. 30, 2014 AKM Medical Group, Inc	Sep. 30, 2014 AKM Medical Group, Inc
Business Acquisition [Line Items]
Business Combination, Consideration Transferred							$ 2,560,391	$ 280,000		$ 276,822
Payments to Acquire Businesses, Gross							2,428,391	140,000		140,000
Business Combination, Consideration Transferred, Liabilities Incurred							132,000	136,822		136,822
Revenues, Total	11,665,294	2,521,421	15,759,780	5,136,115						1,872,529
Other Income										(260,624)
Acquisiton Of Common Stock And Warrants Description			The purchase price for the shares was (i) $2,000,000 in cash, (ii) $428,391 to pay off and discharge certain indebtedness of SCHC (iii) warrants to purchase up to 1,000,000 shares of the Companys common stock at an exercise price of $1.00 per share and (iv) a contingent amount of up to $1,000,000 payable, if at all, in cash.
Costs and Expenses, Related Party									0	37,000
Fair Value Assumptions, Exercise Price					$ 1.00
Fair Value Assumptions, Expected Term					4 years
Fair Value Assumptions, Expected Volatility Rate					54.00%
Fair Value Assumptions, Risk Free Interest Rate					1.35%
Business Combination, Contingent Consideration, Liability					1,000,000
Allocated Share-based Compensation Expense, Total	856,519	568,708	975,658	2,121,012	827,000
Royalty Rate					1.00%
Business Acquisition, Share Price					$ 0.54
Finite-Lived Intangible Asset, Useful Life					5 years
General and Administrative Expense, Total	3,451,907	1,043,565	5,461,239	2,965,395		124,000	124,000
Business Acquisitions Target Amount	$ 461,104		$ 461,104

XML

Warrants Outstanding (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014
Class of Warrant or Right [Line Items]
Weighted Average Per Share Intrinsic Value, Outstanding	$ 0.02
Weighted Average Per Share Intrinsic Value, Granted	0
Weighted Average Per Share Intrinsic Value, Exercised	0
Weighted Average Per Share Intrinsic Value, Cancelled	0
Weighted Average Per Share Intrinsic Value, Outstanding	$ 0
Number Of warrants, Outstanding	7,145,000
Number Of warrants, Granted	2,000,000
Number Of warrants, Exercised	0
Number Of warrants, Cancelled	0
Number Of warrants, Outstanding	9,145,000

XML

Convertible Notes Payable (Tables)

6 Months Ended

Sep. 30, 2014

Convertible Notes [Abstract]

Schedule of Long-term Debt Instruments

Convertible notes payable consist of the following:

	September 30,		March 31,
	2014		2014
9% Senior Subordinated Convertible Notes due February 15, 2016, net of debt discount of $99,973 (September 30, 2014) and $137,393 (March 31, 2014)	$	1,000,398	$	962,978
8% Senior Subordinated Convertible Note Payable to NNA due March 28, 2019, net of debt discount of $1,046,811		953,189		-
	$	1,953,587	$	962,978

Schedule Of Debt Instruments Interest Expense

Interest expense associated with the convertible notes payable consisted of the following:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
Interest expense	$	52,856	$	111,387	$	77,881	$	185,619
Amortization of loan fees and discount		60,884		29,025		97,322		80,766
	$	113,740	$	140,411	$	175,203	$	266,384

XML

Interest Expense on Convertible Notes (Detail) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014 Convertible Notes Payable	Sep. 30, 2013 Convertible Notes Payable	Sep. 30, 2014 Convertible Notes Payable	Sep. 30, 2013 Convertible Notes Payable
Schedule Of Debt Instrument Interest Expense [Line Items]
Interest expense	$ 329,258	$ 200,562	$ 606,125	$ 362,252	$ 52,856	$ 111,387	$ 77,881	$ 185,619
Amortization of loan fees and discount					60,884	29,025	97,322	80,766
Interest expense, debt					$ 113,740	$ 140,411	$ 175,203	$ 266,384

XML

Accounts Payable and Accrued Liabilities (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Account Payable And Accrued Liabilities [Line Items]
Accounts payable	$ 1,456,796	$ 824,334
Physician share of MSSP ACO savings	1,400,000	0
Accrued compensation	809,772	546,078
Income taxes payable	85,477	4,149
Accrued interest	28,049	19,780
Accrued professional fees	12,550	52,699
Accounts payable and accrued liabilities	$ 3,792,645	$ 1,447,040

XML

Pro Forma Results Of Medical Clinic Acquisition (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Acquisition [Line Items]
Net revenue	$ 11,899,142	$ 4,477,640	$ 17,956,326	$ 9,135,956
Net income (loss)	$ 1,410,936	$ (1,067,658)	$ (209,441)	$ (3,054,008)
Basic income (loss) per share	$ 0.03	$ (0.02)	$ 0.00	$ (0.08)
Diluted income (loss) per share	$ 0.03	$ (0.02)	$ 0.00	$ (0.08)

XML

Summary of Company's Restricted Stock (Detail) (USD $)	1 Months Ended	6 Months Ended	12 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Mar. 31, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Unvested or unlapsed shares, Shares		907,407
Granted, Shares		0
Vested / lapsed, Shares		(611,111)
Forfeited, Shares		0
Unvested or unlapsed shares, Shares		296,296	907,407
Unvested or unlapsed shares, Average Life (In Years)		1 year 1 month 6 days	1 year 3 months 18 days
Granted, Average Life (In Years)		0 years
Vested / lapsed, Average Life (In Years)		0 years
Forfeited, Average Life (In Years)		0 years
Unvested or unlapsed shares, Average Intrinsic Value		$ 0
Granted, Average Intrinsic Value		$ 0
Vetsed / lapsed, Average Intrinsic Value		$ 0
Forfeited, Average Intrinsic Value		$ 0
Unvested or unlapsed shares, Average Intrinsic Value		$ 0.06	$ 0
Unvested or unlapsed shares, Fair Value		$ 0.41
Granted, Fair Value		$ 0
Vested / lapsed, Fair Value	$ 0.24	$ 0
Forfeited, Fair Value		$ 0
Unvested or unlapsed shares, Fair Value		$ 0.41	$ 0.41

XML

Convertible Notes Payable - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended			1 Months Ended			6 Months Ended		1 Months Ended			1 Months Ended	6 Months Ended	1 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Feb. 21, 2013 8% Senior Subordinated Convertible Notes due February 1, 2015	Sep. 30, 2014 8% Senior Subordinated Convertible Notes due February 1, 2015	Mar. 31, 2014 8% Senior Subordinated Convertible Notes due February 1, 2015	Sep. 30, 2014 9% Senior Subordinated Convertible Notes due February 15, 2016	Mar. 31, 2014 9% Senior Subordinated Convertible Notes due February 15, 2016	Oct. 16, 2009 10% Senior Subordinated Callable Convertible Notes	Jul. 31, 2014 NNA Financing 8 Convertible Note [Member]	Sep. 30, 2014 NNA Financing 8 Convertible Note [Member]	Jul. 31, 2014 NNA 8 Convertible Notes [Member]	Sep. 30, 2014 NNA 8 Convertible Notes [Member]	Jul. 31, 2014 NNA 8 Convertible Notes [Member] Common Stock [Member]	Jul. 31, 2014 NNA 8 Convertible Notes [Member] Warrant
Debt conversion description [Line Items]
Convertible notes payable, interest payment terms								If the Average Daily Value of Trades (ADVT) during the prior 90 days as reported by Bloomberg is greater than $100,000, the Note is callable at a price of 105% of the Notes par value, and if the ADVT is less than $100,000, the 9% Notes are callable at a price of 110% of the Notes par value.
Debt conversion, price per share of common stock		$ 1.00						$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								660,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.45								$ 1.00
Gross Proceeds From Issuance Of Debt										$ 1,250,000
Payments of Debt Issuance Costs		20,000	0							25,000
Convertible Notes Payable		1,953,587		962,978	150,000	953,189	0	1,000,398	962,978
Debt Instrument Total Cash Payment					106,000
Debt Instrument Total Shares Issuance					182,000
Debt Instrument, Face Amount												2,000,000
Debt Instrument, Unused Borrowing Capacity, Amount											2,000,000
Proceeds from Issuance of Debt											2,000,000
Debt Instrument, Unamortized Discount		1,183,856		1,305,435		1,046,811		99,973	137,393		1,065,775
Debt Instrument, Interest Rate, Stated Percentage	8.00%					8.00%		9.00%			8.00%
Debt Instrument Stock Initial Price											$ 1.00
Debt Instrument, Convertible, Beneficial Conversion Feature		578,155	125,000								578,155
Fair Value Assumptions, Expected Term											4 years 8 months 12 days		6 years 8 months 12 days
Fair Value Assumptions, Risk Free Interest Rate											1.60%		2.10%
Fair Value Assumptions, Expected Dividend Rate													71.80%
Fair Value Assumptions, Expected Volatility Rate											54.80%		0.49%
Share Price	$ 0.49										$ 0.49			$ 0.45
Percentage For Down round financing	100.00%										100.00%			100.00%	100.00%
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																1,000,000
Fair Value Of Warrant Liabilities													487,620
Stock Issued													$ 1,000,000

XML

Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.        Summary of Significant Accounting Policies

Accounting Principles

These condensed consolidated statements reflect all adjustments, consisting of normal recurring adjustments, which, in management’s opinion, are necessary, and should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2014 as filed with the Securities and Exchange Commission (“SEC”) on May 8, 2014.

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of (1) Apollo Medical Holdings, Inc. and its wholly owned subsidiaries AMM, PCCM, and VMM, (2) the Company’s controlling interest in ApolloMed ACO, and APS, which is a newly formed entity with no operations to date to provide home health and hospice medical services and in which a non-controlling interest in APS contributed $550,000 in cash; and (3) PPCs managed under long-term management service agreements including AMH, MMG, ACC, LALC, Hendel, AKM and SCHC. Some states have laws that prohibit business entities, such as ApolloMed, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In California, the Company operates by maintaining long-term management service agreements with the PPCs, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, the Company provides and performs all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. Each management agreement typically has a term from 10 to 20 years unless terminated by either party for cause. The management agreements are not terminable by the PPCs, except in the case of material breach or bankruptcy of the respective PPM.

Through the management agreements and the Company’s relationship with the stockholders of the PPCs, the Company has exclusive authority over all non-medical decision making related to the ongoing business operations of the PPCs. Consequently, the Company consolidates the revenue and expenses of each PPC from the date of execution of the applicable management agreement.

All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

Revenue consists of contracted, fee-for-service, and capitation revenue. Revenue is recorded in the period in which services are rendered. Revenue is principally derived from the provision of healthcare staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services may vary by customer. The following is a summary of the principal forms of the Company’s billing arrangements and how net revenue is recognized for each.

Contracted revenue

Contracted revenue represents revenue generated under contracts for which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates. Revenue in such cases is recognized as the hours are worked by the Company’s staff and contractors. Additionally, contract revenue also includes supplemental revenue from hospitals where the Company may have a fee-for-service contract arrangement or provide physician advisory services to the medical staff at a specific facility. Contract revenue for the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms generally either provides for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or collections per visit compared to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. Additionally, the Company derives a portion of the Company’s revenue as a contractual bonus from collections received by the Company’s partners and such revenue is contingent upon the collection of third-party billings. These revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in accordance with the contractual arrangements for such services.

Fee-for-service revenue 

Fee-for-service revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted and employed physicians. Under the fee-for-service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. Fee-for-service revenue is recognized in the period in which the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the case of those patients having third-party payor coverage. The recognition of net revenue (gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services.

Capitation revenue

Capitation revenue (net of capitation withheld to fund risk share deficits) is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted health maintenance organizations (each, an “HMO”) finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a provider service agreement (PSA) or capitated arrangements directly made with various managed care providers including HMO’s. Capitation revenue under the PSA and HMO contracts is prepaid monthly to the Company based on the number of enrollees electing the Company as their healthcare provider. Additionally, Medicare pays capitation using a “Risk Adjustment model,” which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on an interim basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.

HMO contracts also include provisions to share in the risk for enrollee hospitalization, whereby the Company can earn additional incentive revenue or incur penalties based upon the utilization of hospital services. Typically, any shared risk deficits are not payable until and unless the Company generates future risk sharing surpluses, or if the HMO withholds a portion of the capitation revenue to fund any risk share deficits. At the termination of the HMO contract, any accumulated risk share deficit is typically extinguished. Due to the lack of access to information necessary to estimate the related costs, shared-risk amounts receivable from the HMOs are only recorded when such amounts are known. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following fiscal year.

In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. These incentives, which are included in other revenues, are generally recorded in the third and fourth quarters of the fiscal year and are recorded when such amounts are known.

Under full risk capitation contracts, an affiliated hospital entered into agreements with several HMOs, pursuant to which, the affiliated hospital will provide hospital, medical, and other healthcare services to enrollees under a fixed capitation arrangement ("Capitation Arrangement"). Under the risk pool sharing agreement, the affiliated hospital and medical group agreed to establish a Hospital Control Program to serve the enrollees, pursuant to which, the medical group is allocated a 90% residual interest in the profit or loss, after deductions for costs to affiliated hospitals. The Company participates in the full risk programs under the terms of the PSA, whereby the Company is wholly liable for the deficits allocated to the medical group under the arrangement. The related liability is included in medical liabilities in the accompanying unaudited condensed consolidated balance sheets at September 30 and March 31, 2014 (see "Medical Liabilities" in this Note 2, below).

Medicare Shared Savings Program Revenue

The Company through its subsidiary, ApolloMed ACO, participates in the MSSP sponsored by the Centers for Medicare & Medicaid Services (“CMS”). The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants trailing 24 month medical service history. The MSSP is a newly formed program with minimal history of payments to ACO participants. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined by CMS, and are not considered earned and therefore are not recognized as revenue until notice from CMS that cash payments are to be imminently received.

During the second quarter of 2014, CMS announced that ApolloMed ACO generated $10.98 million in program savings from cost savings created in connection with rendering medical services to Medicare patients in 2012. In connection with these cost savings, the Company earned $5.38 million which has been reported in the line items “Net Revenue and “other receivable” in the September 30, 2014 condensed consolidated financial statements. Revenue from the MSSP is determined and awarded annually, and the Company does not anticipate additional revenue in fiscal 2015. Future ACO program savings for services performed in calendar year 2013 and 2014 are not estimable. 

Concentrations

Excluding the MSSP related revenue, the Company had no major payors during the three months ended September 30, 2014 which contributed more than 10% of net revenues, and had three major payors during the three months ended September 30, 2013 which contributed 16.1%, 16.1% and 16.8% of net revenues, respectively. During the six months ended September 30, 2014, excluding the MSSP related revenue, the Company had no major payors which contributed more than 10% of net revenues and had three major payors during the six months ended September 30, 2013 which contributed 15.8%, 16.1% and 17.6% of net revenues, respectively.

The Company had one major payor that accounted for 12.5 % of accounts receivable as of September 30, 2014, and two major payors that accounted for 21.7% and 9.6% of accounts receivable, respectively, as of March 31, 2014.

Cash Equivalents and Marketable Securities

The Company’s cash equivalents consist of bank demand deposits and highly liquid investments with original maturities of three months or less from the original purchase date.

The Company’s marketable securities consist of our holdings in equity securities and mutual funds. These are classified as available-for-sale, which are measured each reporting period at fair value, with any unrealized change in value reflected in other comprehensive income or loss, and realized gains or losses in the statement of operations in the accompany condensed consolidated statements of operations and comprehensive income (loss). Other than temporary impairments are evaluated for securities that have been in a continuous unrealized loss position longer than one year.

The following is a summary of cash equivalents and marketable securities:

As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
			Unrealized		Unrealized		Fair		Cash		Securities
	Cost		Gain		Loss		Value		Equivalents		(all current)
Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
Money market funds		93,840		-		-		93,840		93,840		-
Mutual funds		148,028		966		-		148,994		-		148,994
Equity securities		241,065		32,122		-		273,187		-		273,187
	$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181

As of March 31, 2014			Gross		Gross		Estimated		Cash and
			Unrealized		Unrealized		Fair		Cash
	Cost		Gain		Loss		Value		Equivalents
Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
	$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478

Medical Liabilities

The Company is responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees under risk-pool arrangements. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in cost of services.

An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying condensed consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates of incurred but not reported claims (“IBNR”). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. The Company has a $20,000 per member professional stop-loss, none on institutional risk pools. Any adjustments to reserves are reflected in current operations. 

The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	274,000
Incurred health care costs:
Current year		1,566,856
Prior years		-
Total incurred health care costs		1,566,856
Acquired medical liabilities (see Note 3 )		292,309
Claims paid:
Current year		(997,390)
Prior years		(64,482)
Total claims paid		(1,061,872)
Adjustments		(197,938)
Balance, end of period	$	873,355

The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	278,561
Acquired medical liabilities (see Note 3)		128,848
Claims paid:		-
Accrual for net deficit from full risk capitation contracts		361,733
Balance, end of period	$	769,142

The Company’s total medical liability at September 30, 2014 and March 31, 2014 was $1,642,497 and $552,561, respectively.

Fair Value of Financial Instruments

The Company’s accounting for Fair Value Measurement and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level one — Quoted market prices in active markets for identical assets or liabilities;

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.

The fair values of the Company’s financial instruments are measured on a recurring basis. The carrying amount reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value because of the short-term maturity of those instruments. The carrying amount for borrowings under the NNA Term Loan and the Convertible Notes approximates fair value which is determined by using interest rates that are available for similar debt obligations with similar terms at the balance sheet date.

Warrant liability

 

The fair value of the warrant liability issued in connection with 2014 NNA Financing at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.5 years, risk free rate of 2.1%, no dividends, volatility of 72.2%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. The fair value of the warrant liability at March 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 50% probability of down-round financing.

The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.

Holdback liability 

The holdback liability (see Note 3) fair value was determined based on the probability adjusted cash consideration, discounted at the Company's cost of debt.

Conversion feature liability

The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.5 years, risk free rate of 1.6%, no dividends, volatility of 55.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability that the Company will participate in a “down-round” financing at price per share lower than the initial NNA Financing 8% Convertible Note conversion price of $1.00 per share.

The carrying amounts and fair values of the Company's financial instruments are presented below as of:

September 30, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market currency funds	$	-	$	93,840	$	-	$	93,840
Mutual funds		-		148,994		-		148,994
Equity securities		273,187		-		-		273,187
	$	273,187	$	242,834	$	-	$	516,021
Liabilities:
Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
Holdback consideration		-		-		136,822		136,822
Conversion feature liability		-		-		547,784		547,784
	$	-	$	-	$	3,435,086	$	3,435,086

March 31, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
	$	-	$	-	$	2,354,624	$	2,354,624

The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:

	Three months			Six months
Balance, beginning of period	$	2,521,451	$	2,354,624
Warrant liability incurred (Note 7)		487,620		487,620
Change in warrant liability		(121,769)		(91,764)
Holdback consideration		-		136,822
Conversion feature liability incurred (Note 7)		578,155		578,155
Change in conversion feature liability		(30,371)		(30,371)
Balance, end of period	$	3,435,086	$	3,435,086

The unrealized gain on changes in fair value of warrant and conversion feature liability is included in the accompanying condensed consolidated statement of operations and comprehensive loss. 

Non-controlling Interest

The non-controlling interest recorded in the Company’s condensed consolidated financial statements represents the pre-acquisition equity of those PPC’s in which the Company has determined that it has a controlling financial interest and for which consolidation is required as a result of management contracts entered into with these entities. The nature of these contracts provide the Company with a monthly management fee to provide the services described above, and as such, the adjustments to non-controlling interests in any period subsequent to initial consolidation would relate to either capital contributions or distributions by the non-controlling parties as well as income or losses attributable to certain non-controlling interests.

Basic and Diluted Earnings per Share

Basic net income (loss) per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income (loss) per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for secured convertible notes, and the treasury stock method for options and warrants.

The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:

	Three Months Ended September 30,		Six Months Ended September 30,
	2014	2013	2014	2013
Options	-	4,373,687	3,657,216	4,547,125
Warrants	-	1,428,067	1,495,803	1,535,402
9% Convertible Notes	799,523	674,528	748,824	785,714
	799,523	6,476,282	5,901,843	6,868,241

New Accounting Standards

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40). The guidance in this ASU requires disclosure of uncertainties about an entity’s ability to continue as a going concern even if an entity’s liquidation is not imminent. There may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting and this guidance should be followed to determine whether to disclose information about the relevant conditions and events. This guidance is effective for the Company on December 31, 2016 and the adoption of this standard is not expected to have a significant impact on its condensed consolidated financial statements or notes thereto.

Use of Estimates

The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may materially differ from these estimates under different assumptions or conditions.

Reclassifications

Certain reclassifications have been made to the accompanying March 31, 2014 condensed consolidated financial statements to conform them to the September 30, 2014 presentation.

XML

Notes and Lines of Credit Payable - Additional Information (Detail) (USD $)	1 Months Ended			6 Months Ended			6 Months Ended			0 Months Ended			6 Months Ended			6 Months Ended				1 Months Ended	6 Months Ended			6 Months Ended
	Jul. 31, 2014	Jul. 31, 2014	Mar. 28, 2014	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Sep. 30, 2014 2014 NNA Financing	Mar. 28, 2014 2014 NNA Financing	Sep. 30, 2014 NNA	Jan. 06, 2014 Medical Clinic Acquisition Promissory Notes	Dec. 07, 2013 Medical Clinic Acquisition Promissory Notes	Sep. 01, 2013 Medical Clinic Acquisition Promissory Notes	Sep. 30, 2014 Revolving Credit Facility	Dec. 20, 2013 Revolving Credit Facility Maximum	Dec. 20, 2013 Revolving Credit Facility Minimum	Sep. 30, 2014 Secured Revolving Credit Facility	Oct. 15, 2013 Secured Revolving Credit Facility	Sep. 30, 2014 Convertible Notes Payable	Mar. 28, 2014 Convertible Notes Payable 2014 NNA Financing	Dec. 20, 2013 Senior secured note Amended SpaGus	Sep. 30, 2014 Senior secured note Amended SpaGus	Sep. 30, 2014 Term Loan	Mar. 28, 2014 Term Loan 2014 NNA Financing	Sep. 30, 2014 Revolving Loan [Member]	Mar. 28, 2014 Revolving Loan [Member] 2014 NNA Financing
Senior Secured Note [Line Items]
Debt, interest rate	8.00%	8.00%							8.00%									8.00%			8.00%
Debt, maturity date													Mar. 28, 2019
Revolving line of credit carrying amount													$ 100,000				$ 2,000,000
Line of credit facility amount outstanding													94,764
Line of credit facility, interest rate description													prime rate (as defined) plus 4.50%			(i) three month LIBOR and (ii) 6.0 %								three month LIBOR plus 6.0%
Line of credit facility, frequency of payment and payment terms													interest only is payable monthly, and matures June 5, 2015
Senior notes																					500,000
Debt Instrument, Payment Terms										five	eight	ten
Business Acquisition Fair Value Of Note Interest Rate										5.30%	5.46%	5.45%
Line of credit facility, maximum borrowing capacity														4,000,000	2,000,000
Proceeds from repayment																				500,000
Proceeds from Issuance of Debt																					230,000
Secured debt																							7,000,000
Secured line of credit																									1,000,000
Convertible debt																			2,000,000
Class of warrant or right, number of securities called by warrants or rights								2,000,000
Repayment of first year term loan																						87,500
Repayment of second year term loan																						122,500
Repayment of third year term loan																						122,500
Repayment of fourth year term loan																						175,000
Repayment of fifth year term loan																						210,000
Term Loan accrued interest																						8.00%
Debt Instrument, Unamortized Discount				1,183,856		1,305,435																1,305,435
Debt Instrument, Fee Amount																						80,000
Amortization Of Debt Discount Premium				177,963	116,248		20,930
Debt Instrument, Face Amount									2,000,000
Related Party Costs				235,119
Deferred Finance Costs Net							150,101
Debt Instrument, Periodic Payment										15,000	10,000	15,000
Proceeds From Issuance Of Debt Instruments On Fair Value							9,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.10%	1.63%	2.31%				2.31%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	71.80%	63.70%	71.40%				71.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price							$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%					50.00%
Stock Issued During Period Value For Financing							899,739
Discount On Shares Issuance							1,100,261
Discount On Term Loan							1,254,363
Fair Value Of Warrant Liabilities							2,354,624
Expected term	6 years 8 months 12 days	6 years	7 years				7 years
Amortization Of Debt Discount							51,072
Amortization Of Debt Discount Premium Related To Equity							7,998
Term Loan Value Under Agreement							$ 5,745,637

XML

Medical Payables (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014
IBNR [Member]
Medical Payables [Line Items]
Balance, beginning of the period	$ 274,000
Incurred health care costs:
Current year	1,566,856
Prior years	0
Total incurred health care costs	1,566,856
Acquired medical liabilities (see Note 3 )	292,309
Claims paid:
Current year	(997,390)
Prior years	(64,482)
Total claims paid	(1,061,872)
Adjustments	(197,938)
Balance, end of period	873,355
Accrual Risk-pool Liability [Member]
Medical Payables [Line Items]
Balance, beginning of the period	278,561
Incurred health care costs:
Acquired medical liabilities (see Note 3 )	128,848
Claims paid:
Accrual for net deficit from full risk capitation contracts	361,733
Balance, end of period	$ 769,142

XML

Cash Equivalents and Marketable Securities (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013
Cash and Cash Equivalents [Line Items]
Cost	$ 4,339,218	$ 6,831,478
Gross Unrealized Gain	33,088	0
Gross Unrealized Loss	0	0
Available-for-sale Securities, Debt Securities, Current	4,372,306	6,831,478
Cash and Cash Equivalents, at Carrying Value, Total	3,950,125	6,831,478	1,075,262	1,094,973
Marketable Securities	422,181	0
Mutual Funds [Member]
Cash and Cash Equivalents [Line Items]
Cost	148,028
Gross Unrealized Gain	966
Gross Unrealized Loss	0
Available-for-sale Securities, Debt Securities, Current	148,994
Cash and Cash Equivalents, at Carrying Value, Total	0
Marketable Securities	148,994
Equity Securities [Member]
Cash and Cash Equivalents [Line Items]
Cost	241,065
Gross Unrealized Gain	32,122
Gross Unrealized Loss	0
Available-for-sale Securities, Debt Securities, Current	273,187
Cash and Cash Equivalents, at Carrying Value, Total	0
Marketable Securities	273,187
Demand Deposits [Member]
Cash and Cash Equivalents [Line Items]
Cost	3,856,285	6,831,478
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Available-for-sale Securities, Debt Securities, Current	3,856,285	6,831,478
Cash and Cash Equivalents, at Carrying Value, Total	3,856,285	6,831,478
Marketable Securities	0
Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cost	93,840
Gross Unrealized Gain	0
Gross Unrealized Loss	0
Available-for-sale Securities, Debt Securities, Current	93,840
Cash and Cash Equivalents, at Carrying Value, Total	93,840
Marketable Securities	$ 0

XML

Summary of Stock-Based Compensation Expense Related to Common Stock and Common Stock Option Awards (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Summary Of Stock Based Compensation Expense Related To Common Stock and Common Stock Option Awards [Line Items]
Stock-based compensation expense	$ 856,519	$ 568,708	$ 975,658	$ 2,121,012
Cost of services
Summary Of Stock Based Compensation Expense Related To Common Stock and Common Stock Option Awards [Line Items]
Stock-based compensation expense	(17,822)	86,630	10,921	575,509
General and administrative
Summary Of Stock Based Compensation Expense Related To Common Stock and Common Stock Option Awards [Line Items]
Stock-based compensation expense	$ 874,341	$ 482,078	$ 964,737	$ 1,545,503

XML

Notes and Lines of Credit Payable (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Senior Secured Note [Line Items]
Notes and Loans Payable	$ 5,648,408	$ 5,789,329
Revolving Credit Facility [Member]
Senior Secured Note [Line Items]
Notes and Loans Payable	94,764	94,764
Loans Payable [Member]
Senior Secured Note [Line Items]
Notes and Loans Payable	$ 5,553,644	$ 5,694,565

XML

Carrying Amounts and Fair Values of Company's Financial Instruments (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Assets
Assets, Fair Value Disclosure	$ 516,021
Liabilities
Financial Liabilities Fair Value Disclosure	3,435,086	2,354,624
Fair Value, Inputs, Level 1
Assets
Assets, Fair Value Disclosure	273,187
Liabilities
Financial Liabilities Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2
Assets
Assets, Fair Value Disclosure	242,834
Liabilities
Financial Liabilities Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3
Assets
Assets, Fair Value Disclosure	0
Liabilities
Financial Liabilities Fair Value Disclosure	3,435,086	2,354,624
Money Market Funds
Assets
Assets, Fair Value Disclosure	93,840
Money Market Funds | Fair Value, Inputs, Level 1
Assets
Assets, Fair Value Disclosure	0
Money Market Funds | Fair Value, Inputs, Level 2
Assets
Assets, Fair Value Disclosure	93,840
Money Market Funds | Fair Value, Inputs, Level 3
Assets
Assets, Fair Value Disclosure	0
Equity Securities
Assets
Assets, Fair Value Disclosure	273,187
Equity Securities | Fair Value, Inputs, Level 1
Assets
Assets, Fair Value Disclosure	273,187
Equity Securities | Fair Value, Inputs, Level 2
Assets
Assets, Fair Value Disclosure	0
Equity Securities | Fair Value, Inputs, Level 3
Assets
Assets, Fair Value Disclosure	0
Warranty Liability
Liabilities
Financial Liabilities Fair Value Disclosure	2,750,480	2,354,624
Warranty Liability | Fair Value, Inputs, Level 1
Liabilities
Financial Liabilities Fair Value Disclosure	0	0
Warranty Liability | Fair Value, Inputs, Level 2
Liabilities
Financial Liabilities Fair Value Disclosure	0	0
Warranty Liability | Fair Value, Inputs, Level 3
Liabilities
Financial Liabilities Fair Value Disclosure	2,750,480	2,354,624
Holdback consideration
Liabilities
Financial Liabilities Fair Value Disclosure	136,822
Holdback consideration | Fair Value, Inputs, Level 1
Liabilities
Financial Liabilities Fair Value Disclosure	0
Holdback consideration | Fair Value, Inputs, Level 2
Liabilities
Financial Liabilities Fair Value Disclosure	0
Holdback consideration | Fair Value, Inputs, Level 3
Liabilities
Financial Liabilities Fair Value Disclosure	136,822
Mutual Funds
Assets
Assets, Fair Value Disclosure	148,994
Mutual Funds | Fair Value, Inputs, Level 1
Assets
Assets, Fair Value Disclosure	0
Mutual Funds | Fair Value, Inputs, Level 2
Assets
Assets, Fair Value Disclosure	148,994
Mutual Funds | Fair Value, Inputs, Level 3
Assets
Assets, Fair Value Disclosure	0
Conversion Feature Liability
Liabilities
Financial Liabilities Fair Value Disclosure	547,784
Conversion Feature Liability | Fair Value, Inputs, Level 1
Liabilities
Financial Liabilities Fair Value Disclosure	0
Conversion Feature Liability | Fair Value, Inputs, Level 2
Liabilities
Financial Liabilities Fair Value Disclosure	0
Conversion Feature Liability | Fair Value, Inputs, Level 3
Liabilities
Financial Liabilities Fair Value Disclosure	$ 547,784

XML

Summary of Activity of Level 3 Inputs Measured on Recurring Basis (Detail) (USD $)	6 Months Ended		3 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014 Fair Value, Inputs, Level 3	Sep. 30, 2014 Fair Value, Inputs, Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance			$ 2,521,451	$ 2,354,624
Warrant liability incurred (Note 7)	487,620	13,316	487,620	487,620
Change in warrant liability			(121,769)	(91,764)
Holdback consideration			0	136,822
Conversion feature liability incurred (Note 7)	578,155	125,000	578,155	578,155
Change in conversion feature liability			(30,371)	(30,371)
Ending Balance			$ 3,435,086	$ 3,435,086

XML

Description of Business

6 Months Ended

Sep. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

1.            Description of Business

Apollo Medical Holdings, Inc. (the “Company” or “ApolloMed”) and its affiliated physician groups are a physician-centric, integrated healthcare delivery system serving Medicare, Commercial and Medi-Cal beneficiaries in California.  ApolloMed’s physician network consists of hospitalists, primary care physicians and specialist physicians primarily through the Company’s owned and affiliated physician groups. ApolloMed operates as a medical management holding company through the following subsidiary management companies: Apollo Medical Management, Inc. (“AMM”), Pulmonary Critical Care Management, Inc. (“PCCM”), Verdugo Medical Management, Inc. (“VMM”), and ApolloMed ACO, Inc. (“ApolloMed ACO). Through AMM, PCCM, and VMM, the Company manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH"), ApolloMed Care Clinic (“ACC”), Maverick Medical Group, Inc. (“MMG”), Los Angeles Lung Center (“LALC”), Eli Hendel, M.D., Inc. (“Hendel”), AKM Medical Group, Inc. (“AKM”) (see Note 3), and Southern California Heart Centers (“SCHC”) (see Note 3); and a controlling interest in ApolloMed Palliative Services, LLC (“APS”). AMM, PCCM and VMM each operate as a physician practice management company (“PPM”) and are in the business of providing management services to physician practice corporations (“PPC”) under long-term management service agreements. ApolloMed ACO participates in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. 

Change in Fiscal Year

On May 16, 2014, the board of directors of the Company approved a change to the Company's fiscal year end from January 31 to March 31. The March 31, 2014 amounts included in the accompanying condensed consolidated financial statements and related notes thereto are unaudited.

XML

Computation of Diluted Earnings Per Share (Detail)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	799,523	6,476,282	5,901,843	6,868,241
9% Convertible Debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	799,523	674,528	748,824	785,714
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,428,067	1,495,803	1,535,402
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	4,373,687	3,657,216	4,547,125

XML

Other Intangible Assets (Detail) (USD $)			6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014 Exclusivity	Sep. 30, 2014 Non-compete	Sep. 30, 2014 Payor relationships	Sep. 30, 2014 Network relationships	Sep. 30, 2014 Trade name
Finite-Lived Intangible Assets [Line Items]
Weighted-average life (Yrs)			4 years	4 years	5 years	5 years	5 years
Intangible assets, Beginning Balance	$ 1,345,400	$ 68,400	$ 40,000	$ 28,400	$ 0	$ 0	$ 0
Intangible assets, Addition	1,277,000		0	120,000	94,000	910,000	153,000
Intangible assets, Ending Balance	1,345,400	68,400	40,000	148,400	94,000	910,000	153,000
Accumulated amortization, Beginning Balance	(139,081)	(8,773)
Accumulated amortization, Addition	(130,308)
Accumulated amortization, Ending Balance	(139,081)	(8,773)
Total other intangibles, net, Beginning Balance	1,206,319	59,627
Total other intangibles, net, Addition	1,146,692
Total other intangibles, net, Ending Balance	$ 1,206,319	$ 59,627

XML

Stock Option Activity (Detail) (USD $)	6 Months Ended	12 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Shares
Beginning balance	6,287,000
Granted	565,000
Cancelled	(100,000)
Exercised	0
Expired	0
Forfeited	0
Ending balance	6,752,000	6,287,000
Vested and exercisable	6,145,889
Weighted Average Per Share Exercise Price
Beginning balance	$ 0.20
Granted	$ 1.00
Cancelled	$ 0
Exercised	$ 0
Expired	$ 0
Forfeited	$ 0
Ending balance	$ 0.22	$ 0.20
Vested and exercisable	$ 0.21
Weighted Average Remaining Life (Years)
Balance	8 years 2 months 12 days	8 years 8 months 12 days
Granted	0 years
Cancelled	0 years
Exercised	0 years
Expired	0 years
Forfeited	0 years
Vested and exercisable	7 years 6 months
Weighted Average Per Share Intrinsic Value
Beginning Balance	$ 0.11
Granted	$ 0
Cancelled	$ 0
Exercised	$ 0
Expired	$ 0
Forfeited	$ 0
Ending balance	$ 0.24	$ 0.11
Vested and exercisable	$ 0.26

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Mar. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 3,950,125	$ 6,831,478
Marketable securities	422,181	0
Restricted cash	40,000	20,000
Accounts receivable, net	3,369,780	1,508,461
Other receivable	5,382,617	0
Due from affiliates	49,377	24,041
Prepaid expenses	145,110	42,200
Total current assets	13,359,190	8,426,180
Deferred financing costs, net	324,003	366,286
Property and equipment, net	620,036	94,948
Intangible assets, net	1,206,319	59,627
Goodwill	439,694	494,700
Other assets	108,747	41,636
TOTAL ASSETS	16,057,989	9,483,377
CURRENT LIABILITIES
Accounts payable and accrued liabilities	3,792,645	1,447,040
Medical liabilities	1,642,497	552,561
Note and line of credit payable, net of discount, current portion	304,764	444,764
Holdback consideration	136,822	0
Total current liabilities	5,876,728	2,444,365
Notes payable, net of discount - non-current portion	5,343,644	5,344,565
Convertible notes payable, net of discount	1,953,587	962,978
Warrant liability	2,750,480	2,354,624
Conversion feature liability	547,784	0
Deferred tax liability	89,791	0
Total liabilities	16,562,014	11,106,532
COMMITMENTS, CONTINGENCIES AND SUBSEQUENT EVENTS (NOTES 10 AND 11)
STOCKHOLDERS' DEFICIT
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued	0	0
Common Stock, par value $0.001; 100,000,000 shares authorized, 49,134,549 shares issued and outstanding as of September 30, 2014 and March 31, 2014, respectively	49,135	49,135
Additional paid-in-capital	16,191,023	15,083,365
Accumulated other comprehensive income	33,088	0
Accumulated deficit	(16,649,019)	(16,347,588)
Stockholders' deficit attributable to Apollo Medical Holdings, Inc.	(375,773)	(1,215,088)
Non-controlling interest	(128,252)	(408,067)
Total	(504,025)	(1,623,155)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 16,057,989	$ 9,483,377

XML

Notes and Lines of Credit Payable (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Debt Instrument [Line Items]
Debt discount	$ 1,183,856	$ 1,305,435

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 28,384	$ (2,913,600)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization expense	205,180	12,883
Deferred income taxes	59,314	0
Stock-based compensation expense	975,658	2,121,012
Amortization of financing costs	62,283	4,298
Amortization of debt discount	177,963	116,248
Change in fair value of warrant and conversion feature liability	(122,135)	0
Changes in assets and liabilities:
Accounts receivable	(993,669)	323,859
Other receivable	(5,382,617)	0
Due from affiliates	42,378	17,706
Prepaid expenses and advances	(14,167)	15,290
Other assets	(347)	(4,100)
Accounts payable and accrued liabilities	2,170,739	(6,276)
Medical liabilities	668,779	0
Net cash used in operating activities	(2,122,257)	(312,680)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions, net of $620,960 in cash and cash equivalents acquired	(1,947,431)	(248,800)
Property and equipment acquired	(15,583)	(2,219)
Net cash used in investing activities	(1,963,014)	(251,019)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of convertible note payable	2,000,000	0
Principal payments on notes payable	(726,082)	55,235
Contribution by non-controlling interest	550,000	0
Distributions to non-controlling interest shareholder	(600,000)	(240,000)
Proceeds from issuance of common stock	0	728,753
Debt issuance costs	(20,000)	0
Net cash provided by financing activities	1,203,918	543,988
NET DECREASE IN CASH & CASH EQUIVALENTS	(2,881,353)	(19,711)
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD	6,831,478	1,094,973
CASH & CASH EQUIVALENTS, END OF PERIOD	3,950,125	1,075,262
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	356,196	169,802
Income taxes paid	18,588	38,356
Non-Cash Financing Activities:
Acquisition related holdback liability consideration	136,822	0
Convertible note warrant	487,620	13,316
Convertible note conversion feature	578,155	125,000
Acquisition related warrant consideration	$ 132,000	$ 101,817

XML

Amount of Shares of Common Stock Reserved (Detail)	Sep. 30, 2014	Mar. 31, 2014
Stock Option Outstanding [Line Items]
Common stock issued and outstanding	49,134,549
Conversion of 9% Notes	2,750,000
Conversion of 8% Notes	2,000,000
Warrants outstanding	9,145,000	7,145,000
Stock options outstanding	6,752,000	6,287,000
Remaining shares issuable under 2013 Equity Incentive Plan	1,900,000
Common stock reserved for future issuance	71,681,549

XML

Allocation of Total Purchase Price (Detail) (USD $)	Sep. 30, 2014	May 30, 2014
Business Acquisition [Line Items]
Cash and cash equivalents		$ 356,359
Marketable securities		389,094
Accounts receivable		27,217
Prepaid expenses and other current assets		26,311
Identifiable intangible assets	1,121,000	156,000
Goodwill		(216,563)
Accounts payable and accrued liabilities		(40,439)
Medical payables		(421,157)
Net assets acquired		276,822
SCHC
Business Acquisition [Line Items]
Cash and cash equivalents	264,601
Accounts receivable	840,433
Prepaid expenses and other current assets	82,430
Identifiable intangible assets	1,121,000
Goodwill	161,559
Accounts payable and accrued liabilities	134,427
Receivable from affiliate	67,714
Net assets acquired	2,560,391
Property and equipment	584,377
Other assets	66,762
Total assets acquired	3,188,876
Note payable to financial institution	463,582
Deferred tax liability	30,477
Total liabilities assumed	$ 628,485

XML

Goodwill and Other Intangible Assets (Tables)

6 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill Activity

The following is a summary of goodwill activity for the six months ended September 30, 2014:

Balance, beginning of period	$	494,700
Acquisition of AKM		(216,565)
Acquisition of SCHC		161,559
Balance, end of period	$	439,694

Other Intangible Assets

Other intangible assets consisted of the following:

	Weighted-average life (Yrs)	Balance at March 31, 2014		Additions		Balance at September 30, 2014
Intangible assets:
Exclusivity	4.0	$	40,000	$	-	$	40,000
Non-compete	4.0		28,400		120,000		148,400
Payor relationships	5.0		-		94,000		94,000
Network relationships	5.0		-		910,000		910,000
Trade name	5.0		-		153,000		153,000
Totals			68,400		1,277,000		1,345,400
Accumulated amortization			(8,773)		(130,308)		(139,081)
Total other intangibles, net		$	59,627	$	1,146,692	$	1,206,319

Future Amortization Expense

Future amortization expense is estimated to be as follows for the period from October 1, 2014 to March 31, 2015 and for each for the five years ending March 31 thereafter:

October 1, 2014 to March 31, 2015	$	255,000
2016	$	326,000
2017	$	259,000
2018	$	192,000
2019	$	125,000
Thereafter	$	46,000

XML

Intangible Assets Acquired (Detail) (USD $)			6 Months Ended
	Sep. 30, 2014	May 30, 2014	Sep. 30, 2014 Network Relationships	Sep. 30, 2014 Trade Names	Sep. 30, 2014 Noncompete Agreements
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 1,121,000	$ 156,000	$ 910,000	$ 110,000	$ 101,000
Finite-Lived Intangible Asset, Useful Life			5 years	5 years	3 years

XML

Notes and Lines of Credit Payable (Tables)

6 Months Ended

Sep. 30, 2014

Notes Payable [Abstract]

Schedule of Notes and lines of credit payable

Notes and line of credit payable consist of the following:

	September 30,		March 31,
	2014		2014
Term loan payable to NNA due March 28, 2019, net of debt discount of $1,183,856 (September 30, 2014) and $1,305,435 (March 31, 2014)	$	5,553,644	$	5,694,565
Unsecured revolving line of credit due to financial institution due June 5, 2015		94,764		94,764
	$	5,648,408	$	5,789,329

Schedule of Interest Expense Associated with Notes Payable

Interest expense associated with the notes and lines of credit payable consisted of the following:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
Interest expense	$	143,845	$	25,089	$	287,998	$	56,087
Amortization of loan fees and discount		71,673		35,061		142,924		39,780
	$	215,518	$	60,151	$	430,922	$	95,868

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	6 Months Ended
	Sep. 30, 2014
Acquisitions, net of cash acquired	$ 620,960

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	49,134,549	49,134,549
Common Stock, shares outstanding	49,134,549	49,134,549

XML

Commitments and Contingencies

6 Months Ended

Sep. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

Regulatory Matters

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medicaid programs. The Company believes that it is in compliance with all applicable laws and regulations.

Legal

On May 16, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., two independent physician associations who compete with the Company in the greater Los Angeles area, filed an action against the Company and two affiliates of the Company, Maverick Medical Group, Inc. and ApolloMed Hospitalists, a Medical Corporation, in Los Angeles County Superior Court. The complaint alleged that the Company and its two affiliates made misrepresentations and engaged in other acts in order to improperly solicit physicians and patient-enrollees from Plaintiffs. The Complaint sought compensatory and punitive damages. On June 30, 2014, the Company and its affiliates filed a motion requesting the Court to stay the court proceeding and order the parties to arbitrate this dispute subject to existing arbitration agreements. On August 11, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. On August 12, 2014, the Plaintiffs served the Company and its affiliates with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration. The Company and its affiliates are preparing a defense to the allegations and the Company intends to vigorously defend the action.

On August 28, 2014, Lakeside Medical Group, Inc. and Regal Medical Group, Inc., filed a similar lawsuit against Warren Hosseinion, the Chief Executive Officer of the Company. Dr. Hosseinion is defending the action and is currently being indemnified by the Company subject to the terms of an indemnification agreement and the Company’s charter. On September 9, 2014, Dr. Hosseinion filed a motion requesting the Court to stay the court proceeding and, pursuant to existing arbitration agreements, order the parties to arbitrate the dispute as part of the pending arbitration proceedings before JAMS (as discussed above). On October 29, 2014, the Plaintiffs filed a request for dismissal without prejudice of the action. Plaintiffs have informed the Company that Plaintiffs will be serving Dr. Hosseinion with Demands for Arbitration before Judicial Arbitration Mediation Services in Los Angeles. Dr. Hosseinion and the Company will seek to consolidate the proceedings against Dr. Hosseinion with the existing proceedings against the Company and its affiliates. The Company is currently examining the merits of the claims to be arbitrated, and it is too early to state whether the likelihood of an unfavorable outcome is probable or remote, or to estimate the potential loss if the outcome should be negative. The Company is aware that punitive damages previously sought in the court proceeding are not available in arbitration.

In the ordinary course of the Company’s business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company’s affiliated hospitalists. The Company may also become subject to other lawsuits which could involve significant claims and/or significant defense costs. The Company believes, based upon the Company’s review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows in a future period

Liability Insurance

The Company believes that the Company’s insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that the Company’s insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company’s affiliated professional organizations or the Company’s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business.

Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to the Company in future years at acceptable costs, and on favorable terms.

XML

Document And Entity Information	6 Months Ended
	Sep. 30, 2014	Nov. 14, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Registrant Name	Apollo Medical Holdings, Inc.
Entity Central Index Key	0001083446
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMEH
Entity Common Stock, Shares Outstanding		48,634,549

XML

Subsequent Events

6 Months Ended

Sep. 30, 2014

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Lease Agreement

The Company had a lease with EOP-700 North Brand, L.L.C., a Delaware limited liability company (“Landlord”),

for 3,111 rentable square feet at 700 North Brand Boulevard, Suite No. 220, Glendale, California that commenced

on December 16, 2011, and was set to expire on January 14, 2014. The lease was amended by a Commencement

Letter dated February 6, 2012 and First Amendment dated November 8, 2012.

On October 14, 2014, the lease was amended by a Second Amendment. The Second Amendment relocates the leased premises from Suite No. 220 to Suite Nos. 1400, 1425 and 1450, which collectively include 16,484 rentable square feet (the “New Premises”). The New Premises will be improved with an allowance of up to $659,360, provided by the Landlord, for construction and installation of equipment for the New Premises. Before the improved New Premises are available, the Company shall also use Suite No. 240 on a temporary basis. The Second Amendment also extends the term of the lease to be for approximately six years after the Company begins operations in the New Premises and increases the Company’s initial security deposit. The Second Amendment sets the New Premises base rent at $37,913.20 per month for the first year and schedules annual increases in base rent each year until the final rental year, which is capped at $43,957.33 per month. However, the base rent will be abated by up to $228,049.27 subject to other terms of the lease.

 Termination of a Material Definitive Agreement

On October 23, 2014, the Company entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Raouf Khalil (“Khalil”). Effective October 23, 2014, the Settlement Agreement terminates the Company’s obligations with respect to Khalil under that certain Stock Purchase Agreement, dated as of February 15, 2011 (the “Purchase Agreement”), among the Company, Aligned Healthcare Group, LLC (“Aligned LLC”), Aligned Healthcare Group – California, Inc. (“Aligned Corp.”), Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC (collectively, the “Aligned Affiliates”), as amended by that certain First Amendment to Stock Purchase Agreement, dated as of July 8, 2011, among the Company, Aligned LLC, Aligned Corp., Khalil, Jamie McReynolds, M.D., BJ Reese and BJ Reese & Associates, LLC.

Under the Settlement Agreement, the Company has reconveyed to Khalil all of the shares of Aligned Healthcare, Inc. (“AHI”) common stock that the Company acquired from Khalil under the Purchase Agreement. In addition, in consideration of a $10,000 cash payment, Khalil has reconveyed to the Company 500,000 shares of the Company’s common stock, constituting all of the shares that were issued to him under the Purchase Agreement. Following these reconveyances, the Company no longer owns any of the outstanding shares of AHI’s capital stock, and neither Khalil nor any of the other Aligned Affiliates own any shares of the Company’s capital stock.

The Settlement Agreement was entered into by the parties to settle and resolve any claims, differences or disagreements that may exist between the Company and Khalil, and the Settlement Agreement provides for a mutual general release of all claims between the Company and Khalil.

Purchase Agreement

On October 27, 2014, Apollo Medical Management, Inc., a Delaware corporation (“AMM”), an affiliate of the Company made an initial capital contribution of $613,889 (the “Initial Contribution”) to Apollo Palliative Services LLC, a California limited liability company (the “APS”) in exchange for 51% of the membership interests of APS. APS used the Initial Contribution, in conjunction with funds provided by other investors in APS, to finance the closing payments described immediately below. In connection with this arrangement, the Company entered into a consulting agreement with one of the members. The term of this agreement is 6 years, and provides for the member to received $15,000 in cash per month, and be eligible to receive stock-based awards under the Company’s 2013 Equity Incentive Plan as determined by the Company’s Board of Directors

Immediately prior to closing the transactions described below, and as condition precedent to APS closing the transactions, the selling equity owners in each transaction described below contributed specific equity interests to APS in return for interests in APS pursuant to contributions agreements.

 

Subject to the terms and conditions of that certain Membership Interest Purchase Agreement (the “BCHC Agreement”), dated October 27, 2014, by and among APS, the Company, the sole members of Best Choice Hospice Care, LLC, a California limited liability company (“BCHC”), and BCHC, APS agreed to purchase all of the remaining membership interests in BCHC for $900,000 in cash, subject to reduction if BCHC’s working capital was less than $145,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $400,000 (the “BCHC Contingent Payment”) to one seller and one employee of BCHC. The BCHC Contingent Payment will be paid in two installments of $100,000 to each of the seller and the employee within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s and the employee’s employment, as applicable, continuing or having been terminated without cause and, for the employee, meeting certain productivity targets. The Company absolutely, unconditionally and irrevocably guaranteed payment of the BCHC Contingent Payment if APS fails to make any payment.

Subject to the terms and conditions of that certain Stock Purchase Agreement (the “HCHHA Agreement”), dated October 27, 2014, by and among APS, the sole shareholder of Holistic Care Home Health Agency, Inc., a California corporation (“HCHHA”), and HCHHA, APS agreed to purchase all of the remaining shares of HCHHA for $300,000 in cash, subject to reduction if HCHHA’s working capital was less than $50,000 as of the closing of the transaction. APS agreed to pay a contingent payment of up to a further $150,000 (the “HCHHA Contingent Payment”). The HCHHA Contingent Payment will be paid in two installments of $75,000 to the seller within sixty days of each of the first and second anniversaries of the transaction, and is contingent upon, as of each applicable date, the seller’s employment continuing or having been terminated without cause and meeting certain productivity targets.

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net revenues	$ 11,665,294	$ 2,521,421	$ 15,759,780	$ 5,136,115
Costs and expenses
Cost of services	6,161,645	2,257,945	9,421,484	4,715,875
General and administrative	3,451,907	1,043,565	5,461,239	2,965,395
Depreciation and amortization	193,281	6,528	205,180	12,883
Total costs and expenses	9,806,833	3,308,038	15,087,903	7,694,153
Income (loss) from operations	1,858,461	(786,617)	671,877	(2,558,038)
Other (expense) income
Interest expense	(329,258)	(200,562)	(606,125)	(362,252)
Gain on change in fair value of warrant and conversion feature liabilities	152,140	0	122,135	0
Other	(58,436)	6,441	(60,912)	7,490
Total other expense	(235,554)	(194,121)	(544,902)	(354,762)
Income (loss) before provision for income taxes	1,622,907	(980,738)	126,975	(2,912,800)
Provision for income taxes	86,989	0	98,591	800
Net income (loss)	1,535,918	(980,738)	28,384	(2,913,600)
Net income attributable to noncontrolling interest	(159,608)	0	(329,815)	0
Net income (loss) attributable to Apollo Medical Holdings, Inc.	1,376,310	(980,738)	(301,431)	(2,913,600)
Other comprehensive income (loss):
Unrealized change in value of marketable securities	14,499	0	33,088
Comprehensive income (loss)	$ 1,390,809	$ (980,738)	$ (268,343)	$ (2,913,600)
NET INCOME (LOSS) PER SHARE:
BASIC	$ 0.03	$ (0.03)	$ (0.01)	$ (0.08)
DILUTED	$ 0.03	$ (0.03)	$ (0.01)	$ (0.08)
WEIGHTED AVERAGE SHARES OF COMMON STOCK OUTSTANDING:
BASIC	49,134,549	36,353,413	49,134,549	37,261,375
DILUTED	54,393,442	36,353,413	49,134,549	37,261,375

XML

Accounts Payable and Accrued Liabilities

6 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities

5. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consisted of the following:

	September 30,		March 31,
	2014		2014
Accounts payable	$	1,456,796	$	824,334
Physician share of MSSP ACO savings		1,400,000		-
Accrued compensation		809,772		546,078
Income taxes payable		85,477		4,149
Accrued interest		28,049		19,780
Accrued professional fees		12,550		52,699
	$	3,792,645	$	1,447,040

XML

Goodwill and Other Intangible Assets

6 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

4. Goodwill and Other Intangible Assets

Goodwill

The following is a summary of goodwill activity for the six months ended September 30, 2014:

Balance, beginning of period	$	494,700
Acquisition of AKM		(216,565)
Acquisition of SCHC		161,559
Balance, end of period	$	439,694

Other Intangible Assets

Other intangible assets consisted of the following:

	Weighted-average life (Yrs)	Balance at March 31, 2014		Additions		Balance at September 30, 2014
Intangible assets:
Exclusivity	4.0	$	40,000	$	-	$	40,000
Non-compete	4.0		28,400		120,000		148,400
Payor relationships	5.0		-		94,000		94,000
Network relationships	5.0		-		910,000		910,000
Trade name	5.0		-		153,000		153,000
Totals			68,400		1,277,000		1,345,400
Accumulated amortization			(8,773)		(130,308)		(139,081)
Total other intangibles, net		$	59,627	$	1,146,692	$	1,206,319

The amortization expense for the three and six months ended September 30, 2014 was approximately $125,000 and $130,000, respectively. The amortization expense for the three and six months ended September 30, 2013 was approximately $1,000 in each period.

Future amortization expense is estimated to be as follows for the period from October 1, 2014 to March 31, 2015 and for each for the five years ending March 31 thereafter:

October 1, 2014 to March 31, 2015	$	255,000
2016	$	326,000
2017	$	259,000
2018	$	192,000
2019	$	125,000
Thereafter	$	46,000

XML

Accounts Payable and Accrued Liabilities (Tables)

6 Months Ended

Sep. 30, 2014

Payables and Accruals [Abstract]

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities consisted of the following:

	September 30,		March 31,
	2014		2014
Accounts payable	$	1,456,796	$	824,334
Physician share of MSSP ACO savings		1,400,000		-
Accrued compensation		809,772		546,078
Income taxes payable		85,477		4,149
Accrued interest		28,049		19,780
Accrued professional fees		12,550		52,699
	$	3,792,645	$	1,447,040

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Accounting Principles

Accounting Principles

These condensed consolidated statements reflect all adjustments, consisting of normal recurring adjustments, which, in management’s opinion, are necessary, and should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2014 as filed with the Securities and Exchange Commission (“SEC”) on May 8, 2014.

Principles of Consolidation

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of (1) Apollo Medical Holdings, Inc. and its wholly owned subsidiaries AMM, PCCM, and VMM, (2) the Company’s controlling interest in ApolloMed ACO, and APS, which is a newly formed entity with no operations to date to provide home health and hospice medical services and in which a non-controlling interest in APS contributed $550,000 in cash; and (3) PPCs managed under long-term management service agreements including AMH, MMG, ACC, LALC, Hendel, AKM and SCHC. Some states have laws that prohibit business entities, such as ApolloMed, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (collectively known as the corporate practice of medicine), or engaging in certain arrangements with physicians, such as fee-splitting. In California, the Company operates by maintaining long-term management service agreements with the PPCs, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide hospitalist services. Under the management agreements, the Company provides and performs all non-medical management and administrative services, including financial management, information systems, marketing, risk management and administrative support. Each management agreement typically has a term from 10 to 20 years unless terminated by either party for cause. The management agreements are not terminable by the PPCs, except in the case of material breach or bankruptcy of the respective PPM.

Through the management agreements and the Company’s relationship with the stockholders of the PPCs, the Company has exclusive authority over all non-medical decision making related to the ongoing business operations of the PPCs. Consequently, the Company consolidates the revenue and expenses of each PPC from the date of execution of the applicable management agreement.

All intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition

Revenue Recognition

Revenue consists of contracted, fee-for-service, and capitation revenue. Revenue is recorded in the period in which services are rendered. Revenue is principally derived from the provision of healthcare staffing services to patients within healthcare facilities. The form of billing and related risk of collection for such services may vary by customer. The following is a summary of the principal forms of the Company’s billing arrangements and how net revenue is recognized for each.

Contracted revenue

Contracted revenue represents revenue generated under contracts for which the Company provides physician and other healthcare staffing and administrative services in return for a contractually negotiated fee. Contract revenue consists primarily of billings based on hours of healthcare staffing provided at agreed-to hourly rates. Revenue in such cases is recognized as the hours are worked by the Company’s staff and contractors. Additionally, contract revenue also includes supplemental revenue from hospitals where the Company may have a fee-for-service contract arrangement or provide physician advisory services to the medical staff at a specific facility. Contract revenue for the supplemental billing in such cases is recognized based on the terms of each individual contract. Such contract terms generally either provides for a fixed monthly dollar amount or a variable amount based upon measurable monthly activity, such as hours staffed, patient visits or collections per visit compared to a minimum activity threshold. Such supplemental revenues based on variable arrangements are usually contractually fixed on a monthly, quarterly or annual calculation basis considering the variable factors negotiated in each such arrangement. Such supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. Additionally, the Company derives a portion of the Company’s revenue as a contractual bonus from collections received by the Company’s partners and such revenue is contingent upon the collection of third-party billings. These revenues are not considered earned and therefore not recognized as revenue until actual cash collections are achieved in accordance with the contractual arrangements for such services.

Fee-for-service revenue 

Fee-for-service revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted and employed physicians. Under the fee-for-service arrangements, the Company bills patients for services provided and receives payment from patients or their third-party payers. Fee-for-service revenue is reported net of contractual allowances and policy discounts. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. Fee-for-service revenue is recognized in the period in which the services are rendered to specific patients and reduced immediately for the estimated impact of contractual allowances in the case of those patients having third-party payor coverage. The recognition of net revenue (gross charges less contractual allowances) from such visits is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services.

Capitation revenue

Capitation revenue (net of capitation withheld to fund risk share deficits) is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted health maintenance organizations (each, an “HMO”) finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a provider service agreement (PSA) or capitated arrangements directly made with various managed care providers including HMO’s. Capitation revenue under the PSA and HMO contracts is prepaid monthly to the Company based on the number of enrollees electing the Company as their healthcare provider. Additionally, Medicare pays capitation using a “Risk Adjustment model,” which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on an interim basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.

HMO contracts also include provisions to share in the risk for enrollee hospitalization, whereby the Company can earn additional incentive revenue or incur penalties based upon the utilization of hospital services. Typically, any shared risk deficits are not payable until and unless the Company generates future risk sharing surpluses, or if the HMO withholds a portion of the capitation revenue to fund any risk share deficits. At the termination of the HMO contract, any accumulated risk share deficit is typically extinguished. Due to the lack of access to information necessary to estimate the related costs, shared-risk amounts receivable from the HMOs are only recorded when such amounts are known. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following fiscal year.

In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. These incentives, which are included in other revenues, are generally recorded in the third and fourth quarters of the fiscal year and are recorded when such amounts are known.

Under full risk capitation contracts, an affiliated hospital entered into agreements with several HMOs, pursuant to which, the affiliated hospital will provide hospital, medical, and other healthcare services to enrollees under a fixed capitation arrangement ("Capitation Arrangement"). Under the risk pool sharing agreement, the affiliated hospital and medical group agreed to establish a Hospital Control Program to serve the enrollees, pursuant to which, the medical group is allocated a 90% residual interest in the profit or loss, after deductions for costs to affiliated hospitals. The Company participates in the full risk programs under the terms of the PSA, whereby the Company is wholly liable for the deficits allocated to the medical group under the arrangement. The related liability is included in medical liabilities in the accompanying unaudited condensed consolidated balance sheets at September 30 and March 31, 2014 (see "Medical Liabilities" in this Note 2, below).

Medicare Shared Savings Program Revenue

The Company through its subsidiary, ApolloMed ACO, participates in the MSSP sponsored by the Centers for Medicare & Medicaid Services (“CMS”). The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants trailing 24 month medical service history. The MSSP is a newly formed program with minimal history of payments to ACO participants. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined by CMS, and are not considered earned and therefore are not recognized as revenue until notice from CMS that cash payments are to be imminently received.

During the second quarter of 2014, CMS announced that ApolloMed ACO generated $10.98 million in program savings from cost savings created in connection with rendering medical services to Medicare patients in 2012. In connection with these cost savings, the Company earned $5.38 million which has been reported in the line items “Net Revenue and “other receivable” in the September 30, 2014 condensed consolidated financial statements. Revenue from the MSSP is determined and awarded annually, and the Company does not anticipate additional revenue in fiscal 2015. Future ACO program savings for services performed in calendar year 2013 and 2014 are not estimable. 

Concentrations

Concentrations

Excluding the MSSP related revenue, the Company had no major payors during the three months ended September 30, 2014 which contributed more than 10% of net revenues, and had three major payors during the three months ended September 30, 2013 which contributed 16.1%, 16.1% and 16.8% of net revenues, respectively. During the six months ended September 30, 2014, excluding the MSSP related revenue, the Company had no major payors which contributed more than 10% of net revenues and had three major payors during the six months ended September 30, 2013 which contributed 15.8%, 16.1% and 17.6% of net revenues, respectively.

The Company had one major payor that accounted for 12.5 % of accounts receivable as of September 30, 2014, and two major payors that accounted for 21.7% and 9.6% of accounts receivable, respectively, as of March 31, 2014.

Cash Equivalents and Marketable Securities

Cash Equivalents and Marketable Securities

The Company’s cash equivalents consist of bank demand deposits and highly liquid investments with original maturities of three months or less from the original purchase date.

The Company’s marketable securities consist of our holdings in equity securities and mutual funds. These are classified as available-for-sale, which are measured each reporting period at fair value, with any unrealized change in value reflected in other comprehensive income or loss, and realized gains or losses in the statement of operations in the accompany condensed consolidated statements of operations and comprehensive income (loss). Other than temporary impairments are evaluated for securities that have been in a continuous unrealized loss position longer than one year.

The following is a summary of cash equivalents and marketable securities:

As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
			Unrealized		Unrealized		Fair		Cash		Securities
	Cost		Gain		Loss		Value		Equivalents		(all current)
Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
Money market funds		93,840		-		-		93,840		93,840		-
Mutual funds		148,028		966		-		148,994		-		148,994
Equity securities		241,065		32,122		-		273,187		-		273,187
	$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181

As of March 31, 2014			Gross		Gross		Estimated		Cash and
			Unrealized		Unrealized		Fair		Cash
	Cost		Gain		Loss		Value		Equivalents
Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
	$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478

Medical Liabilities

Medical Liabilities

The Company is responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees under risk-pool arrangements. The Company provides integrated care to health plan enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements, company-operated clinics and staff physicians. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services in the accompanying condensed consolidated statements of operations and comprehensive loss. Costs for operating medical clinics, including the salaries of medical and non-medical personnel and support costs, are also recorded in cost of services.

An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying condensed consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates of incurred but not reported claims (“IBNR”). Such estimates are developed using actuarial methods and are based on many variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. The Company has a $20,000 per member professional stop-loss, none on institutional risk pools. Any adjustments to reserves are reflected in current operations. 

The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	274,000
Incurred health care costs:
Current year		1,566,856
Prior years		-
Total incurred health care costs		1,566,856
Acquired medical liabilities (see Note 3 )		292,309
Claims paid:
Current year		(997,390)
Prior years		(64,482)
Total claims paid		(1,061,872)
Adjustments		(197,938)
Balance, end of period	$	873,355

The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	278,561
Acquired medical liabilities (see Note 3)		128,848
Claims paid:		-
Accrual for net deficit from full risk capitation contracts		361,733
Balance, end of period	$	769,142

The Company’s total medical liability at September 30, 2014 and March 31, 2014 was $1,642,497 and $552,561, respectively.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s accounting for Fair Value Measurement and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level one — Quoted market prices in active markets for identical assets or liabilities;

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.

The fair values of the Company’s financial instruments are measured on a recurring basis. The carrying amount reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates fair value because of the short-term maturity of those instruments. The carrying amount for borrowings under the NNA Term Loan and the Convertible Notes approximates fair value which is determined by using interest rates that are available for similar debt obligations with similar terms at the balance sheet date.

Warrant liability

 

The fair value of the warrant liability issued in connection with 2014 NNA Financing at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.5 years, risk free rate of 2.1%, no dividends, volatility of 72.2%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. The fair value of the warrant liability at March 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 50% probability of down-round financing.

The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.

Holdback liability 

The holdback liability (see Note 3) fair value was determined based on the probability adjusted cash consideration, discounted at the Company's cost of debt.

Conversion feature liability

The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at September 30, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.5 years, risk free rate of 1.6%, no dividends, volatility of 55.4%, share price of $0.45 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability that the Company will participate in a “down-round” financing at price per share lower than the initial NNA Financing 8% Convertible Note conversion price of $1.00 per share.

The carrying amounts and fair values of the Company's financial instruments are presented below as of:

September 30, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market currency funds	$	-	$	93,840	$	-	$	93,840
Mutual funds		-		148,994		-		148,994
Equity securities		273,187		-		-		273,187
	$	273,187	$	242,834	$	-	$	516,021
Liabilities:
Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
Holdback consideration		-		-		136,822		136,822
Conversion feature liability		-		-		547,784		547,784
	$	-	$	-	$	3,435,086	$	3,435,086

March 31, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
	$	-	$	-	$	2,354,624	$	2,354,624

The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:

	Three months			Six months
Balance, beginning of period	$	2,521,451	$	2,354,624
Warrant liability incurred (Note 7)		487,620		487,620
Change in warrant liability		(121,769)		(91,764)
Holdback consideration		-		136,822
Conversion feature liability incurred (Note 7)		578,155		578,155
Change in conversion feature liability		(30,371)		(30,371)
Balance, end of period	$	3,435,086	$	3,435,086

The unrealized gain on changes in fair value of warrant and conversion feature liability is included in the accompanying condensed consolidated statement of operations and comprehensive loss. 

Non-controlling Interest

Non-controlling Interest

The non-controlling interest recorded in the Company’s condensed consolidated financial statements represents the pre-acquisition equity of those PPC’s in which the Company has determined that it has a controlling financial interest and for which consolidation is required as a result of management contracts entered into with these entities. The nature of these contracts provide the Company with a monthly management fee to provide the services described above, and as such, the adjustments to non-controlling interests in any period subsequent to initial consolidation would relate to either capital contributions or distributions by the non-controlling parties as well as income or losses attributable to certain non-controlling interests.

Basic and Diluted Earnings per Share

Basic and Diluted Earnings per Share

Basic net income (loss) per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income (loss) by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income (loss) per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for secured convertible notes, and the treasury stock method for options and warrants.

The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:

	Three Months Ended September 30,		Six Months Ended September 30,
	2014	2013	2014	2013
Options	-	4,373,687	3,657,216	4,547,125
Warrants	-	1,428,067	1,495,803	1,535,402
9% Convertible Notes	799,523	674,528	748,824	785,714
	799,523	6,476,282	5,901,843	6,868,241

New Accounting Standards

New Accounting Standards

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40). The guidance in this ASU requires disclosure of uncertainties about an entity’s ability to continue as a going concern even if an entity’s liquidation is not imminent. There may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting and this guidance should be followed to determine whether to disclose information about the relevant conditions and events. This guidance is effective for the Company on December 31, 2016 and the adoption of this standard is not expected to have a significant impact on its condensed consolidated financial statements or notes thereto.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may materially differ from these estimates under different assumptions or conditions.

Reclassifications

Reclassifications

Certain reclassifications have been made to the accompanying March 31, 2014 condensed consolidated financial statements to conform them to the September 30, 2014 presentation.

XML

Income Taxes

6 Months Ended

Sep. 30, 2014

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

Deferred income taxes are provided on a liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Significant management judgment is required in determining the Company’s provision for income taxes and the recoverability of the Company’s deferred tax assets. Such determination is based primarily on the Company’s historical taxable income, with some consideration given to the Company’s estimates of future taxable income by jurisdictions in which the Company operates and the period over which the Company’s deferred tax assets will be recoverable. Due to overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets as of September 30, 2014 and March 31, 2014. The Company is subject to U.S. federal income tax, as well as income tax of multiple state tax jurisdictions.

ASC No. 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC No. 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC No. 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure requirements. The Company and its subsidiaries are currently open to audit under the statute of limitations by the Internal Revenue Service for the years ended December 31, 2010 and later. The Company’s state income tax returns are open to audit under the statute of limitations for the years ended December 31, 2009 and later. The Company does not anticipate any material unrecognized tax benefits within the next twelve months.

XML

Subsequent Events - Additional Information (Detail) (USD $)	1 Months Ended				1 Months Ended
	Oct. 27, 2014	Oct. 27, 2014 Subsequent Event	Oct. 14, 2014 Subsequent Event	Oct. 23, 2014 Subsequent Event	Oct. 23, 2014 Subsequent Event Common Stock	Oct. 27, 2014 Subsequent Event BCHC Agreement	Oct. 27, 2014 Subsequent Event HCHHA Agreement
Subsequent Event [Line Items]
Business Acquisition Contingent Consideration Cash Payment				10,000
Description for Purchase Agreement Interest	51% of the membership interests
Cash Received Monthly		$ 15,000
Business Acquisition Working Capital						145,000	50,000
Business Acquisition Contingent Payment						400,000	150,000
Business Acquisition Installments Payment						100,000	75,000
Stock Issued During Period, Shares, Other					500,000
Capital		613,889
Business Acquisition, Transaction Costs						900,000	300,000
Maximum Allowance For New Premises Improved Provided By Landlord			659,360
Operating Leases, Rent Expense			37,913.20
Annual Increases In Base Rent Each Year			43,957.33
Maximum Amount of Increase In Lease Rent Subject To Other Terms of Lease			$ 228,049.27

XML

Notes and Lines of Credit Payable

6 Months Ended

Sep. 30, 2014

Notes Payable [Abstract]

Notes and Lines of Credit Payable

6. Notes and Line of Credit Payable

Notes and line of credit payable consist of the following:

	September 30,		March 31,
	2014		2014
Term loan payable to NNA due March 28, 2019, net of debt discount of $1,183,856 (September 30, 2014) and $1,305,435 (March 31, 2014)	$	5,553,644	$	5,694,565
Unsecured revolving line of credit due to financial institution due June 5, 2015		94,764		94,764
	$	5,648,408	$	5,789,329

Senior Secured Note

The Company entered into a Senior Secured Note (“Note”) agreement on February 1, 2012 with SpaGus Capital Partners, LLC (“SpaGus”) an entity in which Gary Augusta, a director and shareholder of the Company, holds an ownership interest.    

On September 15, 2012, SpaGus agreed to allow the Company to defer payment of the scheduled principal payments due on September 15 and October 15, 2012, and amended the Note effective October 15, 2012 in which SpaGus agreed to provide additional principal to the Company in the amount of $230,000. The terms of the amended Note in the amount of $500,000 provided for borrowings to bear interest at 8.0 % per annum with accrued interest payable in arrears on each of December 28, 2012, March 31, 2013, June 30, 2013, and October 15, 2013. The amended Note matured and was repaid, including accrued unpaid interest, on October 16, 2013.

Medical Clinic Acquisition Promissory Notes

In connection with the September 1, 2013 acquisition of a Los Angeles, CA medical clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in ten installments of $15,000 per month commencing December 1, 2013.  The Company determined the fair value of the note using an interest rate of 5.45% per annum to discount future cash flows, which was based on Moody’s Baa-rated corporate bonds at the valuation date.  The note was secured by substantially all assets of the clinic.

In connection with the January 6, 2014 acquisition of Fletcher Medical Clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in installments of $15,000 per month for five months commencing April 1, 2014 under a non-interest bearing promissory note. The Company determined the fair value of the note using an interest rate of 5.30% per annum to discount future cash flows, which was based on Moody’s Baa-rated corporate bonds at the valuation date. The note was secured by substantially all assets of the acquired clinic.

In connection with the December 7, 2013 acquisition of Eagle Rock Medical Clinic, ACC issued a non-interest bearing promissory note to the seller, which was due in installments of $10,000 per month for eight months commencing March 1, 2014 under a non-interest bearing promissory. The Company determined the fair value of the note using an interest rate of 5.46 % per annum to discount future cash flows, which was based on based on index of Moody's Baa-rated corporate bonds at of the valuation date. The note was secured by substantially all assets of the acquired clinic.

The medical clinic acquisition promissory notes described above were repaid in connection with the equity and debt financing with NNA of Nevada, Inc. that closed on March 28, 2014 (see 2014 NNA Financing below).

NNA Credit Agreements

On October 15, 2013, the Company entered into a $2.0 million secured revolving credit facility (the “Revolving Credit Agreement”) with NNA of Nevada, Inc., (“the Lender” or “NNA”). On December 20, 2013 the Company entered into the First Amendment to the Credit Agreement (the “Amended Credit Agreement”), which increased the revolving credit facility from $2 million to $4 million.   The proceeds of the Amended Credit Agreement were used by the Company to repay the $500,000 Note to SpaGus Apollo, LLC, and were used to pay or repay certain of the Company’s 10% Notes (see Note 7), to refinance certain other indebtedness of the Company, and for working capital and for general corporate purposes. The Amended Credit Agreement was refinanced on March 28, 2014 in connection with 2014 NNA Financing.

2014 NNA Financing

On March 28, 2014, the Company entered into certain credit and investment agreements with NNA (the “2014 NNA Financing”) which provided for a $7.0 million secured term loan (“Term Loan”), a $1.0 million secured line of credit (“Revolving Loan”), and a $2.0 million convertible note commitment (“Convertible Note”). In addition, NNA acquired 2,000,000 shares of the Company’s common stock, warrants to acquire the Company’s common stock, and certain registration rights (see Note 9). The Term Loan and Revolving Loan are secured by substantially all assets of the Company, and are guaranteed by the Company’s subsidiaries and certain of its consolidated medical corporations.

The Company determined the fair value of the proceeds of $9.0 million in part based on the following inputs for the warrant liability: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share and a 50% probability of down-round financing. The common stock issuance was recorded at $899,739 (a discount of $1,100,261 to the face amount), the Term Loan was recorded at $5,745,637 (a discount of $1,254,363 to the face amount), and a corresponding warrant liability of $2,354,624 was recorded.

The Term Loan accrues interest at a rate of 8.0% per annum. A portion of the principal amount of the Term Loan is repaid on the last business day of each calendar quarter, which provides for quarterly payments of $87,500 in the first year, $122,500 in the second year, $122,500 in the third year, $175,000 in the fourth year, and $210,000 in the fifth year. The Term Loan reflected an original issue discount of $1,305,435 associated with the issuance of 3 million warrants to acquire the Company’s common stock (see Note 9) and payment of a fee to NNA of $80,000 of which $51,072 was considered a debt discount, $7,998 was recorded to equity, and $20,930 allocated to warrant liability was immediately recorded as interest expense. The discount will be amortized to interest expense over the expected term of the loan using the effective interest method.

The Revolving Loan will bear interest at the rate of three month LIBOR plus 6.0% per annum. No amounts were borrowed under the Revolving Loan at September 30, 2014. The Term Loan and Revolving Loan mature on March 28, 2019.

The NNA 8% Convertible Note commitment provided for a convertible note commitment of $2,000,000, which, on July 31, 2014, the Company fully exercised (see Note 7).

The Company incurred $235,119 in third party costs related to the 2014 NNA Financing, which were allocated to the related debt and equity instruments based on their relative fair values, of which $150,101 was classified as deferred financing costs which will be deferred and amortized over the life of the loan using the effective interest method.

The 2014 NNA Financing credit agreement and the Convertible Note provide for certain financial covenants which financial covenants the Company was in compliance with as of and for the six-month period ended September 30, 2014.

In addition, the 2014 NNA Financing credit agreement and the Convertible Note include: (1) certain negative covenants that, subject to exceptions, limit the Company’s ability to, among other things incur additional indebtedness, engage in future mergers, consolidations, liquidations and dissolutions, sell assets, pay dividends and distributions on or repurchase capital stock, and enter into or amend other material agreements; and (2) certain customary representations and warranties, affirmative covenants and events of default, which are set forth in more detail in the 2014 NNA Financing credit agreement and Convertible Note.

Unsecured revolving line of credit

Included in “Note and line of credit payable” in the accompanying condensed consolidated balance sheet is a $100,000 revolving line of credit with a financial institution of which $94,764 was outstanding at September 30, 2014 and March 31, 2014. Borrowings under the line of credit bear interest at the prime rate (as defined) plus 4.50% (7.75% per annum at March 31, 2014 and September 30, 2014), interest only is payable monthly, and the line of credit matures June 5, 2015. The line of credit is unsecured.

Interest expense associated with the notes and lines of credit payable consisted of the following:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
Interest expense	$	143,845	$	25,089	$	287,998	$	56,087
Amortization of loan fees and discount		71,673		35,061		142,924		39,780
	$	215,518	$	60,151	$	430,922	$	95,868

XML

Convertible Notes Payable

6 Months Ended

Sep. 30, 2014

Convertible Notes [Abstract]

Convertible Notes Payable

7.  Convertible Notes Payable

Convertible notes payable consist of the following:

	September 30,		March 31,
	2014		2014
9% Senior Subordinated Convertible Notes due February 15, 2016, net of debt discount of $99,973 (September 30, 2014) and $137,393 (March 31, 2014)	$	1,000,398	$	962,978
8% Senior Subordinated Convertible Note Payable to NNA due March 28, 2019, net of debt discount of $1,046,811		953,189		-
	$	1,953,587	$	962,978

10% Senior Subordinated Callable Convertible Notes

On October 16, 2009, the Company issued $1,250,000 of 10% Senior Subordinated Callable Convertible Notes (the “10% Notes”). The 10% Notes were sold through a placement agent in the form of Units. Each Unit comprised one 10% Senior Subordinated Callable Convertible Note with a par value $25,000, and warrants to purchase shares of the Company’s common stock.

On December 20, 2013, the Company redeemed the 10% Notes for cash and/or conversion into shares of the Company’s Common Stock.

8% Senior Subordinated Convertible Promissory Notes due February 1, 2015

On or about February 21, 2013, the Company entered into a Settlement Agreement and Release (collectively, the “Settlement Agreements”) with each of the holders of 8% Notes (each, an “8% Holder” and, collectively, the “8% Holders”). Under the Settlement Agreements, the Company agreed to redeem for cash and/or convert into shares of the Company’s common stock the 8% Notes of the 8% Holders. In February 2014 the Company redeemed and converted $150,000 in original principal amount plus accrued interest thereon, for total cash payments of approximately $106,000 and issuance of approximately182,000 shares of the Company’s common stock.

9% Senior Subordinated Callable Convertible Promissory Notes due February 15, 2016

The 9% Notes bear interest at a rate of 9% per annum, payable semi-annually on August 15 and February 15, and mature February 15, 2016, and are subordinated. The principal of the 9% Notes plus any accrued yet unpaid interest is convertible at any time by the holder at a conversion price of $0.40 per share of Common Stock, subject to adjustment for stock splits, stock dividends and reverse stock splits. After 60 days prior notice, the Note is callable in full or in part by the Company at any time after January 31, 2015. If the Average Daily Value of Trades (“ADVT”) during the prior 90 days as reported by Bloomberg is greater than $100,000, the Note is callable at a price of 105% of the Note’s par value, and if the ADVT is less than $100,000, the 9% Notes are callable at a price of 110% of the Note’s par value.

In connection with the issuance of the 9% Notes, the holders of the 9% Notes received warrants to purchase 660,000 shares of the Company’s common stock at an exercise price of $0.45 per share, subject to adjustment for stock splits, reverse stock splits and stock dividends, and which are exercisable at any date prior to January 31, 2018, and were classified in equity. The fair value of the 9% Notes warrants was based on the Company’s closing stock price at the transaction date and inputs to the Black-Scholes option pricing model.

NNA 8% Convertible Note

The NNA 8% Convertible Note commitment provided for the Company to borrow up to $2,000,000. On July 31, 2014, the Company exercised its option to borrow $2,000,000, received $2,000,000 of proceeds and recorded a debt discount of $1,065,775 related to the fair value of a conversion feature liability and warrant liability discussed below. Borrowings bear interest at the rate of 8.0 % per annum payable semi-annually, and are convertible into shares of the Company’s common stock initially at $1.00 per share. The conversion price will be subject to adjustment in the event of subsequent down-round equity financings, if any, by the Company. The conversion feature included a non-standard anti-dilution feature that has been bifurcated and recorded as a conversion feature liability at the issuance date of $578,155. The fair value of the conversion feature liability issued in connection with 2014 NNA Financing 8% Convertible Note at July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 4.7 years, risk free rate of 1.6%, no dividends, volatility of 54.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing. In addition the Company was required to issue 1,000,000 warrants to NNA with an exercise price of $1.00 per share. The fair value of the warrant liability of $487,620 related to 1,000,000 common shares issuable in connection with NNA 8% Convertible Note at issuance date of July 31, 2014 was estimated using the Monte Carlo valuation model which used the following inputs: term of 6.7 years, risk free rate of 2.1%, no dividends, volatility of 71.8%, share price of $0.49 per share based on the trading price of the Company’s common stock adjusted for a marketability discount, and a 100% probability of down-round financing.

Interest expense associated with the convertible notes payable consisted of the following:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
Interest expense	$	52,856	$	111,387	$	77,881	$	185,619
Amortization of loan fees and discount		60,884		29,025		97,322		80,766
	$	113,740	$	140,411	$	175,203	$	266,384

XML

Stockholders' Equity

6 Months Ended

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

Stockholders' Deficit

9. Stockholders’ Equity

Common Stock Placement

On March 28, 2014, the Company entered into an equity and debt investment for up to $12.0 million with NNA. As part of the investment, the Company entered into an Investment Agreement with NNA, dated March 28, 2014 (the “Investment Agreement”), pursuant to which the Company sold NNA 2,000,000 shares of the Company’s common stock (the “Purchased Shares”) at a purchase price of $1.00 per share. In addition with the issuance of common shares, the Company issued to NNA 1,000,000 warrants to purchase the Company’s common stock for $1.00 per share. The Company used the Monte Carlo Method to value the warrants, which used the following inputs: term of 7 years, risk free rate of 2.31%, no dividends, volatility of 71.4%, share price of $0.45 per share and a 50% probability of down-round financing. The Company determined that the fair value of the shares issued was approximately $900,000, or approximately $0.45 per share. The Company also entered into a registration rights agreement (“RRA”) with NNA which requires the Company to file a registration statement to register its shares with the Securities and Exchange Commission no later than March 28, 2015. The RRA requires the Company to use commercially reasonable efforts to cause the RRA to be declared effective by the SEC. If the Initial Registration Statement is not filed with the SEC on or prior to the filing deadline the Company must pay to NNA an amount in Common Stock based upon its then fair market value, as liquidated damages equal to 1.50% of the aggregate purchase price paid by NNA.

Equity Incentive Plans

The Company’s amended 2010 Equity Incentive Plan (the “2010 Plan”) allowed the Board to grant up to 12,000,000 shares of the Company’s common stock, and provided for awards including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. As of September 30, 2014, there were no shares available for grant.

On April 29, 2013 the Company’s Board of Directors approved the Company’s 2013 Equity Incentive Plan (the “2013 Plan”), pursuant to which 5,000,000 shares of the Company’s common stock were reserved for issuance thereunder. The Company received approval of the 2013 Plan from the Company’s stockholders on May 19, 2013. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of September 30, 2014 there were approximately 1,900,000 shares available for future grants under the 2013 Plan.

Stock options and restricted common stock issued to non-employees as compensation for services to be provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair value of the option or share, whichever can be more clearly determined. The Company recognizes this expense over the period in which the services are provided.   

Share Issuances

A summary of the Company’s restricted stock sold to employees, directors and consultants with a right of repurchase of unlapsed or unvested shares is as follows for the six months ended September 30, 2014:

			Weighted Average Remaining Vesting		Weighted Average Per Share		Weighted- average Per Share
			Life		Intrinsic		Grant Date
	Shares		(In years)		Value		Fair Value
Unvested or unlapsed shares, beginning of period		907,407		1.3	$	-	$	0.41
Granted		-		-		-		-
Vested / lapsed		(611,111)		-		-		-
Forfeited		-		-		-		-
Unvested or unlapsed shares, end of period		296,296		1.1	$	0.06	$	0.41

Options

In July 2014, the Company issued 565,000 options to acquire the Company’s common stock to certain employees and consultants. The Company determined that the weighted average fair value of the options of $0.24 per share using the Black-Scholes method with the following weighted-average inputs: term of 6 years, risk free rate of 1.63%, no dividends, volatility of 63.7%, share price of $0.54 per share.

Stock option activity for the six months ended September 30, 2014 is summarized below:

	Shares		Weighted Average Per Share Exercise Price		Weighted Average Remaining Life (Years)		Weighted Average Per Share Intrinsic Value
Balance, beginning of period		6,287,000	$	0.20		8.7	$	0.11
Granted		565,000		1.00		-		-
Cancelled		(100,000)		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Forfeited		-		-		-		-
Balance, end of period		6,752,000	$	0.22		8.2	$	0.24
Vested and exercisable, end of period		6,145,889	$	0.21		7.5	$	0.26

ApolloMed ACO 2012 Equity Incentive Plan

On October 18, 2012 ApolloMed ACO’s Board of Directors adopted the ApolloMed Accountable Care Organization, Inc. 2012 Equity Incentive Plan (the “ACO Plan”) and reserved 9,000,000 shares of ApolloMed ACO’s common stock for issuance thereunder. The purpose of the ACO Plan is to encourage selected employees, directors, consultants and advisers to improve operations and increase the profitability of ApolloMed ACO and encourage selected employees, directors, consultants and advisers to accept or continue employment or association with ApolloMed ACO.

The following table summarizes the restricted stock award in the ACO Plan during the six months ended September 30, 2014:

	Shares		Weighted Average Remaining Vesting Life (Years)		Weighted Average Per Share Intrinsic Value		Weighted Average Per Share Fair Value
Balance, beginning of period		3,752,000		0.8	$	0.02	$	0.03
Granted		112,000		-		-		0.78
Released		(183,996)		-		-		-
Balance, end of period		3,680,004		0.6	$	0.73	$	0.05
Vested and exercisable, end of period		2,461,694

Awards of restricted stock under the Plan vest (i) one-third on the date of grant; (ii) one-third on the first anniversary of the date of grant, if the grantee has remained in service continuously until that date; and (iii) one-third on the second anniversary of the date of grant if the grantee has remained in service continuously until that date. 

As of September 30, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Company’s 2010 and 2013 Equity Plans, and the ACO Plan’s and the weighted-average period of years expected to recognize those costs are as follows:

Common stock options	$	198,195
Restricted stock	$	139,400
ACO Plan restricted stock	$	57,179

Stock-based compensation expense related to common stock and common stock option awards is recognized over their respective vesting periods and was included in the accompanying condensed consolidated statement of operations as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
Stock-based compensation expense:
Cost of services	$	(17,822)	$	86,630	$	10,921	$	575,509
General and administrative		874,341		482,078		964,737		1,545,503
	$	856,519	$	568,708	$	975,658	$	2,121,012

Warrants

Warrants consisted of the following for the six months ended September 30, 2014:

	Weighted Average Per Share
	Intrinsic		Number of
	Value		warrants
Outstanding, beginning of period	$	0.02		7,145,000
Granted		-		2,000,000
Exercised		-		-
Cancelled		-		-
Outstanding, end of period	$	-		9,145,000

				Weighted
				average				Weighted
	Exercise Price Per	Warrants		remaining		Warrants		average
	Share	outstanding		contractual life		exercisable		exercise price per share
$	0.11485		1,250,000		1.8		1,250,000	$	0.1149
$	0.11485		250,000		1.8		250,000	$	0.1149
$	0.45000		500,000		1.8		500,000	$	0.4500
$	0.50000		100,000		3.1		100,000	$	0.5000
$	0.45000		825,000		3.3		825,000	$	0.4500
$	0.40000		220,000		3.3		220,000	$	0.4000
$	1.00000		2,000,000		6.5		2,000,000	$	1.0000
$	2.00000		2,000,000		6.5		2,000,000	$	1.0000
$	1.00000		1,000,000		6.5		1,000,000	$	1.0000
$	1.00000		1,000,000		3.8		1,000,000	$	1.0000
			9,145,000		4.8		9,145,000		0.9700

In connection with the 2014 NNA Financing, NNA received warrants to purchase up to 2,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and up to 2,000,000 shares at an exercise price of $2.00 per share, subject to adjustment for stock splits, reverse stock splits and stock dividends, and which are exercisable at any date prior to March 28, 2021. The warrants also contained down-round protection under which the exercise price of the warrants is subject to adjustment in the event the Company issues future common shares at a price below $0.90 per share. The Company determined that the warrants should be classified as liabilities under ASC 815-40, which requires the Company to determine the fair value of the warrants at the transaction date and at each subsequent reporting date (see Notes 2 and 6). Following the funding of the Convertible Note on July 30, 2014, additional warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share that had been issued in connection with the 2014 NNA Financing became exercisable (see Note 6).

Authorized stock

At September 30, 2014 the Company was authorized to issue up to 100,000,000 shares of common stock. The Company is required to reserve and keep available out of the authorized but unissued shares of common stock such number of shares sufficient to effect the conversion of all outstanding shares of the 9% Senior Subordinated Callable Notes, the exercise of all outstanding warrants exercisable into shares of common stock, and shares granted and available for grant under the Company’s 2013 Plan. The amount of shares of common stock reserved for these purposes is as follows at September 30, 2014: 

Common stock issued and outstanding	49,134,549
Conversion of 9% Notes	2,750,000
Conversion of 8% Notes	2,000,000
Warrants outstanding	9,145,000
Stock options outstanding	6,752,000
Remaining shares issuable under 2013 Equity Incentive Plan	1,900,000
	71,681,549

XML

Fair Value of Consideration Transferred (Detail) (USD $)	1 Months Ended	6 Months Ended
	May 31, 2014	Sep. 30, 2014
AKM Medical Group, Inc [Member]
Business Acquisition [Line Items]
Cash consideration	$ 140,000	$ 140,000
Fair value of warrant consideration	136,822	136,822
Total purchase consideration	280,000	276,822
Southern California Heart Centers [Member]
Business Acquisition [Line Items]
Cash consideration		2,428,391
Fair value of warrant consideration		132,000
Total purchase consideration		$ 2,560,391

XML

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended			6 Months Ended		1 Months Ended	6 Months Ended		1 Months Ended						1 Months Ended	6 Months Ended	1 Months Ended
	Jul. 31, 2014	Jul. 31, 2014	Mar. 28, 2014	Sep. 30, 2014	Mar. 31, 2014	Mar. 28, 2014 NNA of Nevada, Inc	Sep. 30, 2014 Monte Carlo method	Sep. 30, 2014 Equity and Debt Financing	Mar. 28, 2014 Equity and Debt Financing NNA of Nevada, Inc	Sep. 30, 2014 Note warrant	Sep. 30, 2014 Placement agent warrants	Sep. 30, 2014 Maximum	Sep. 30, 2014 Maximum Equity and Debt Financing	Sep. 30, 2014 9% Notes Payable	Jul. 31, 2014 Restricted Stock	Sep. 30, 2014 2010 Equity Incentive Plan	Oct. 18, 2012 2012 Equity Incentive Plan	Sep. 30, 2014 2013 Equity Incentive Plan	Apr. 29, 2013 2013 Equity Incentive Plan
Stockholders Equity Note [Line Items]
Equity incentive plan, shares authorized for issuance																			5,000,000
Equity incentive plan, additional shares authorized for issuance																	9,000,000
Equity incentive plan, shares available for future grant				1,900,000														1,900,000
Issuance of common stock for services (shares)																12,000,000
Common Stock, shares authorized				100,000,000	100,000,000							100,000,000
Convertible notes, interest rate	8.00%	8.00%												9.00%
Restricted shares granted to agent									2,000,000
Share price	$ 0.49	$ 0.49							$ 1
Exercise price									$ 0.45
Expected term	6 years 8 months 12 days	6 years	7 years
Expected volatility rate	71.80%	63.70%	71.40%
Risk free interest rate	2.10%	1.63%	2.31%
Expected dividend rate		0.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									1,000,000	2,000,000	2,000,000		1,000,000
Class Of Warrant Or Right Price Per Share			$ 0.45
Warrants and Rights Outstanding									$ 900,000
Price Per Share Level For Future Issuance Of Common Shares							$ 0.90
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 1.00	$ 1.00	$ 1.00	$ 2.00
Equity and debt investment						$ 12			$ 12,000,000
Percentage For Down Round Finance			50.00%
Percentage For Liquidated Damages Equal Of Purchase Price			1.50%
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross				0											565,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value		$ 0.24		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 8 months 12 days	6 years	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.10%	1.63%	2.31%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	71.80%	63.70%	71.40%

XML

Acquisitions (Tables)

6 Months Ended

Sep. 30, 2014

Business Acquisition [Line Items]

Weighted-average amortization period for intangible assets acquired

The intangible assets acquired consisted of the following:

	Life (yrs)	Additions
Network relationships	5	$	910,000
Trade name	5		110,000
Non-compete agreements	3		101,000
		$	1,121,000

AKM

Business Acquisition [Line Items]

Schedule Of Business Acquisitions By Acquisition Consideration Transferred

The acquisition-date fair value of the consideration transferred was as follows:

Cash consideration	$	140,000
Fair value of holdback consideration due to seller		136,822
Total purchase consideration	$	276,822

Schedule of Purchase Prices Allocations

Under the acquisition method of accounting, the total purchase price was allocated to AKM’s net tangible assets based on their estimated fair values as of the closing date. The preliminary allocation of the total purchase price to the net assets acquired and included in the Company’s condensed consolidated balance sheet is as follows:

Cash and cash equivalents	$	356,359
Marketable securities		389,094
Accounts receivable		27,217
Prepaid expenses and other assets		26,311
Intangibles		156,000
Goodwill		(216,563)
Accounts payable and accrued liabilities		(40,439)
Medical payables		(421,157)
Net assets acquired	$	276,822

SCHC

Business Acquisition [Line Items]

Schedule Of Business Acquisitions By Acquisition Consideration Transferred

The acquisition-date fair value of the consideration transferred was as follows:

Cash consideration	$	2,428,391
Fair value of warrant consideration		132,000
	$	2,560,391

Schedule of Purchase Prices Allocations

The preliminary allocation of the total purchase price to the net assets acquired and liabilities assumed and included in the Company’s condensed consolidated balance sheet at September 30, 2014 is as follows:

Cash and cash equivalents	$	264,601
Accounts receivable		840,433
Receivable from affiliate		67,714
Prepaid expenses and other current assets		82,430
Property and equipment		584,377
Identifiable intangible assets		1,121,000
Goodwill		161,559
Other assets		66,762
Total assets acquired		3,188,876
Accounts payable and accrued liabilities		134,427
Note payable to financial institution		463,582
Deferred tax liability		30,477
Total liabilities assumed		628,485
Net assets acquired	$	2,560,391

AKM & SCHC

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information

The following unaudited pro forma results of operations for the three and six months ended September 30, 2014 assume both the AKM and SCHC acquisitions had occurred on April 1, 2014, and for the six months ended September 30, 2013 assume the acquisitions had occurred on April 1, 2013:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
	(unaudited)		(unaudited)		(unaudited)		(unaudited)
Net revenue	$	11,899,142	$	4,477,640	$	17,956,326	$	9,135,956
Net income (loss)	$	1,410,936	$	(1,067,658)	$	(209,441)	$	(3,054,008)
Basic income (loss) per share	$	0.03	$	(0.02)	$	(0.00)	$	(0.08)
Diluted income (loss) per share	$	0.03	$	(0.02)	$	(0.00)	$	(0.08)

XML

Stockholders' Equity (Tables)

6 Months Ended

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

Schedule of Nonvested Share Activity

A summary of the Company’s restricted stock sold to employees, directors and consultants with a right of repurchase of unlapsed or unvested shares is as follows for the six months ended September 30, 2014:

			Weighted Average Remaining Vesting		Weighted Average Per Share		Weighted- average Per Share
			Life		Intrinsic		Grant Date
	Shares		(In years)		Value		Fair Value
Unvested or unlapsed shares, beginning of period		907,407		1.3	$	-	$	0.41
Granted		-		-		-		-
Vested / lapsed		(611,111)		-		-		-
Forfeited		-		-		-		-
Unvested or unlapsed shares, end of period		296,296		1.1	$	0.06	$	0.41

Stock Option Transactions Under Stock Option Plans

Stock option activity for the six months ended September 30, 2014 is summarized below:

	Shares		Weighted Average Per Share Exercise Price		Weighted Average Remaining Life (Years)		Weighted Average Per Share Intrinsic Value
Balance, beginning of period		6,287,000	$	0.20		8.7	$	0.11
Granted		565,000		1.00		-		-
Cancelled		(100,000)		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Forfeited		-		-		-		-
Balance, end of period		6,752,000	$	0.22		8.2	$	0.24
Vested and exercisable, end of period		6,145,889	$	0.21		7.5	$	0.26

Summary of Restricted Stock Award

The following table summarizes the restricted stock award in the ACO Plan during the six months ended September 30, 2014:

	Shares		Weighted Average Remaining Vesting Life (Years)		Weighted Average Per Share Intrinsic Value		Weighted Average Per Share Fair Value
Balance, beginning of period		3,752,000		0.8	$	0.02	$	0.03
Granted		112,000		-		-		0.78
Released		(183,996)		-		-		-
Balance, end of period		3,680,004		0.6	$	0.73	$	0.05
Vested and exercisable, end of period		2,461,694

Total Unrecognized Compensation Costs Related To Non-Vested Stock-Based Compensation Arrangements

As of September 30, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Company’s 2010 and 2013 Equity Plans, and the ACO Plan’s and the weighted-average period of years expected to recognize those costs are as follows:

Common stock options	$	198,195
Restricted stock	$	139,400
ACO Plan restricted stock	$	57,179

Summary of Stock Based Compensation Expense Related To Restricted Stock and Option Awards

Stock-based compensation expense related to common stock and common stock option awards is recognized over their respective vesting periods and was included in the accompanying condensed consolidated statement of operations as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2014		2013		2014		2013
Stock-based compensation expense:
Cost of services	$	(17,822)	$	86,630	$	10,921	$	575,509
General and administrative		874,341		482,078		964,737		1,545,503
	$	856,519	$	568,708	$	975,658	$	2,121,012

Warrants Outstanding

Warrants consisted of the following for the six months ended September 30, 2014:

	Weighted Average Per Share
	Intrinsic		Number of
	Value		warrants
Outstanding, beginning of period	$	0.02		7,145,000
Granted		-		2,000,000
Exercised		-		-
Cancelled		-		-
Outstanding, end of period	$	-		9,145,000

				Weighted
				average				Weighted
	Exercise Price Per	Warrants		remaining		Warrants		average
	Share	outstanding		contractual life		exercisable		exercise price per share
$	0.11485		1,250,000		1.8		1,250,000	$	0.1149
$	0.11485		250,000		1.8		250,000	$	0.1149
$	0.45000		500,000		1.8		500,000	$	0.4500
$	0.50000		100,000		3.1		100,000	$	0.5000
$	0.45000		825,000		3.3		825,000	$	0.4500
$	0.40000		220,000		3.3		220,000	$	0.4000
$	1.00000		2,000,000		6.5		2,000,000	$	1.0000
$	2.00000		2,000,000		6.5		2,000,000	$	1.0000
$	1.00000		1,000,000		6.5		1,000,000	$	1.0000
$	1.00000		1,000,000		3.8		1,000,000	$	1.0000
			9,145,000		4.8		9,145,000		0.9700

Amount of Shares of Common Stock Reserved

The amount of shares of common stock reserved for these purposes is as follows at September 30, 2014: 

Common stock issued and outstanding	49,134,549
Conversion of 9% Notes	2,750,000
Conversion of 8% Notes	2,000,000
Warrants outstanding	9,145,000
Stock options outstanding	6,752,000
Remaining shares issuable under 2013 Equity Incentive Plan	1,900,000
	71,681,549

XML

Convertible Notes (Parenthetical) (Detail) (USD $)				6 Months Ended
	Sep. 30, 2014	Jul. 31, 2014	Mar. 31, 2014	Sep. 30, 2014 9% Senior Subordinated Convertible Notes due February 15, 2016	Mar. 31, 2014 9% Senior Subordinated Convertible Notes due February 15, 2016	Sep. 30, 2014 8% Senior Subordinated Convertible Notes due February 1, 2015
Debt Instrument [Line Items]
Debt, interest rate		8.00%		9.00%		8.00%
Debt discount	$ 1,183,856		$ 1,305,435	$ 99,973	$ 137,393	$ 1,046,811
Debt instrument, maturity date				Feb. 15, 2016

XML

Future Amortization Expense (Detail) (USD $)	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]
October 1, 2014 to March 31, 2015	$ 255,000
2016	326,000
2017	259,000
2018	192,000
2019	125,000
Thereafter	$ 46,000

XML

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Preferred Shares	Common Shares	Additional paid-in capital	Accumulated other comprehensive income	Accumulated Deficit	Stockholders' Deficit Attributable to Apollo Medical Holdings, Inc.	Non-controlling Interest
Balance at Mar. 31, 2014	$ (1,623,155)	$ 0	$ 49,135	$ 15,083,365	$ 0	$ (16,347,588)	$ (1,215,088)	$ (408,067)
Balance (in shares) at Mar. 31, 2014		0	49,134,549
Net income	28,384	0	0	0	0	(301,431)	(301,431)	329,815
Issuance of warrants	132,000			132,000			132,000	0
Contribution by non-controlling interest	550,000			0	0	0	0	550,000
Distribution to non-controlling interest	(600,000)			0	0	0	0	(600,000)
Unrealized change in value of marketable securities	33,088	0	0	0	33,088	0	33,088	0
Stock-based compensation expense	975,658	0	0	975,658	0	0	975,658	0
Balance at Sep. 30, 2014	$ (504,025)	$ 0	$ 49,135	$ 16,191,023	$ 33,088	$ (16,649,019)	$ (375,773)	$ (128,252)
Balance (in shares) at Sep. 30, 2014		0	49,134,549

XML

Acquisitions

6 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Acquisition

3.  Acquisitions

SCHC

On July 22, 2014, pursuant to a Stock Purchase Agreement dated as of July 21, 2014 (the “Purchase Agreement”) among the Southern California Heart Centers, a Medical Corporation, a medical group that provides professional medical services in Los Angeles County, California (“SCHC”), the shareholders of SCHC (the “Sellers”) and a Company affiliate, SCHC Acquisition, A Medical Corporation (the “Affiliate”), solely owned by Dr. Warren Hosseinion as physician shareholder and the Chief Executive Officer of the Company, the Affiliate acquired all of the outstanding shares of capital stock of SCHC from the Sellers. The purchase price for the shares was (i) $2,000,000 in cash, (ii) $428,391 to pay off and discharge certain indebtedness of SCHC (iii) warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.00 per share and (iv) a contingent amount of up to $1,000,000 payable, if at all, in cash. The acquisition was funded by an intercompany loan from AMM, which also provided an indemnity in favor of one of the Sellers relating to certain indebtedness of SCHC that remained outstanding following the closing of the acquisition. Following the acquisition of SCHC, the Affiliate was merged with and into SCHC, with SCHC being the surviving corporation. The indebtedness of SCHC was paid off following the acquisition and did not remain outstanding as of September 30, 2014.

In connection with the acquisition of SCHC, AMM entered into a management services agreement with the Affiliate on July 21, 2014. As a result of the Affiliate’s merger with and into SCHC, SCHC is now the counterparty to this management services agreement and bound by its terms. Pursuant to the management services agreement, AMM will manage all non-medical services for SCHC, will have exclusive authority over all non-medical decision making related to the ongoing business operations of SCHC, and is the primary beneficiary of SCHC, and the financial statements of SCHC will be consolidated as a variable interest entity with those of the Company from July 21, 2014.

The Company accounted for the acquisition as a business combination using the acquisition method of accounting which requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates. The acquisition-date fair value of the consideration transferred was as follows:

Cash consideration	$	2,428,391
Fair value of warrant consideration		132,000
	$	2,560,391

The warrants were classified as equity. The fair value of the warrants was determined using the Black-Scholes option pricing model using the following inputs: share price of $0.54 (adjusted for a lack of control discount), exercise price of $1.00, expected term of 4 years, volatility of 54% and a risk free interest rate of 1.35%.

A contingent payment obligation of $1,000,000 was considered a post-combination transaction and therefore it will be recorded as post-combination compensation expense over the term of the arrangement and not as purchase consideration. The compensation expense will be accrued in each reporting period using the total probability weighted payment of $827,000, allocated to each quarter, and between each Seller, pro rata over the term of the arrangement according to the relative weight of the payment milestones. The remaining liability will be re-measured at every reporting period date, with any adjustment reflected prospectively in compensation expense.

Transaction costs are not included as a component of consideration transferred and were expensed as incurred. The related transaction costs expensed for the three and six months ended September 30, 2014 were approximately $124,000 in each period and are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive income (loss).

Under the acquisition method of accounting, the total purchase price was allocated to the underlying tangible and intangible assets acquired and liabilities assumed based on their respective fair values, with the remainder allocated to goodwill. The preliminary allocation of the total purchase price to the net assets acquired and liabilities assumed and included in the Company’s condensed consolidated balance sheet at September 30, 2014 is as follows:

Cash and cash equivalents	$	264,601
Accounts receivable		840,433
Receivable from affiliate		67,714
Prepaid expenses and other current assets		82,430
Property and equipment		584,377
Identifiable intangible assets		1,121,000
Goodwill		161,559
Other assets		66,762
Total assets acquired		3,188,876
Accounts payable and accrued liabilities		134,427
Note payable to financial institution		463,582
Deferred tax liability		30,477
Total liabilities assumed		628,485
Net assets acquired	$	2,560,391

The intangible assets acquired consisted of the following:

	Life (yrs)	Additions
Network relationships	5	$	910,000
Trade name	5		110,000
Non-compete agreements	3		101,000
		$	1,121,000

The network relationships were valued using the multi-period excess earnings method based on projected revenue and earnings over a 5 year period. The trade name was computed using the relief from royalty method, assuming a 1% royalty rate, and the non-compete agreements were valued using a with-and-without method.

See below for the combined SCHC and AKM pro forma results of operations.

AKM

In May 2014, AMM entered into a management services agreement with AKM Acquisition Corp, Inc. (“AKMA”), a newly-formed provider of physician services and an affiliate of the Company owned by Dr. Warren Hosseinion as a physician shareholder, to manage all non-medical services for AKMA. AMM has exclusive authority over all non-medical decision making related to the ongoing business operations of AKMA and is the primary beneficiary; consequently, AMM consolidated the revenue and expenses of AKMA from the date of execution of the management services agreements. On May 30, 2014 (the “Closing Date”) AKMA entered into a stock purchase agreement (the “AKM Purchase Agreement”) with the shareholders of AKM Medical Group, Inc.(“AKM”), a Los Angeles, CA-based independent practice association (“IPA”).  Immediately following the closing, AKMA merged with and into AKM, with AKM being the surviving entity and assuming the rights and obligations under the management services agreement. Under the AKM Purchase Agreement all of the issued and outstanding shares of capital stock of AKM was acquired for approximately $280,000, of which $140,000 was paid at closing and $136,822 (the “Holdback Liability”) is payable subject to the outcome of incurred but not reported risk-pool claims and other contingent claims that existed at the acquisition date. The acquisition allows the Company to execute on its strategy to provide high-quality, cost-efficient healthcare delivery through integrated services and network offerings.

The Company accounted for the acquisition as a business combination using the acquisition method of accounting which requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values as of the purchase date and be recorded on the balance sheet. The process for estimating the fair values of identifiable intangible assets involves the use of significant estimates and assumptions, including estimating future cash flows and developing appropriate discount rates.  The acquisition-date fair value of the consideration transferred was as follows:

Cash consideration	$	140,000
Fair value of holdback consideration due to seller		136,822
Total purchase consideration	$	276,822

Under the acquisition method of accounting, the total purchase price was allocated to AKM’s net tangible assets based on their estimated fair values as of the closing date. The preliminary allocation of the total purchase price to the net assets acquired and included in the Company’s condensed consolidated balance sheet is as follows:

Cash and cash equivalents	$	356,359
Marketable securities		389,094
Accounts receivable		27,217
Prepaid expenses and other assets		26,311
Intangibles		156,000
Goodwill		(216,563)
Accounts payable and accrued liabilities		(40,439)
Medical payables		(421,157)
Net assets acquired	$	276,822

Before recognizing a gain from a bargain purchase, the Company is required to reassess its identification of assets acquired and liabilities assumed to validate that all assets and liabilities that the acquirer is able to identify at the acquisition date are properly recognized. The guidance in ASC 805 requires that this additional reassessment be performed to verify that the identification and measurement of all components of the business combination were consistent with the requirements of ASC 805. Accordingly, as the purchase price allocation is preliminary and subject to reassessment, the Company will classify the goodwill bargain purchase as a contra to goodwill until it has completed its review of the procedures used to measure the included amounts, which is expected to be during the quarter ending December 31, 2014.

Under the AKM Purchase Agreement, former shareholders of AKM are entitled to be paid the Holdback Amount of up to approximately $140,000 within 6 months of the Closing Date. No later than 30 days after the six month period, AKM will prepare a closing statement which will state the actual cash position (as defined) (“Actual Cash Position”) of AKM. If the actual cash position of AKM is less than $461,104 (the “Target Amount”), the former shareholders of AKM will pay the difference between the Target Amount and the Actual Cash Position, which will be deducted from the Holdback Amount, but in no case will exceed the amount previously paid to the former shareholders of AKM in connection with the transaction. If the Actual Cash Position exceeds the Target Amount, then that difference will be added to the Holdback Amount. Any indemnification payment made by the former shareholders of AKM will also be paid from the Holdback Amount; if the Holdback Amount is insufficient, the former shareholders of AKM are liable for paying the balance, which cannot exceed amounts previously paid to the former shareholders of AKM under the AKM Purchase Agreement. The Company determined the preliminary fair value was determined based on the cash consideration discounted at the Company's cost of debt.

Transaction costs are not included as a component of consideration transferred and were expensed as incurred. The related transaction costs expensed for the three and six months ended September 30, 2014 were approximately $0 and $37,000, respectively.

Pro Forma Financial Information

The results of operations for AKM and SCHC are included in the condensed consolidated statements of operations from the acquisition date of each. The pro forma results of operations are prepared for comparative purposes only and do not necessarily reflect the results that would have occurred had the acquisitions occurred at the beginning of the years presented or the results which may occur in the future. The following unaudited pro forma results of operations for the three and six months ended September 30, 2014 assume both the AKM and SCHC acquisitions had occurred on April 1, 2014, and for the six months ended September 30, 2013 assume the acquisitions had occurred on April 1, 2013:

	Three months ended September 30,				Six months ended September 30,
	2014		2013		2014		2013
	(unaudited)		(unaudited)		(unaudited)		(unaudited)
Net revenue	$	11,899,142	$	4,477,640	$	17,956,326	$	9,135,956
Net income (loss)	$	1,410,936	$	(1,067,658)	$	(209,441)	$	(3,054,008)
Basic income (loss) per share	$	0.03	$	(0.02)	$	(0.00)	$	(0.08)
Diluted income (loss) per share	$	0.03	$	(0.02)	$	(0.00)	$	(0.08)

From the applicable closing date to September 30, 2014, revenues and net loss related to AKM and SCHC included the accompanying condensed and consolidated statement of operations were $1,872,529 and $(260,624), respectively.

XML

Warrants (Detail) (USD $)	6 Months Ended
	Sep. 30, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding	9,145,000
Weighted average remaining contractual life	4 years 9 months 18 days
Warrants exercisable	9,145,000
Weighted average exercise price per share	$ 0.9700
Warrant Exercise Price Range One 0.11485
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 0.11485
Warrants outstanding	1,250,000
Weighted average remaining contractual life	1 year 9 months 18 days
Warrants exercisable	1,250,000
Weighted average exercise price per share	$ 0.1149
Warrant Exercise Price Range Two 0.11485
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 0.11485
Warrants outstanding	250,000
Weighted average remaining contractual life	1 year 9 months 18 days
Warrants exercisable	250,000
Weighted average exercise price per share	$ 0.1149
Warrant Exercise Price Range Three 0.45000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 0.45000
Warrants outstanding	500,000
Weighted average remaining contractual life	1 year 9 months 18 days
Warrants exercisable	500,000
Weighted average exercise price per share	$ 0.4500
Warrant Exercise Price Range Four 0.50000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 0.50000
Warrants outstanding	100,000
Weighted average remaining contractual life	3 years 1 month 6 days
Warrants exercisable	100,000
Weighted average exercise price per share	$ 0.5000
Warrant Exercise Price Range Five 0.45000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 0.45000
Warrants outstanding	825,000
Weighted average remaining contractual life	3 years 3 months 18 days
Warrants exercisable	825,000
Weighted average exercise price per share	$ 0.4500
Warrant Exercise Price Range Six 0.40000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 0.40000
Warrants outstanding	220,000
Weighted average remaining contractual life	3 years 3 months 18 days
Warrants exercisable	220,000
Weighted average exercise price per share	$ 0.4000
Warrant Exercise Price Range Seven 1.00000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 1.00000
Warrants outstanding	2,000,000
Weighted average remaining contractual life	6 years 6 months
Warrants exercisable	2,000,000
Weighted average exercise price per share	$ 1.0000
Warrant Exercise Price Range Eight 2.00000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 2.00000
Warrants outstanding	2,000,000
Weighted average remaining contractual life	6 years 6 months
Warrants exercisable	2,000,000
Weighted average exercise price per share	$ 1.0000
Warrant Exercise Price Range Nine 1.00000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 1.00000
Warrants outstanding	1,000,000
Weighted average remaining contractual life	6 years 6 months
Warrants exercisable	1,000,000
Weighted average exercise price per share	$ 1.0000
Warrant Exercise Price Range Ten 1.00000
Class of Warrant or Right [Line Items]
Exercise Price Per Share	$ 1.00000
Warrants outstanding	1,000,000
Weighted average remaining contractual life	3 years 9 months 18 days
Warrants exercisable	1,000,000
Weighted average exercise price per share	$ 1.0000

XML

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended			6 Months Ended					6 Months Ended	12 Months Ended	6 Months Ended		3 Months Ended	6 Months Ended			3 Months Ended		6 Months Ended	3 Months Ended	6 Months Ended	3 Months Ended	6 Months Ended
	Jul. 31, 2014	Jul. 31, 2014	Mar. 28, 2014	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Jul. 31, 2014 Warrant [Member]	Sep. 30, 2014 Convertible Notes Payable [Member]	Sep. 30, 2014 2014 NNA Financing	Mar. 31, 2014 2014 NNA Financing	Sep. 30, 2014 Maximum [Member]	Sep. 30, 2014 Minimum [Member]	Sep. 30, 2013 Three Major Customers	Sep. 30, 2014 Three Major Customers	Sep. 30, 2014 NNA 8 Convertible Notes	Sep. 30, 2014 Customer A	Sep. 30, 2014 Customer A Three Major Customers	Sep. 30, 2013 Customer A Three Major Customers	Sep. 30, 2014 Customer A Three Major Customers	Sep. 30, 2013 Customer B Three Major Customers	Sep. 30, 2014 Customer B Three Major Customers	Sep. 30, 2014 ApolloMed ACO	Sep. 30, 2014 ApolloMed ACO
Summary Of Significant Accounting Policies [Line Items]
Management agreement, initial term											20 years	10 years
Revenue Of Major Customers Percentage Of Total Revenue													16.10%	17.60%		10.00%	10.00%	16.10%	15.80%	16.80%	16.10%
Percentage Of Accounts Receivable From Customers														9.60%			12.50%		12.50%		21.70%
Expected term	6 years 8 months 12 days	6 years	7 years						6 years 6 months	7 years					4 years 6 months
Risk free interest rate	2.10%	1.63%	2.31%						2.10%	2.31%					1.60%
Expected volatility rate	71.80%	63.70%	71.40%							71.40%					55.40%
Expected dividend rate		0.00%							72.20%						0.00%
Share Price	$ 0.49	$ 0.49							$ 0.45	$ 0.45					$ 0.45
Percentage For Down round financing		100.00%							100.00%	50.00%					100.00%
Health Care Organization, Patient Service Revenue				$ 20,000																		$ 5,380,000	$ 10,980,000
Medical Liability Current				1,642,497		552,561
non-controlling interest				550,000	0
Derivative Liability							$ 487,620
Common Shares Issuable	1,000,000	1,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%						8.00%
Debt Instrument, Convertible, Conversion Price				$ 1.00

XML

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amortization of Intangible Assets	$ 125,000	$ 1,000	$ 130,000	$ 1,000

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Sep. 30, 2014

Accounting Policies [Abstract]

Schedule Of Cash Equivalents And Marketable Securities

The following is a summary of cash equivalents and marketable securities:

As of September 30, 2014			Gross		Gross		Estimated		Cash and		Marketable
			Unrealized		Unrealized		Fair		Cash		Securities
	Cost		Gain		Loss		Value		Equivalents		(all current)
Bank demand deposits	$	3,856,285	$	-	$	-	$	3,856,285	$	3,856,285	$	-
Money market funds		93,840		-		-		93,840		93,840		-
Mutual funds		148,028		966		-		148,994		-		148,994
Equity securities		241,065		32,122		-		273,187		-		273,187
	$	4,339,218	$	33,088	$	-	$	4,372,306	$	3,950,125	$	422,181

As of March 31, 2014			Gross		Gross		Estimated		Cash and
			Unrealized		Unrealized		Fair		Cash
	Cost		Gain		Loss		Value		Equivalents
Bank demand deposits	$	6,831,478		-		-	$	6,831,478	$	6,831,478
	$	6,831,478	$	-	$	-	$	6,831,478	$	6,831,478

Schedule of Medical Payables

The Company’s IBNR reserve for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	274,000
Incurred health care costs:
Current year		1,566,856
Prior years		-
Total incurred health care costs		1,566,856
Acquired medical liabilities (see Note 3 )		292,309
Claims paid:
Current year		(997,390)
Prior years		(64,482)
Total claims paid		(1,061,872)
Adjustments		(197,938)
Balance, end of period	$	873,355

Company Accrual Risk Pool Liability

The Company’s accrual for its risk-pool liability for the six months ended September 30, 2014 was as follows:

Balance, beginning of period	$	278,561
Acquired medical liabilities (see Note 3)		128,848
Claims paid:		-
Accrual for net deficit from full risk capitation contracts		361,733
Balance, end of period	$	769,142

Fair Value Measurements, Recurring and Nonrecurring

The carrying amounts and fair values of the Company's financial instruments are presented below as of:

September 30, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Money market currency funds	$	-	$	93,840	$	-	$	93,840
Mutual funds		-		148,994		-		148,994
Equity securities		273,187		-		-		273,187
	$	273,187	$	242,834	$	-	$	516,021
Liabilities:
Warranty liability	$	-	$	-	$	2,750,480	$	2,750,480
Holdback consideration		-		-		136,822		136,822
Conversion feature liability		-		-		547,784		547,784
	$	-	$	-	$	3,435,086	$	3,435,086

March 31, 2014
	Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrant liability	$	-	$	-	$	2,354,624	$	2,354,624
	$	-	$	-	$	2,354,624	$	2,354,624

Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation

The following summarizes the activity of Level 3 inputs measured on a recurring basis for the three and six months ended September 30, 2014:

	Three months			Six months
Balance, beginning of period	$	2,521,451	$	2,354,624
Warrant liability incurred (Note 7)		487,620		487,620
Change in warrant liability		(121,769)		(91,764)
Holdback consideration		-		136,822
Conversion feature liability incurred (Note 7)		578,155		578,155
Change in conversion feature liability		(30,371)		(30,371)
Balance, end of period	$	3,435,086	$	3,435,086

Basic and Diluted Earnings per Share

The following table sets forth the number of shares excluded from the computation of diluted earnings per share, as their inclusion would be anti-dilutive:

	Three Months Ended September 30,		Six Months Ended September 30,
	2014	2013	2014	2013
Options	-	4,373,687	3,657,216	4,547,125
Warrants	-	1,428,067	1,495,803	1,535,402
9% Convertible Notes	799,523	674,528	748,824	785,714
	799,523	6,476,282	5,901,843	6,868,241